Appendix A Protection Factors for Respirators

Statement of Requirement:

Table A.1. Appendix A to Part 20 – Protection Factors for Respirators^a

	Operating mode	Assigned Protection Factors
I. Air-Purifying Respirators [Pa	articulate ^b only] ^c :	
Filtering facepiece disposable ^d	Negative Pressure	(^d)
Facepiece, halfe	Negative Pressure	10
Facepiece, full	Negative Pressure	100
Facepiece, half	Powered air-purifying respirators	50
Facepiece, full	Powered air-purifying respirators	1000
Helmet/hood	Powered air-purifying respirators	1000
Facepiece, loose-fitting	Powered air-purifying respirators	25
II. Atmosphere supplying respi	rators [particulate, gases and	vapors ^f]:
1. Air-line respirator:		
Facepiece, half	Demand	10
Facepiece, half	Continuous Flow	50
Facepiece, half	Pressure Demand	50
Facepiece, full	Demand	100
Facepiece, full	Continuous Flow	1000
Facepiece, full	Pressure Demand	1000
Helmet/hood	Continuous Flow	1000
Facepiece, loose-fitting	Continuous Flow	25
Suit	Continuous Flow	(^g)
2. Self-Contained Breathing Ap	pparatus (SCBA):	
Facepiece, full	Demand	h100
Facepiece, full	Pressure Demand	10,000
Facepiece, full	Demand, Recirculating	h100

APPENDIX A

	Operating mode	Assigned Protection Factors
Facepiece, full	Positive Pressure Recirculating	ⁱ 10,000
III. Combination Respirators:		
Any combination of air-purifying and atmosphere-supplying respirators	(1) Assigned protection factor for type and mode of operation as listed above.	

These assigned protection factors apply only in a respiratory protection program that meets the requirements of this Part. They are applicable only to airborne radiological hazards and may not be appropriate to circumstances when chemical or other respiratory hazards exist instead of, or in addition to, radioactive hazards. Selection and use of respirators for such circumstances must also comply with Department of Labor regulations.

Radioactive contaminants for which the concentration values in Table 1, Column 3 of Appendix B to Part 20 are based on internal dose due to inhalation may, in addition, present external exposure hazards at higher concentrations. Under these circumstances, limitations on occupancy may have to be governed by external dose limits.

- ^b Air-purifying respirators with APF <100 must be equipped with particulate filters that are at least 95% efficient. Air-purifying respirators with APF = 100 must be equipped with particulate filters that are at least 99% efficient. Air-purifying respirators with APFs >100 must be equipped with particulate filters that are at least 99.97% efficient.
- ^c The licensee may apply to the Commission for the use of an APF greater than 1 for sorbent cartridges as protection against airborne radioactive gases and vapors (e.g., radioiodine).
- d Licensees may permit individuals to use this type of respirator who have not been medically screened or fit tested on the device provided that no credit be taken for their use in estimating intake or dose. It is also recognized that it is difficult to perform an effective positive or negative pressure pre-use user seal check on this type of device. All other respiratory protection program requirements listed in 10 CFR 20.1703 apply. An assigned protection factor has not been assigned for these devices. However, an APF equal to 10 may be used if the licensee can demonstrate a fit factor of at least 100 by use of a validated or evaluated, qualitative or quantitative fit test.
- ^e Under-chin type only. No distinction is made in this Appendix between elastomeric half-masks with replaceable cartridges and those designed with the filter medium as an integral part of the facepiece (e.g., disposable or reusable disposable). Both types are acceptable so long as the seal area of the latter contains some substantial type of seal-enhancing material such as rubber or plastic, the two or more suspension straps are adjustable, the filter medium is at least 95% efficient and all other requirements of this Part are met.

- The assigned protection factors for gases and vapors are not applicable to radioactive contaminants that present an absorption or submersion hazard. For tritium oxide vapor, approximately one-third of the intake occurs by absorption through the skin so that an overall protection factor of 3 is appropriate when atmosphere-supplying respirators are used to protect against tritium oxide. Exposure to radioactive noble gases is not considered a significant respiratory hazard, and protective actions for these contaminants should be based on external (submersion) dose considerations.
- ^g No NIOSH approval schedule is currently available for atmosphere supplying suits. This equipment may be used in an acceptable respiratory protection program as long as all the other minimum program requirements, with the exception of fit testing, are met (i.e., 10 CFR 20.1703).
- h The licensee should implement institutional controls to assure that these devices are not used in areas immediately dangerous to life or health (IDLH).
- This type of respirator may be used as an emergency device in unknown concentrations for protection against inhalation hazards. External radiation hazards and other limitations to permitted exposure such as skin absorption shall be taken into account in these circumstances. This device may not be used by any individual who experiences perceptible outward leakage of breathing gas while wearing the device.

Discussion:

Appendix A to Part 20, Subpart H, provides the APFs for respirators. The information is provided in a table, with footnotes provided for explanation. The APFs are listed for each broad class of respirators (e.g., air-purifying). Each class is subdivided into respirator types (e.g., full facepiece). Each type is characterized by how it operates (operating mode, e.g., negative pressure).

Statement of Applicability:

The information in this appendix applies to all licensees that use respirators to limit worker intakes of radioactive materials.

Guidance Statement:

Licensees may use APF values only if the requirements of Subpart H are met. Lower APFs may be assigned by the licensee without prior notification and approval by NRC. The use of higher APFs must have prior approval by NRC. The definitions for the table's respirator classes, types and modes of operation are found in section 20.1003, Definitions. Appendix A APFs are only applicable to airborne radiological hazards, and may not be appropriate for chemical or other non-radiological respiratory hazards. See specific guidance on OSHA, Department of Labor respiratory requirements in NRC's Regulatory Guide, 8.15 Revision 1.

A-3 NUREG-1736

APPENDIX A

List of Existing Regulatory Guidance:

NUREG-0041 Manual of Respiratory Protection Against Airborne Radioactive Materials Reg. Guide 8.15 Acceptable Programs For Respiratory Protection (Revision 1)

List of Implementing Guidance:

HPPOS-037 Farley 1 & 2 – 10 CFR Part 20 Exemption Request, MSA GMR-I Canister Radioiodine Protection Factor (describes example of NRC approval process to use non-NIOSH approved equipment to protect against radio-iodine gases and vapors)

HPPOS-118 Airflow Measurement and Control for Supplied-Air Respirators (provides guidance to effectively use and control airline respirators)

Q&A 91 Clarifies the need to comply with programmatic requirements when using respirators

List of Outdated Implementing Guidance:

HPPOS-225 Footnote (g) of Appendix A to 10 CFR 20 Concerning Protection Factor for Respirator (discusses NRC policy on use of non-elastomeric (disposable) half-facepieces)

Appendix B

Annual Limits on Intake (ALIs) and Derived Air Concentrations (DACs) of Radionuclides for Occupational Exposure; Effluent Concentrations; Concentrations for Release to Sewerage

Statement of Requirement:

Note: The accompanying tables (3) and footnotes/notes that comprise the rest of Appendix B can be found on the web at: http://www.nrc.gov/NRC/CFR/TABLES/ISOTOPES/PART020-APPB/radionuclides.html.

Appendix B to Part 20 — Annual Limits on Intake (ALIs) and Derived Air Concentrations (DACs) of Radionuclides for Occupational Exposure; Effluent Concentrations; Concentrations for Release to Sewerage

Introduction

For each radionuclide, Table 1 indicates the chemical form which is to be used for selecting the appropriate ALI or DAC value. The ALIs and DACs for inhalation are given for an aerosol with an activity median aerodynamic diameter (AMAD) of 1 m and for three classes (D,W,Y) of radioactive material, which refer to their retention (approximately days, weeks or years) in the pulmonary region of the lung. This classification applies to a range of clearance half-times of less than 10 days for D, for W from 10 to 100 days, and for Y greater than 100 days. The class (D, W, or Y) given in the column headed "Class" applies only to the inhalation ALIs and DACs given in Table 1, columns 2 and 3. Table 2 provides concentration limits for airborne and liquid effluents released to the general environment. Table 3 provides concentration limits for discharges to sanitary sewer systems.

Notation

The values in Tables 1, 2, and 3 are presented in the computer "E" notation. In this notation a value of 6E-02 represents a value of 6×10^{-2} or 0.06, 6E+2 represents 6×10^{2} or 600, and 6E+0 represents 6×10^{0} or 6.

Note that the columns in Table 1 of this appendix captioned "Oral Ingestion ALI," "Inhalation ALI," and "DAC," are applicable to occupational exposure to radioactive material.

The ALIs in this appendix are the annual intakes of a given radionuclide by "Reference Man" which would result in either: (1) a CEDE of 5 rems (stochastic ALI); or (2) a committed dose equivalent of 50 rems to an organ or tissue (non-stochastic ALI). The stochastic ALIs were derived to result in a risk, due to irradiation of organs and tissues, comparable to the risk associated with deep-dose equivalent to the whole body of 5 rems. The derivation includes multiplying the committed dose equivalent to an organ or tissue by a weighting factor, w_T. This weighting factor is the proportion of the risk of stochastic effects resulting from irradiation of the organ or tissue, T, to the total risk of stochastic effects when the whole body is irradiated uniformly. The values of w_T are listed under the definition of weighting factor in 10 CFR 20.1003. The non-stochastic ALIs were derived to avoid non-stochastic effects, such as prompt damage to tissue or reduction in organ function.

B-1 NUREG-1736

A value of w_T =0.06 is applicable to each of the five organs or tissues in the "remainder" category receiving the highest dose equivalents, and the dose equivalents of all other remaining tissues may be disregarded. The following parts of the GI tract – stomach, small intestine, upper large intestine, and lower large intestine – are to be treated as four separate organs. Note that the dose equivalents for extremities (hands and forearms, feet and lower legs), skin, and lens of the eye are not considered in computing the CEDE, but are subject to limits that must be met separately.

When an ALI is defined by the stochastic dose limit, this value alone, is given. When an ALI is determined by the non-stochastic dose limit to an organ, the organ or tissue to which the limit applies is shown, and the ALI for the stochastic limit is shown in parentheses. (Abbreviated organ or tissue designations are used: LLI wall = lower large intestine wall; St. wall = stomach wall; Blad wall = bladder wall; and Bone surf = bone surface.)

The use of the ALIs listed first, the more limiting of the stochastic and non-stochastic ALIs, will ensure that non-stochastic effects are avoided and that the risk of stochastic effects is limited to an acceptably low value. If, in a particular situation involving a radionuclide for which the non-stochastic ALI is limiting, and use of that non-stochastic ALI is considered unduly conservative, the licensee may use the stochastic ALI to determine the CEDE. However, the licensee shall also ensure that the 50-rem dose equivalent limit for any organ or tissue is not exceeded by the sum of the external deep-dose equivalent plus the internal committed dose to that organ (not the effective dose). For the case where there is no external dose contribution, this would be demonstrated if the sum of the fractions of the nonstochastic ALIs (ALI_{ns}) that contribute to the committed dose equivalent to the organ receiving the highest dose does not exceed unity (i.e., (intake (in μ Ci) of each radionuclide/ALI_{ns}) <1.0). If there is an external deep-dose equivalent contribution of H_d then this sum must be less than l-(H_d/50) instead of being <1.0.

The derived air concentration (DAC) values are derived limits intended to control chronic occupational exposures. The relationship between the DAC and the ALI is given by: DAC = ALI (in μ Ci)/(2,000 hours per working year x 60 minutes/hour x 2 x 10⁴ ml per minute) = [ALI/2.4 x 10⁹] μ Ci/ml, where 2 x 10⁴ ml is the volume of air breathed per minute at work by "Reference Man" under working conditions of "light work."

The DAC values relate to one of two modes of exposure: either external submersion or the internal committed dose equivalents resulting from inhalation of radioactive materials. Derived air concentrations based upon submersion are for immersion in a semi-infinite cloud of uniform concentration and apply to each radionuclide separately.

The ALI and DAC values relate to exposure to the single radionuclide named, but also include contributions from the in-growth of any daughter radionuclide produced in the body by the decay of the parent. However, intakes that include both the parent and daughter radionuclides should be treated by the general method appropriate for mixtures.

The value of ALI and DAC do not apply directly when the individual both ingests and inhales a radionuclide, when the individual is exposed to a mixture of radionuclides by either inhalation or ingestion or both, or when the individual is exposed to both internal and external radiation (see 10 CFR 20.1202). When an individual is exposed to radioactive materials which fall under several of the translocation classifications (i.e., Class D, Class W, or Class Y) of the same radionuclide, the exposure may be evaluated as if it were a mixture of different radionuclides.

It should be noted that the classification of a compound as Class D, W, or Y is based on the chemical form of the compound and does not take into account the radiological half-life of different radioisotopes. For this reason, values are given for Class D, W, and Y compounds, even for very short-lived radionuclides.

The columns in Table 2 of this appendix captioned "Effluents," "Air," and "Water," are applicable to the assessment and control of dose to the public, particularly in the implementation of the provisions of 10 CFR 20.1302. The concentration values given in Columns 1 and 2 of Table 2 are equivalent to the radionuclide concentrations which, if inhaled or ingested continuously over the course of a year, would produce a total effective dose equivalent of 0.05 rem (50 millirem or 0.5 millisieverts).

Consideration of non-stochastic limits has not been included in deriving the air and water effluent concentration limits because non-stochastic effects are presumed not to occur at the dose levels established for individual members of the public. For radionuclides, where the non-stochastic limit was governing in deriving the occupational DAC, the stochastic ALI was used in deriving the corresponding airborne effluent limit in Table 2. For this reason, the DAC and airborne effluent limits are not always proportional as was the case in Appendix B to 10 CFR 20.1-20.601.

The air concentration values listed in Table 2, Column 1, were derived by one of two methods. For those radionuclides for which the stochastic limit is governing, the occupational steehastic inhalation ALI was divided by 2.4 x 10 ml, relating the inhalation ALI to the DAC, as explained above, and then divided by a factor of 300. The factor of 300 includes the following components: a factor of 50 to relate the 5-rem annual occupational dose limit to the 0.1-rem limit for members of the public, a factor of 3 to adjust for the difference in exposure time and the inhalation rate for a worker and that for members of the public; and a factor of 2 to adjust the occupational values (derived for adults) so that they are applicable to other age groups.

For those radionuclides for which submersion (external dose) is limiting, the occupational DAC in Table 1, Column 3, was divided by 219. The factor of 219 is composed of a factor of 50, as described above, and a factor of 4.38 relating occupational exposure for 2,000 hours per year to full-time exposure (8,760 hours per year). Note that an additional factor of 2 for age considerations is not warranted in the submersion case.

The water concentrations were derived by taking the most restrictive occupational stochastic oral ingestion ALI and dividing by 7.3×10^7 . The factor of 7.3×10^7 (ml) includes the following components: the factors of 50 and 2 described above and a factor of 7.3×10^5 (ml) which is the annual water intake of "Reference Man."

Note 2 of this appendix provides groupings of radionuclides which are applicable to unknown mixtures of radionuclides. These groupings (including occupational inhalation ALIs and DACs, air and water effluent concentrations and sewerage) require demonstrating that the most limiting radionuclides in successive classes are absent. The limit for the unknown mixture is defined when the presence of one of the listed radionuclides cannot be definitely excluded either from knowledge of the radionuclide composition of the source or from actual measurements.

The monthly average concentrations for release to sanitary sewers are applicable to the provisions in 10 CFR 20.2003. The concentration values were derived by taking the most restrictive occupational stochastic oral ingestion ALI and dividing by 7.3×10^6 (ml). The factor of 7.3×10^6 (ml) is composed of a factor of 7.3×10^5 (ml), the annual water intake by "Reference Man," and a factor of 10, such that the concentrations, if the sewage released by the licensee were the only source of water ingested by a reference man during a year, would result in a CEDE of 0.5 rem.

List of Elements

Name	Aton	nic
	Symbol	No.
Actinium	Ac	89
Aluminum	Al	13
Americium	Am	95
Antimony	Sb	51
Argon	Ar	18
Arsenic	As	33
Astatine	At	85
Barium	Ва	56
Berkelium	Bk	97
Beryllium	Be	4
Bismuth	Bi	83
Bromine	Br	35

Name	Aton	nic
	Symbol	No.
Cadmium	Cd	48
Calcium	Ca	20
Californium	Cf	98
Carbon	С	6
Cerium	Се	58
Cesium	Cs	55
Chlorine	Cl	17
Chromium	Cr	24
Cobalt	ſn	27
Copper	Cu	29
Curium	Cm	96
Dysprosium	Dy	66
Einsteinium	Es	99
Erbium	Er	68
Europium	Eu	63
Fermium	Fm	100
Fluorine	F	9
Francium	Fr	87
Gadolinium	Gd	64
Gallium	Ga	31
Germanium	Ge	32
Gold	Au	79
Hafnium	Hf	72
Holmium	Но	67
Hydrogen	Н	1

Name	Atomic				
	Symbol	No.			
Indium	In	49			
Iodine	I	53			
Iridium	Ir	77			
Iron	Fe	26			
Krypton	Kr	36			
Lanthanum	La	57			
Lead	Pb	82			
Lutetium	Lu	71			
Magnesium	Mg	12			
Manganese	Mn	25			
Mendelevium	Md	101			
Mercury	Hg	80			
Molybdenum	Мо	42			
Neodymium	Nd	60			
Neptunium	Np	93			
Nickel	Ni	28			
Niobium	Nb	41			
Osmium	Os	76			
Palladium	Pd	46			
Phosphorus	P	15			
Platinum	Pt	78			
Plutonium	Pu	94			
Polonium	Po	84			
Potassium	K	19			
Praseodymium	Pr	59			

Name	Atomic				
	Symbol	No.			
Promethium	Pm	61			
Protactinium	Pa	91			
Radium	Ra	88			
Radon	Rn	86			
Rhenium	Re	75			
Rhodium	Rh	45			
Rubidium	Rb	37			
Ruthenium	Ru	44			
Samarium	Sm	62			
Scandium	Sc	21			
Selenium	Se	34			
Silicon	Si	14			
Silver	Ag	47			
Sodium	Na	11			
Strontium	Sr	38			
Sulfur	S	16			
Tantalum	Ta	73			
Technetium	Тс	43			
Tellurium	Те	52			
Terbium	Tb	65			
Thallium	Tl	81			
Thorium	Th	90			
Thulium	Tm	69			
Tin	Sn	50			
Titanium	Ti	22			

Name	Atomic				
	Symbol	No.			
Tungsten	W	74			
Uranium	Ŭ	92			
Vanadium	V	23			
Xenon	Xe	54			
Ytterbium	Yb	70			
Yttrium	Y	39			
Zinc	Zn	30			
Zirconium	Zr	40			

			Table 1 Occupational Values			Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
1	Hydrogen-3	Water, DAC includes skin absorption	8E+4	8E+4	2E-5	1E-7	1E-3	1E-2
		Gas (HT or T ₂) Submersion ¹ :	Use above va	alues as HT a	nd T ₂ oxidize i	n air and in t	he body to H	го
4	Beryllium-7	W, all compounds except those given for Y	4E+4	2E+4	9E-6	3E-8	6E-4	6E-3
		Y, oxides, halides, and nitrates	-	2E+4	8E-6	3E-8	-	-
4	Beryllium-10	W, see ⁷ Be	lE+3 LLI wall	2E+2	6E-8	2E-10	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see ⁷ Be	-	1E+1	6E-9	2E-11	-	-
6	Carbon-11(2)	Monoxide	-	1E+6	5E-4	2E-6	-	-
		Dioxide	-	6E+5	3E-4	9E-7	-	-
		Compounds	4E+5	4E+5	2E-4	6E-7	6E-3	6E-2
6	Carbon-14	Monoxide	-	2E+6	7E-4	2E-6	-	-
		Dioxide	-	2E+5	9E-5	3E-7	-	-
		Compounds	2E+3	2E+3	1E-6	3E-9	3E-5	3E-4
9	Fluorine-18(2)	D, fluorides of H, Li, Na, K, Rb, Cs, and Fr	5E+4 St wall	7E+4	3E-5	1E-7	-	-
	1		(5E+4)	-	-	-	7E-4	7E-3
		W. fluorides of Be. Mg. Ca. Sr. Ba, Ra, Al. Ga. In. Tl, As, Sb. Bi, Fe. Ru, Os, Co. Ni, Pd, Pt, Cu, Ag, Au. Zn. Cd, Hg, Sc. Y, Ti, Zr, V, Nb, Ta, Mn, Tc, and Re	-	9E+4	4E-5	1E-7	-	-
		Y, lanthanum fluoride	-	8E+4	3E-5	1E-7	-	-
11	Sodium-22	D, all compounds	4E+2	6E+2	3E-7	9E-10	6E-6	6E-5
11	Sodium-24	D, all compounds	4E+3	5E+3	2E-6	7E-9	5E-5	5E-4

			Occ	Table 1 supational V	alues	Table 2 nes Effluent Concentrati		Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	alation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/mł)	Concentration (µCi/ml)
12	Magnesium-28	D, all compounds except those given for W	7E+2	2E+3	7E-7	2E-9	9E-6	9E-5
		W, oxides, hydroxides, carbides, halides, and nitrates	-	1E+3	5E-7	2E-9	-	-
13	Aluminum-26	D, all compounds except those given for W	4E+2	6E+1	3E-8	9E-11	6E-6	6E-5
		W, oxides, hydroxides, carbides, halides, and nitrates	-	9E+1	4E-8	1E-10	-	-
14	Silicon-31	D, all compounds except those given for W and Y	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		W, oxides, hydroxides, carbides, and nitrates	-	3E+4	1E-5	5E-8	-	-
		Y, aluminosilicate glass	-	3E+4	1E-5	4E-8	-	-
14	Silicon-32	D, see ³⁴ Si	2E+3 LLI wall	2E+2	1E-7	3E-10	-	
			(3E+3)	-	-	-	4E-5	4E-4
		W. see 31Si	-	1E+2	5E-8	2E-10	-	
		Y, see 31Si	-	5E+0	2E-9	2E-12	-	-
15	Phosphorus-32	D, all compounds except phosphates given for W	6E+2	9E+2	4E-7	1E-9	9E-6	9E-5
		W, phosphates of Zn ²⁺ , S ³⁺ , Mg ²⁺ , Fe ³⁺ , Bi ³⁺ , and lanthanides	-	4E+2	2E-7	5E-10	-	-
15	Phosphorous-33	D, see ³² P	6E+3	8E+3	4E-6	1E-8	8E-5	8E-4
		W. see ³² P	-	3E+3	IE-6	4E-9		-

				Table 1 Occupational Values			Table 2 Effluent Concentrations	
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
16	Sulfur-35	Vapor	-	1E+4	6E-6	2E-8	-	-
		D, sulfides and sulfates except those given for W	1E+4 LLI wall	2E+4	7E-6	2E-8	-	-
	ļ		(8E+3)	-	-	-	1E-4	1E-3
		W, elemental sulfur, sulfides of Sr, Ba, Ge, Sn, Pb, As, Sb, Bi, Cu, Ag, Au, Zn, Cd, Hg, W, and Mo. Sulfates of Ca, Sr, Ba, Ra, As, Sb, and Bi	6E+3	2E+3	9E-7	3E-9	-	-
17	Chlorine-36	D, chlorides of H, Li, Na, K, Rb, Cs, and Fr	2E+3	2E+3	1E-6	3E-9	2E-5	2E-4
		W, chlorides of lanthanides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, W, Mn, Tc, and Re	-	2E+2	1E-7	3E-10	-	-
17	Chlorine-38 ⁽²⁾	D, see ³⁶ Cl	2E+4 St. wall	4E+4	2E-5	6E-8	-	-
	ļ		(3E+4)	-	-	-	3E-4	3E-3
		W, see ³⁶ Cl	-	5E+4	2E-5	6E-8	-	-
17	Chlorine-39 ⁽²⁾	D, see ³⁶ Cl	2E+4 St. wall	5E+4	2E-5	7E-8	-	-
			(4E+4)	-	-		5E-4	5E-3
		W, see ³⁶ Cl	-	6E+4	2E-5	8E-8	-	-
18	Argon-37	Submersion ⁽¹⁾	-	-	1E+0	6E-3	-	-
18	Argon-39	Submersion ⁽¹⁾	-	-	2E-4	8E-7	-	-
18	Argon-41	Submersion ⁽¹⁾	-	•	3E-6	1E-8	-	
19	Potassium-40	D, all compounds	3E+2	4E+2	2E-7	6E-10	4E-6	4E-5
19	Potassium-42	D, all compounds	5E+3	5E+3	2E-6	7E-9	6E-5	6E-4
19	Potassium-43	D, all compounds	6E+3	9E+3	4E-6	1E-8	9E-5	9E-4

			Occ	Table 1 Occupational Values			ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1 Col. 2		
			Oral Ingestion	Inba	lation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
19	Potassium-44 ⁽²⁾	D, all compounds	2E+4 St. wall	7E+4	3E-5	9E-8		-
			(4E+4)	-	-	-	5E-4	5E-3
19	Potassium-45 ⁽²⁾	D, all compounds	3E+4 St. wall	1E+5	5E-5	2E-7	-	*
			(5E±4)	-	-	-	7E-4	7E-3
20	Calcium-41	W, all compounds	3E+3 Bone Surf	4E+3 Bone Surf	2E-6	-	-	-
			(4E+3)	(4E+3)	-	5E-9	6E-5	6E-4
20	Calcium-45	W. all compounds	2E+3	8E+2	4E-7	1E-9	2E-5	2E-4
20	Calcium-47	W. all compounds	8E+2	9E+2	4E-7	1E-9	1E-5	1E-4
21	Scandium-43	Y, all compounds	7E+3	2E+4	9E-6	3E-8	1E-4	1E-3
21	Scandium-44m	Y, all compounds	5E+2	7E+2	3E-7	1E-9	7E-6	7E-5
21	Scandium-44	Y, all compounds	4E+3	1E+4	5E-6	2E-8	5E-5	5E-4
21	Scandium-46	Y, all compounds	9E+2	2E+2	1E-7	3E-10	1E-5	1E-4
21	Scandium-47	Y, all compounds	2E+3 LLI wall	3E+3	1E-6	4E-9	-	-
			(3E+3)	-	-	-	4E-5	4E-4
21	Scandium-48	Y, all compounds	8E+2	1E+3	6E-7	2E-9	1E-5	1E-4
21	Scandium-49(2)	Y, all compounds	2E+4	5E+4	2E-5	8E-8	3E-4	3E-3
22	Titanium-44	D, all compounds except those given for W and Y	3E+2	1E+1	5E-9	2E-11	4E-6	4E-5
		W, oxides, hydroxides, carbides, halides, and nitrates	-	3E+1	1E-8	4E-11	-	-
		Y, SrTiO ₃	-	6E+0	2E-9	8E-12	-	-
22	Titanium-45	D, see "Ti	9E+3	3E+4	1E-5	3E-8	1E-4	1E-3
		W, see ⁴⁴ Ti	-	4E+4	1E-5	5E-8	-	-
ļ		Y, see Ti	_	3E+4	IE-5	4E-8	-	-

				Table 1 Occupational Values			ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
23	Vanadium-47 ⁽²⁾	D, all compounds except those given for W	3E+4 St. wall	8E+4	3E-5	1E-7	-	-
	ļ		(3E+4)	-	-	-	4E-4	4E-3
		W, oxides, hydroxides, carbides, and halides	-	1E+5	4E-5	1E-7	-	-
23	Vanadium-48	D, see ¹⁷ V	6E+2	1E+3	5E-7	2E-9	9E-6	9E-5
		W, see 47V	-	6E+2	3E-7	9E-10	-	-
23	Vanadium-49	D, see ⁴⁷ V	7E+4 LLI wall	3E+4 Bone Surf	1E-5	-	-	-
			(9E+4)	(3E+4)	-	5E-8	1E-3	1E-2
		W, see ⁴⁷ V	-	2E+4	8E-6	2E-8	-	-
24	Chromium-48	D, all compounds except those given for W and Y	6E+3	1E+4	5E-6	2E-8	8E-5	8E-4
		W, halides and nitrates	-	7E+3	3E-6	1E-8	-	-
		Y, oxides and hydroxides	-	7E+3	3E-6	1E-8	-	-
24	Chromium-49 ⁽²⁾	D, see ⁴⁸ Cr	3E+4	8E+4	4E-5	1E-7	4E-4	4E-3
		W, see ⁴⁸ Cr	-	1E+5	4E-5	1E-7	_	_
		Y, see 48Cr	-	9E+4	4E-5	1E-7	-	-
24	Chromium-51	D, see 4xCr	4E+4	5E+4	2E-5	6E-8	5E-4	5E-3
		W, see ⁴8Cr	-	2E+4	1E-5	3E-8	-	-
	1	Y, see ⁴⁸ Cr	-	2E+4	8E-6	3E-8	-	-
25	Manganese-51 ⁽²⁾	D, all compounds except those given for W	2E+4	5E+4	2E-5	7E-8	3E-4	3E-3
		W, oxides, hydroxides, halides, and nitrates	-	6E+4	3E-5	8E-8	-	-
25	Manganese- 52m ⁽²⁾	D, see ^{SI} Mn	3E+4 St. wall	9E+4	4E-5	1E-7	-	-
			(4E+4)	-	-		5E-4	5E-3
		W, see ⁵¹ Mn	-	IE+5	4E-5	IE-7	-	-
25	Manganese-52	D, see 51Mn	7E+2	1E+3	5E-7	2E-9	1E-5	iE-4
		W, see 51Mn	-	9E+2	4E-7	!E-9	-	-

B-13 NUREG-1736

			Oc	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
25	Manganese-53	D, see ⁵¹ Mn	5E+4	1E+4 Bone Surf	5E-6	-	7E-4	7E-3
			-	(2E+4)	-	3E-8	-	-
		W, see 51Mn	-	1E+4	5E-6	2E-8	-	-
25	Manganese-54	D, see 51Mn	2E+3	9E+2	4E-7	1E-9	3E-5	3E-4
		W, see ⁵¹ Mn	-	8E+2	3E-7	1E-9	-	-
25	Manganese-56	D, see ⁵¹ Mn	5E+3	2E+4	6E-6	2E-8	7E-5	7E-4
		W, see 51Mn	-	2E+4	9E-6	3E-8	-	-
26	Iron-52	D, all compounds except those given for W	9E+2	3E+3	1 E -6	4E-9	1E-5	1E-4
		W, oxides, hydroxides, and halides	-	2E+3	1E-6	3E-9	-	-
26	Iron-55	D, see ⁵² Fe	9E+3	2E+3	8E-7	3E-9	1E-4	1E-3
		W, see 52Fe	-	4E+3	2E-6	6E-9	-	-
26	Iron-59	D, see ⁵² Fe	8E+2	3E+2	1E-7	5E-10	1E-5	1E-4
		W, see 52Fe	-	5E+2	2E-7	7E-10	-	-
26	Iron-60	D, see ^{S2} Fe	3E+1	6E+0	3E-9	9E-12	4E-7	4E-6
		W, see ⁵² Fe		2E+1	8E-9	3E-11	-	-
27	Cobalt-55	W, all compounds except those given for Y	1E+3	3E+3	lE-6	4E-9	2E-5	2E-4
		Y, oxides, hydroxides, halides, and nitrates	-	3E+3	1E-6	4E-9	-	
27	Cobalt-56	W, see 55Co	5E+2	3E+2	1E-7	4E-10	6E-6	6E-5
		Y, see 55Co	4E+2	2E+2	8E-8	3E-10	-	-
27	Cobalt-57	W, see 55Co	8E+3	3E+3	1E-6	4E-9	6E-5	6E-4
		Y, see ⁵⁵ Co	4E+3	7E+2	3E-7	9E-10	-	-
27	Cobalt-58m	W, see 55Co	6E+4	9E+4	4E-5	1E-7	8E-4	8E-3
		Y, see 55Co	-	6E+4	3E-5	9E-8	-	-
27	Cobalt-58	W, see 55Co	2E+3	1E+3	5E-7	2E-9	2E-5	2E-4
		Y, see 55Co	1E+3	7E+2	3E-7	1E-9	-	-

			Occ	Table 1 upational V	alues	Eff	ble 2 uent atrations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	Inha ALI (μCi)	DAC (µCi/ml)	Air . (μCi/ml)	Water (μCi/ml)	Monthly Average Concentration (µCi/ml) 2E-1 3E-5 - 3E-3 - 7E-3 - 2E-4 - 3E-4 - 1E-3
27	Cobalt-60m(2)	W, see ⁵⁵ Co	IE+6 St. wall	4E+6	2E-3	6E-6	-	-
			(1E+6)	-	-	-	2E-2	2E-1
		Y, see 55Co	-	3E+6	1E-3	4E-6	-	-
27	Cobalt-60	W, see 55Co	5E+2	2E+2	7E-8	2E-10	3E-6	3E-5
		Y, see 55Co	2E+2	3E+1	1E-8	5E-11	-	-
27	Cobalt-61(2)	W, see 55Co	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		Y, see 55Co	2E+4	6E+4	2E-5	8E-8	-	-
27	Cobalt-62m ⁽²⁾	W, see 55Co	4E+4 St. wan	2E+5	7E-5	2E-7	-	-
			(5E+4)	-	-	-	7E-4	7E-3
		Y, see 55Co	-	2E+5	6E-5	2E-7	-	
28	Nickel-56	D, all compounds except those given for W	IE+3	2E+3	8E-7	3E-9	2E-5	2E-4
		W, oxides, hydroxides, and carbides	-	1E+3	5E-7	2E-9	*	-
		Vapor		1E#3	5E=7	?E=9	=	
28	Nickel-57	D, see ⁵⁶ Ni	2E+3	5E+3	2E-6	7E-9	2E-5	2E-4
		W, see 55Ni		3E+3	1E-6	4E-9	-	-
		Vapor	-	6E+3	3E-6	9E-9	-	-
28	Nickel-59	D, see ⁵⁶ Ni	2E+4	4E+3	2E-6	5E-9	3E-4	3E-3
		W, sce ⁵⁶ Ni	-	7E+3	3E-6	1E-8	-	-
		Vapor	-	2E+3	8E-7	3E-9	-	-
28	Nickel-63	D, see ⁵⁶ Ni	9E+3	2E+3	7E-7	2E-9	1E-4	1E-3
		W, see ⁵⁶ Ni	-	3E+3	1E-6	4E-9	-	-
		Vapor	-	8E+2	3E-7	1E-9	-	-
28	Nickel-65	D, see ⁵⁶ Ni	8E+3	2E+4	IE-5	3E-8	1E-4	1E-3
		W, see ⁵⁰ Ni	-	3E+4	1E-5	4E-8	-	-
		Vapor	-	2E+4	7E-6	2E-8	-	-
28	Nickel-66	D, see ⁵⁶ Ni	4E+2 LLI wall	2E+3	7E-7	2E-9	-	-

				Table 1 cupational V		Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
			(5E+2)	-	-	-	6E-6	6E-5
		W, see ⁵⁶ Ni	-	6E+2	3E-7	9E-10	-	-
		Vapor	-	3E+3	1E-6	4E-9	-	-
29	Copper-60 ⁽²⁾	D, all compounds except those given for W and Y	3E+4 St. wall	9E+4	4E-5	1E-7	-	-
			(3E+4)		-	-	4E-4	4E-3
		W, sulfides, halides, and nitrates	-	1E+5	5E-5	2E-7	-	-
		Y,.oxides and hydroxides	-	1E+5	4E-5	1E-7	-	-
29	Copper-61	D, see 60Cu	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
		W, see [∞] Cu	-	4E+4	2E-5	6E-8		-
		Y, see [∞] Cu	-	4E+4	1E-5	5E-8	-	-
29	Copper-64	D, see ⁶⁰ Cu	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
		W, see 60Cu	-	2E+4	1E-5	3E-8	-	-
		Y, see [∞] Cu		2E+4	9E-6	3E-8	-	-
29	Copper-67	D, see ⁶⁰ Cu	5E+3	8E+3	3E-6	1E-8	6E-5	6E-4
		W, see 60Cu	-	5E+3	2E-6	7E-9	-	-
		Y, see [∞] Cu	-	5E+3	2E-6	6E-9	-	-
30	Zinc-62	Y, all compounds	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4
30	Zinc-63 ⁽²⁾	Y, all compounds	2E+4 St. wall	7E+4	3E-5	9E-8	-	-
			(3E+4)	-	-	-	3E-4	3E-3
30	Zinc-65	Y, all compounds	4E+2	3E+2	IE-7	4E-10	5E-6	5E-5
30	Zinc-69m	Y, all compounds	4E+3	7E+3	3E-6	1E-8	6E-5	6E-4
30	Zinc-69 ⁽²⁾	Y, all compounds	6E+4	1E+5	6E-5	2E-7	8E-4	8E-3
30	Zinc-71m	Y, all compounds	6E+3	2E+4	7E-6	2E-8	8E-5	8E-4
30	Zinc-72	Y, call compounds	1E+3	1E+3	5E-7	2E-9	1E-5	1E-4
31	Gallium-65 ⁽²⁾	D, all compounds except those given for W	5E+4 St. wall	2E+5	7E-5	2E-7	-	-
			(6E+4)	- 1	-	-	9E-4	9E-3

B-16

NUREG-1736

1

			Occ	Table 1 upational V	alues	Effl	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	Ingestion ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (μCi/ml)
		W, oxides, hydroxides, carbides, halides, and nitrates	-	2E+5	8E-5	3E-7	-	-
31	Gallium-66	D, see 65Ga	1E+3	4E+3	1E-6	5E-9	1E-5	1E-4
	1	W, see 65Ga	-	3E+3	1E-6	4E-9	-	-
31	Gallium-67	D, see 65Ga	7E+3	1E+4	6E-6	2E-8	1E-4	1E-3
		W, see 65Ga	-	1E+4	4E-6	1E-8	-	-
31	Gallium-68 ⁽²⁾	D, see 65Ga	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see 65Ga	-	5E+4	2E-5	7E-8	-	-
31	Gallium-70(2)	D, see 65Ga	5E+4 St. wall	2E+5	7E-5	2E-7	-	-
			(7E+4)	-	-	-	1E-3	1E-2
		W, see 65Ga	-	2E+5	8E-5	3E-7	-	-
31	Gallium-72	D, see 65Ga	1E+3	4E+3	1E-6	5E-9	2E-5	2E-4
		W, see 65Ga	-	3E+3	1E-6	4E-9	-	-
31	Gallium-73	D, see 65Ga	5E+3	2E+4	6E-6	2E-8	7E-5	7E-4
		W, see 65Ga	-	2E+4	6E-6	2E-8	-	-
32	Germanium-66	D, all compounds except those given for W	2E+4	3E+4	1E-5	4E-8	3E-4	3E-3
		W, oxides, sulfides, and halides	-	2E+4	8E-6	3E-8	-	-
32	Germanium-67 ⁽²⁾	D, see [∞] Ge	3E+4 St. wall	9E+4	4E-5	1E-7	-	-
			(4E+4)	-	-	-	6E-4	6E-3
		W, see ⁶⁶ Ge	-	1E+5	4E-5	1E-7	-	
32	Germanium-68	D, see "Ge	5E+3	4E+3	2E-6	5E-9	6E-5	6E-4
		W, see [™] Ge	-	1E+2	4E-8	1E-10	-	-
32	Germanium-69	D, see ⁶⁶ Ge	1E+4	2E+4	6E-6	2E-8	2E-4	2E-3
		W, see ⁶⁶ Ge	-	8E+3	3E-6	1E-8	-	-
32	Germanium-71	D, see ⁶⁶ Ge	5E+5	4E+5	2E-4	6E-7	7E-3	7E-2
		W, see [™] Ge	-	4E+4	2E-5	6E-8		-

B-17 NUREG-1736

			Occ	Table 1 upational V	alues	Effi	ble 2 luent itrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion		lation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
32	Germanium-75 ⁽²⁾	D, see ⁶⁶ Ge	4E+4 St. wall	8E+4	3E-5	1E-7	-	-
			(7E+4)	-	-	-	9E-4	9E-3
		W, see ⁶⁶ Ge	-	8E+4	4E-5	1E-7	-	-
32	Germanium-77	D, see ⁶⁶ Ge	9E+3	1E+4	4E-6	1E-8	1E-4	1E-3
-		W, see ⁶⁶ Ge	-	6E+3	2E-6	8E-9	-	-
32	Germanium-78 ⁽²⁾	D, see ⁶⁶ Ge	2E+4 St. wall	2E+4	9E-6	3E-8	-	-
			(2E+4)	-	-	-	3E-4	3E-3
		W, see ⁶⁶ Ge	-	2E+4	9E-6	3E-8	-	-
33	Arsenic-69 ⁽²⁾	W, all compounds	3E+4 St. wall	1E+5	5E-5	2E-7		-
			(4E+4)	-	-	-	6E-4	6E-3
33	Arsenic-70 ⁽²⁾	W, all compounds	1E+4	5E+4	2E-5	7E-8	2E-4	2E-3
33	Arsenic-71	W, all compounds	4E+3	5E+3	2E-6	6E-9	5E-5	5E-4
33	Arsenic-72	W, all compounds	9E+2	1E+3	6E-7	2E-9	1E-5	1E-4
33	Arsenic-73	W, all compounds	8E+3	2E+3	7E-7	2E-9	1E-4	1E-3
33	Arsenic-74	W, all compounds	1E+3	8E+2	3E-7	1E-9	2E-5	2E-4
33	Arsenic-76	W, all compounds	1E+3	1E+3	6E-7	2E-9	1E-5	1E-4
33	Arsenic-77	W, all compounds	4E+3 LLI wali	5E+3	2E-6	7E-9	-	-
			(5E+3)	-		-	6E-5	6E-4
33	Arsenic-78 ⁽²⁾	W, all compounds	8E+3	2E+4	9E-6	3E-8	1E-4	1E-3

			Occ	Table 1 upational V	alues	EM	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Oral		Col. 1 Col. 2		Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
34	Selenium-70 ⁽²⁾	D, all compounds except those given for W	2E+4	4E+4	2E-5	5E-8	1E-4	1E-3
		W, oxides, hydroxides, carbides, and elemental Se	1E+4	4E+4	2E-5	6E-8	-	-
34	Selenium-73m ⁽²⁾	D, see ⁷⁰ Se	6E+4	2E+5	6E-5	2E-7	4E-4	4E-3
	İ	W, se [™] Se	3E+4	1E+5	6E-5	2E-7	-	-
34	Selenium-73	D, see ⁷⁰ Se	3E+3	1E+4	5E-6	2E-8	4E-5	4E-4
		W, see ⁷⁰ Se	-	2E+4	7E-6	2E-8	-	-
34	Selenium-75	D, see 70Se	5E+2	7E+2	3E-7	1E-9	7E-6	7E-5
		W, see 70Se	-	6E+2	3E-7	8E-10	-	-
34	Selenium-79	D, see ⁷⁰ Se	6E+2	8E+2	3E-7	1E-9	8E-6	8E-5
		W, see ⁷⁰ Se	-	6E+2	2E-7	8E-10		-
34	Selenium-81m(2)	D, see ⁷⁰ Se	4E+4	7E+4	3E-5	9E-8	3E-4	3E-3
		W, see ™Se	2E+4	7E+4	3E-5	IE-7	-	-
34	Selenium-81 ⁽²⁾	D, see ⁷⁰ Se	6E+4 St. wall	2E+5	9E-5	3E-7	-	-
			(8E+4)	-	-	-	1E-3	1E-2
		W, see ⁷⁰ Se	-	2E+5	1E-4	3E-7	-	-
34	Selenium-83 ⁽²⁾	D, see 70Se	4E+4	1E+5	5E-5	2E-7	4E-4	4E-3
		W, see ™Se	3E+4	1E+5	5E-5	2E-7	-	-
35	Bromine-74m ⁽²⁾	D, bromides of H, Li, Na, K, Rb, Cs, and Fr	lE+4 St. wall	4E+4	2E-5	5E-8	-	-
			(2E+4)	-	-	-	3E-4	3E-3
		W, bromides of lanthanides, Be, Mg, Ca, Sr, Ba, Ra, Al, Ga, In, Tl, Ge, Sn, Pb, As, Sb, Bi, Fe, Ru, Os, Co, Rh, Ir, Ni, Pd, Pt, Cu, Ag, Au, Zn, Cd, Hg, Sc, Y, Ti, Zr, Hf, V, Nb, Ta, Mn, Tc, and Re	-	4E+4	2E-5	6E-8	-	-
35	Bromine-74 ⁽²⁾	D, see ^{74m} Br	2E+4 St. Wall	7E+4	3E-5	1E-7	-	

B-19 NUREG-1736

			Occ	Table 1 upational V	alues	Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
			(4E+4)	-	-	-	5E-4	5E-3
		W, see 74mBr		8E+4	4E-5	lE-7		-
35	Bromine-75 ⁽²⁾	D, see 74mBr	3E+4 St. wall	5E+4	2E-5	7E-8	-	-
			(4E+4)	-	-	-	5E-4	5E-3
		W, see ^{74m} Br	-	5E+4	2E-5	7E-8	-	-
35	Bromine-76	D, see ^{74m} Br	4E+3	5E+3	2E-6	7E-9	5E-5	5E-4
		W, see ^{74m} Br	-	4E+3	2E-6	6E-9	-	-
35	Bromine-77	D, see 74mBr	2E+4	2E+4	1E-5	3E-8	2E-4	2E-3
		W, see ^{?4m} Br	-	2E+4	8E-6	3E-8	-	-
35	Bromine-80m	D, see ⁷⁴ⁿ Br	2E+4	2E+4	7E-6	2E-8	3E-4	3E-3
		W, see ^{?4m} Br	-	1E+4	6E-6	2E-8	-	-
35	Bromine-80 ⁽²⁾	D, see ^{74m} Br	5E+4 St. wall	2E+5	8E-5	3E-7	-	
		:	(9E+4)	-	-	-	IE-3	1E-2
		W, see 74mBr	-	2E+5	9E-5	3E-7	-	-
35	Bromine-82	D, see ^{74m} Br	3E+3	4E+3	2E-6	6E-9	4E-5	4E-4
		W, see 14mBr	-	4E+3	2E-6	5E-9	-	-
35	Bromine-83	D, see ^{74m} Br	5E+4 St. wall	6E+4	3E-5	9E-8	-	w
			(7E+4)	-	-	-	9E-4	9E-3
		W, see ^{74m} Br	-	6E+4	3E-5	9E-8	-	-
35	Bromine-84(2)	D, see ^{74m} Br	2E+4 St. wall	6E+4	2E-5	8E-8	-	-
			(3E+4)	-	-	-	4E-4	4E-3
		W, see ^{74nt} Br	-	6E+4	3E-5	9E-8		-
36	Krypton-74(2)	Submersion ⁽¹⁾	-	-	3E-6	1E-8	-	-
36	Krypton-76	Submersion ⁽¹⁾	-	-	9E-6	4E-8	-	-
36	Krypton-77 ⁽²⁾	Submersion ⁽¹⁾	-		4E-6	2E-8	-	
36	Krypton-79	Submersion ⁽¹⁾	-	-	2E-5	7E-8		-

			Occ	Table 1 upational V	alues	Eff	ole 2 uent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly Average
Atomic			ALI	ALI	DAC	Air	Water	Concentration
No.	Radionuclide	Class Submersion ⁽¹⁾	(μCi)	(μCi)	(μCi/ml) .	(μCi/ml)	(μCi/ml)	(μCi/ml)
36	Krypton-81	Submersion ⁽¹⁾	-	-	7E-4	3E-6	-	-
36	Krypton-83m ⁽²⁾		-	-	1E-2	5E-5	-	-
36	Krypton-85m	Submersion ⁽¹⁾	-	-	2E-5	1E-7	-	-
36	Krypton-85	Submersion ⁽¹⁾	-	-	1E-4	7E-7	-	
36	Krypton-87 ⁽²⁾	Submersion ⁽¹⁾	-	-	5E-6	2E-8	-	-
36	Krypton-88	Submersion ⁽¹⁾	-	•	2E-6	9E-9	-	-
37	Rubidium-79 ⁽²⁾	D, all compounds	4E+4 St. wall	1E+5	5E-5	2E-7	-	-
			(6E+4)	1	-	-	8E-4	8E-3
37	Rubidium-81m ⁽²⁾	D, all compounds	2E+5 St. wall	3E+5	1E-4	5E-7		-
			(3E+5)	-	-	-	4E-3	4E-2
37	Rubidium-81	D, all compounds	4E+4	5E+4	2E-5	7E-8	5E-4	5E-3
37	Rubidium-82m	D, all compounds	1E+4	2E+4	7E-6	2E-8	2E-4	2E-3
37	Rubidium-83	D, all compounds	6E+2	1E+3	4E-7	1E-9	9E-6	9E-5
37	Rubidium-84	D, all compounds	5E+2	8E+2	3E-7	1E-9	7E-6	7E-5
37	Rubidium-86	D, all compounds	5E+2	8E+2	3E-7	1E-9	7E-6	7E-5
37	Rubidium-87	D, all compounds	1E+3	2E+3	6E-7	2E-9	1E-5	1E-4
37	Rubidium-88 ⁽²⁾	D, all compounds	2E+4 St. wall	6E+4	3E-5	9E-8	-	-
			(3E+4)	-	-	-	4E-4	4E-3
37	Rubidium-89 ⁽²⁾	D, all compounds	4E+4 St. wall	1E+5	6E-5	2E-7	-	-
			(6E+4)	-	-	-	9E-4	9E-3
38	Strontium-80 ⁽²⁾	D, all soluble compounds except SrTiO ₃	4 E +3	1E+4	5E-6	2E-8	6E-5	6E-4
		Y, all insoluble compounds and SrTiO ₃	-	1E+4	5E-6	2E-8	-	-

B-21 NUREG-1736

·			Occ	Table 1 upational Va	alues	Effi	ole 2 uent itrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	nuclide Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
38	Strontium-81(2)	D, see ⁸⁰ Sr	3E+4	8E+4	3E-5	1E-7	3E-4	3E-3
		Y, see ⁸⁰ Sr	2E+4	8E+4	3E-5	1E-7	-	-
38	Strontium-82	D, see ⁸⁰ Sr	3E+2 LLI wall	4E+2	2E-7	6E-10	-	-
			(2E+2)	-	-	-	3E-6	3E-5
		Y, see ⁸⁰ Sr	2E+2	9E+1	4E-8	1E-10	-	-
38	Strontium-83	D, see ⁸⁰ Sr	3E+3	7E+3	3E-6	1E-8	3E-5	3E-4
		Y, see ⁸⁰ Sr	2E+3	4E+3	1E-6	5E-9	-	-
38	Strontium-85m ⁽²⁾	D, see ⁸⁰ Sr	2E+5	6E+5	3E-4	9E-7	3E-3	3E-2
		Y, see ⁸⁰ Sr	-	8E+5	4E-4	1E-6	-	-
38	Strontium-85	D, see ***Sr	3E+3	3E+3	1E-6	4E-9	4E-5	4E-4
		Y, see ***Sr		2E+3	6E-7	2E-9		•
38	Strontium-87m	D, see ⁸⁰ Sr	5E+4	1E+5	5E-5	2E-7	6E-4	6E-3
		Y, see ⁸⁰ Sr	4E+4	2E+5	6E-5	2E-7	-	÷
38	Strontium-89	D, see ⁸⁰ Sr	6E+2 LLI wall	8E+2	4E-7	1E-9	-	-
			(6E+2)	-	-		8E-6	8E-5
		Y, see ⁸⁰ Sr	5E+2	1E+2	6E-8	2E-10	-	-
38	Strontium-90	D, see ⁸⁰ Sr	3E+1 Bone Surf	2E+1 Bone Surf	8E-9	-	-	-
			(4E+1)	(2E+1)	-	3E-11	5E-7	5E-6
		Y, see ⁸⁰ Sr	-	4E+0	2E-9	6E-12	-	-
38	Strontium-91	D, see 80Sr	2E+3	6E+3	2E-6	8E-9	2E-5	2E-4
		Y, see *0Sr	-	4E+3	IE-6	5E-9	-	-
38	Strontium-92	D, see ⁸⁰ Sr	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		Y, see ⁸⁰ Sr	-	7E+3	3E-6	9E-9	-	-
39	Yttrium-86m ⁽²⁾	W, all compounds except those given for Y	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
		Y, oxides and hydroxides	-	5E+4	2E-5	8E-8	-	-

			Occ	Table 1 upational V	alues	Eff	ole 2 uent itrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average Concentration (µCi/ml)
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	
39	Yttrium-86	W, see 86mY	1E+3	3E+3	1E-6	5E-9	2E-5	2E-4
		Y, see 86thY	-	3E+3	1E-6	5E-9	-	-
39	Yttrium-87	W, see 86mY	2E+3	3E+3	1E-6	5E-9	3E-5	3E-4
		Y, see 86mY	-	3E+3	1E-6	5E-9	-	-
39	Yttrium-88	W, see 86mY	1E+3	3E+2	1E-7	3E-10	1E-5	1E-4
		Y, see 86mY	-	2E+2	1E-7	3E-10	-	-
39	Yttrium-90m	W, see *6mY	8E+3	1E+4	5E-6	2E-8	1E-4	1E-3
		Y, see *6mY	-	lE+4	5E-6	2E-8	-	-
39	Yttrium-90	W, see 86mY	4E+2 LLI wall	7E+2	3E-7	9E-10	-	-
			(5E+2)	-	-	-	7E-6	7E-5
		Y, see 86mY	-	6E+2	3E-7	9E-10	-	-
39	Yttrium-91m(2)	W, see *forY	1E+5	2E+5	1E-4	3E-7	2E-3	2E-2
		Y, see *6mY	-	2E+5	7E-5	2E-7	-	-
39	Yttrium-91	W, see 86mY	5E+2 LLI wall	2E+2	7E-8	2E-10	-	-
			(6E+2)	-	-	-	8E-6	8E-5
		Y, see 86mY	-	1E+2	5E-8	2E-10	-	-
39	Yttrium-92	W, see 86mY	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		Y, see NamiY	-	8E+3	3E-6	1E-8		-
39	Yttrium-93	W, see 86mY	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4
		Y, see 86miY	-	2E+3	1E-6	3E-9	-	-
39	Yttrium-94 ⁽²⁾	W, see ***Y	2E+4 St. wall	8E+4	3E-5	1E-7	<u>-</u>	-
			(3E+4)	-	-	-	4E-4	4E-3
		Y, see ^{86m} Y	-	8E+4	3E-5	1E-7	_	
39	Yttrium-95 ⁽²⁾	W, see 86mY	4E+4 St. wall	2E+5	6E-5	2E-7	-	-
			(5E+4)	-	-	-	7E-4	7E-3
		Y, see 86mY	-	1E+5	6E-5	2E-7	-	-

			Occ	Table 1 upational Va	alues	Eff	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
40	Zirconium-86	D, all compounds except those given for W and Y	1E+3	4E+3	2E-6	6E-9	2E-5	2E-4
		W, oxides, hydroxides, halides, and nitrates	-	3E+3	1E-6	4E-9	-	
		Y, carbide		2E+3	1E-6	3E-9		-
40	Zirconium-88	D, see 86Zr	4E+3	2E+2	9E-8	3E-10	5E-5	5E-4
		W, see 86Zr	-	5E+2	2E-7	7E-10	-	-
		Y, see 86Zr	-	3E+2	1E-7	4E-10	-	-
40	Zirconium-89	D, see 80Zr	2E+3	4E+3	1E-6	5E-9	2E-5	2E-4
]	W, see *Zr	-	2E+3	1E-6	3E-9	*	-
		Y, see *6Zr	-	2E+3	1E-6	3E-9	-	-
40	Zirconium-93	D, see ⁸⁶ Zr	1E+3 Bone Surf	6E+0 Bone Surf	3E-9	_		-
	-		(3E+3)	(2E+1)	-	2E-11	4E-5	Monthly Average Concentration (μCi/ml) 2E-4 - 5E-4 - 2E-4
		W, see ⁸⁶ Zr	-	2E+1 Bone Surf	1E-8	-	-	-
			-	(6E+1)	-	9E-11		-
		Y, see ⁸⁶ Zr	-	6E+1 Bone Surf	2E-8	-	-	_
			-	(7E+1)	-	9E-11	-	
40	Zirconium-95	D, see ⁸⁶ Zr	1E+3	1E+2 Bone Surf	5E-8	-	2E-5	2E-4
			-	(3E+2)	-	4E-10	,	-
		W, see NoZr	-	4E+2	2E-7	5E-10		-
		Y, see 86Zr	-	3E+2	1E-7	4E-10	•	
40	Zirconium-97	D, see *6Zr	6E+2	2E+3	8E-7	3E-9	9E-6	9 E -5
		W, see ⁸⁶ Zr	-	1E+3	6E-7	2E-9	-	-
		Y, see 86Zr	-	1E+3	5E-7	2E-9	-	
41	Niobium-88 ⁽²⁾	W, all compounds except those given for Y	5E+4 St. wall	2E+5	9E-5	3E-7	-	-
			(7E+4)	-	-	-	1E-3	1E-2

			Occ	Table 1 upational V	alues	Effi	ole 2 vent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	Inhalation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (μCi/ml)	Releases to Sewers Monthly
		Y, oxides and hydroxides	-	2E+5	9E-5	3E-7	-	
41	Niobium-89m²	W, see 88Nb	1E+4	4E+4	2E-5	6E-8	1E-4	1E-3
	(66min)	Y, see ⁸⁸ Nb	-	4E+4	2E-5	5E-8	-	-
41	Niobium-89	W, see ⁸⁸ Nb	5E+3	2E+4	8E-6	3E-8	7E-5	7E-4
	(122min)	Y, see 88Nb	-	2E+4	6E-6	2E-8	-	-
41	Niobium-90	W, see 88Nb	1E+3	3E+3	1E-6	4E-9	1E-5	1E-4
		Y, see 88Nb		2E+3	1E-6	3E-9	-	-
41	Niobium-93m	W, see ⁸⁸ Nb	9E+3 LLI wall	2E+3	8E-7	3E-9	-	-
			(1E+4)	-	-	-	2É-4	2E-3
		Y, see 88Nb	-	2E+2	7E-8	2E-10	-	-
41	Niobium-94	W, see ⁸⁸ Nb	9E+2	2E+2	8E-8	3E-10	1E-5	1E-4
		Y, see ⁸⁸ Nb	-	2E+1	6E-9	2E-11	-	-
41	Niobium-95m	W, see *8Nb	2E+3 LLI wall	3E+3	1E-6	4E-9	•	-
			(2E+3)	-	-	-	3E-5	3E-4
		Y, see **Nb	-	2E+3	9E-7	3E-9	•	
41	Niobium-95	W, see 88Nb	2E+3	1E+3	5E-7	2E-9	3E-5	3E-4
		Y, see ⁸⁸ Nb	-	1E+3	5E-7	2E-9	-	
41	Niobium-96	W, see [™] Nb	1E+3	3E+3	1E-6	4E-9	2E-5	2E-4
		Y, see **Nb	-	2E+3	1E-6	3E-9	-	-
41	Niobium-97 ⁽²⁾	W, see 88Nb	2E+4	8E+4	3E-5	1E-7	3E-4	3E-3
		Y, see 88Nb	-	7E+4	3E-5	1E-7		-
41	Niobium-98 ⁽²⁾	W, see **Nb	1E+4	5E+4	2E-5	8E-8	2E-4	2E-3
		Y, see **Nb	-	5E+4	2E-5	7E-8	-	-
42	Molybdenum-90	D, all compounds except those given for Y	4E+3	7E+3	3E-6	1E-8	3E-5	3E-4
		Y, oxides, hydroxides, and MoS ₂	2E+3	5E+3	2E-6	6E-9		-
42	Molybdenum-	D, see ⁵⁰ Mo	9E+3	2E+4	7E-6	2E-8	6E-5	6E-4

B-25 NUREG-1736

			Occ	Table 1 Occupational Values			ble 2 luent itrations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2			Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
		Y, see ⁹⁰ Mo	4E+3	1E+4	6E-6	2E-8	-	
42	Molybdenum-93	D, see 90Mo	4E+3	5E+3	2E-6	8E-9	5E-5	5E-4
		Y, see ⁹⁰ Mo	2E+4	2E+2	8E-8	2E-10	-	-
42	Molybdenum-99	D, see ⁹⁰ Mo	2E+3 LLI wall	3E+3	1E-6	4E-9	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see ⁹⁰ Mo	1E+3	1E+3	6E-7	2E-9	-	-
42	Molybdenum- 101 ⁽²⁾	D, see ⁹⁰ Mo	4E+4 St. wall	1E+5	6E-5	2E-7	_	-
			(5E+4)	-	-	-	7E-4	7E-3
		Y, see ⁹⁰ Mo	-	1E+5	6E-5	2E-7	-	-
43	Technetium- 93m ⁽²⁾	D, all compounds except those given for W	7E+4	2E+5	6E-5	2E-7	1E-3	1E-2
		W, oxides, hydroxides, halides, and nitrates	-	3E+5	1E-4	4E-7	-	-
43	Technetium-93	D, see ^{93m} Tc	3E+4	7E+4	3E-5	1E-7	4E-4	4E-3
		W, see 93mTc	-	1E+5	4E-5	1E-7	-	-
43	Technetium- 94m ⁽²⁾	D, see ^{93m} Tc	2E+4	4E+4	2E-5	6E-8	3E-4	3E-3
		W, see 43mTc	-	6E+4	2E-5	8E-8	-	
43	Technetium-94	D, see ⁹³ mTc	9E+3	2E+4	8E-6	3E-8	1E-4	1E-3
		W, see ^{93m} Tc	-	2E+4	1E-5	3E-8	-	-
43	Technetium-95m	D, see ^{93m} Tc	4E+3	5E+3	2E-6	8E-9	5E-5	5E-4
		W, see 93nrTc	-	2E+3	8E-7	3E-9	-	-
43	Technetium-95	D, see 93mTc	1E+4	2E+4	9E-6	3E-8	1E-4	1E-3
		W, see 93mTc	-	2E+4	8E-6	3E-8	-	
43	Technetium- 96m ⁽²⁾	D, see ^{93m} Tc	2E+5	3E+5	1E-4	4E-7	2E-3	2E-2
		W, see 93mTc	-	2E+5	1E-4	3E-7	-	-
43	Technetium-96	D, see 93mTc	2E+3	3E+3	1E-6	5E-9	3E-5	3E-4
		W, see 93mTc	-	2E+3	9E-7	3E-9	-	-
43	Technetium-97m	D, see ^{93m} Tc	5E+3	7E+3 St. wali	3E-6	-	6E-5	6E-4

NUREG-1736

			Occ	Table 1 cupational V	alues	Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly
Atomic			ALI	ALI	DAC	Air	Water	Average Concentration
No.	Radionuclide	Class	(μCi)	(μCi)	(μCi/ml)	(μCi/ml)	(μCi/ml)	(µCi/ml)
		(1)		(7E+3)	-	1E-8	-	<u>.</u>
		W, see 93mTc	-	1E+3	5E-7	2E-9	-	-
43	Technetium-97	D, see ^{93m} Tc	4E+4	5E+4	2E-5	7E-8	5E-4	5E-3
		W, see ^{93m} Tc	-	6E+3	2E-6	8E-9	-	-
43	Technetium-98	D, see 93m Tc	1E+3	2E+3	7E-7	2E-9	1E-5	1E-4
		W, see ^{93m} Tc	-	3E+2	1E-7	4E-10	-	-
43	Technetium-99m	D, see ^{93m} Tc	8E+4	2E+5	6E-5	2E-7	1 E -3	1E-2
		W, see 93nrTc	-	2E+5	1E-4	3E-7	-	-
43	Technetium-99	D, see ^{93m} Tc	4E+3	5E+3 St. wall	2E-6	-	6E-5	6E-4
			-	(6E+3)	-	8E-9	-	-
		W, see ^{93m} Tc	-	7E+2	3E-7	9E-10	-	-
43	Technetium- 101 ⁽²⁾	D, see 93mTc	9E+4 St. wall	3E+5	1E-4	5E-7	-	-
			(1E+5)	-	-		2E-3	2E-2
		W, see 93mTc		4E+5	2E-4	5E-7	-	-
43	Technetium- 104 ⁽²⁾	D, see 93mTc	2E+4 St. wall	7E+4	3E-5	1E-7	-	-
			(3E+4)	-	-		4E-4	4E-3
		W, see 930 Tc	-	9E+4	4E-5	1E-7	-	
44	Ruthenium-94 ⁽²⁾	D, all compounds except those given for W and Y	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, halides	-	6E+4	3E-5	9E-8	-	-
		Y, oxides and hydroxides	-	6E+4	2E-5	8E-8	-	-
44	Ruthenium-97	D, see 94Ru	8E+3	2E+4	8E-6	3E-8	1E-4	1E-3
		W, see 94Ru	-	1E+4	5E-6	2E-8	-	-
		Y, see 44Ru		1E+4	5E-6	2E-8	-	-
44	Ruthenium-103	D, see 94Ru	2E+3	2E+3	7E-7	2E-9	3E-5	3E-4
		W, see 94Ru	-	1E+3	4E-7	1E-9	-	
ŀ	j	Y, see 94Ru	-	6E+2	3E-7	9E-10	-	-

B-27 NUREG-1736

			Table 1 Occupational Values			Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
	Radionuclide		Oral Ingestion	Inhalation				Monthly Average
Atomic No.		Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
44	Ruthenium-105	D, see 94Ru	5E+3	1E+4	6E-6	2E-8	7E-5	7E-4
		W, see ⁹⁴ Ru	-	1E+4	6E-6	2E-8	-	
		Y, see 94Ru	-	1E+4	5E-6	2E-8	-	-
44	Ruthenium-106	D, see ⁹⁴ Ru	2E+2 LLI wall	9E+1	4E-8	1E-10	-	-
			(2E+2)		-	-	3E-6	3E-5
		W, see 94Ru	-	5E+1	2E-8	8E-11	-	-
		Y, see ⁹⁴ Ru	-	1E+1	5E-9	2E-11	-	-
45	Rhodium-99m	D, all compounds except those given for W and Y	2E+4	6E+4	2E-5	8E-8	2E-4	2E-3
		W, halides	-	8E+4	3E-5	1E-7	-	-
		Y, oxides and hydroxides	-	7E+4	3E-5	9E-8	-	-
45	Rhodium-99	D, see ^{99m} Rh	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4
		W, see 99mRh	-	2E+3	9E-7	3E-9	-	-
		Y, see 99mRh	-	2E+3	8E-7	3E-9	-	-
45	Rhodium-100	D, see ^{99m} Rh	2E+3	5E+3	2E-6	7E-9	2E-5	2E-4
		W, see 99mRh	-	4E+3	2E-6	6E-9	-	-
		Y, see 94mRh	-	4E+3	2E-6	5E-9	-	-
45	Rhodium-101m	D, see 99mRh	6E+3	1E+4	5E-6	2E-8	8E-5	8E-4
		W, see 99mRh	-	8E+3	4E-6	1E-8	-	-
		Y, see 99mRh	-	8E+3	3E-6	1E-8	-	-
45	Rhodium-101	D, see 99mRh	2E+3	5E+2	2E-7	7E-10	3E-5	3E-4
		W, see 99mRh	-	8E+2	3E-7	1E-9	-	-
		Y, see 49mRh	-	2E+2	6E-8	2E-10	-	-
45	Rhodium-102m	D, see ^{99m} Rh	1E+3 LLI wall	5E+2	2E-7	7E-10	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		W, see 99mRh	-	4E+2	2E-7	5E-10	-	-
		Y, see 99mRh	-	1E+2	5E-8	2E-10	-	-
45	Rhodium-102	D, see 99mRh	6E+2	9E+1	4E-8	1E-10	8E-6	8E-5

			Table 1 Occupational Values		dues	Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
		W, see 99mRh	-	2E+2	7E-8	2E-10	-	-
		Y, see ^{99m} Rh	-	6E+1	2E-8	8E-11	-	-
45	Rhodium-103m ⁽²⁾	D, see 99mRh	4E+5	1E+6	5E-4	2E-6	6E-3	6E-2
		W, see 99mRh	-	1E+6	5E-4	2E-6	-	-
		Y, see ^{99m} Rh	-	1E+6	5E-4	2E-6	-	-
45	Rhodium-105	D, see ^{99m} Rh	4E+3 LLI wall	1E+4	5E-6	2E-8	-	-
			(4E+3)	-	-	-	5E-5	5E-4
		W, see 99mRh	-	6E+3	3E-6	9E-9	-	-
		Y, see 99mRh	-	6E+3	2E-6	8E-9		-
45	Rhodium-106m	D, see 99mRh	8E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		W, see ^{99m} Rh	-	4E+4	2E-5	5E-8	-	-
		Y, see 99mRh	-	4E+4	1E-5	5E-8	-	-
45	Rhodium-107 ⁽²⁾	D, see ^{99m} Rh	7E+4 St. wall	2E+5	1E-4	3E-7	-	-
			(9E+4)	-	-	-	1E-3	1E-2
		W, see ^{99m} Rh	-	3E+5	1E-4	4E-7	-	-
		Y, see 99mRh	-	3E+5	1E-4	3E-7	<u> </u>	-
46	Palladium-100	D, all compounds except those given for W and Y	1E+3	1E+3	6E-7	2E-9	2E-5	2E-4
		W, nitrates	-	1E+3	5E-7	2E-9		-
		Y, oxides and hydroxides	-	1E+3	6E-7	2E-9	-	-
46	Palladium-101	D, see 100Pd	1E+4	3E+4	1E-5	5E-8	2E-4	2E-3
		W, see 100Pd	-	3E+4	1E-5	5E-8	-	-
		Y, see 100Pd	-	3E+4	1E-5	4E-8	-	-
46	Palladium-103	D, see ¹⁰⁰ Pd	6E+3 LLI wall	6E+3	3E-6	9E-9	-	-
			(7E+3)	-	-	-	1E-4	1E-3
		W, see 100Pd	-	4E+3	2E-6	6E-9	-	-
		Y, see 100Pd	-	4E+3	1E-6	5E-9	-	-

Atomic	Radionuclide		Occ	Table 1 cupational V	'alues Col. 3	Table 2 Effluent Concentrations Col. 1 Col. 2		Table 3 Releases to Sewers Monthly Average
			Oral Ingestion	Inhalation		Con. 1	Col. 2	
No.		Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
46	Palladium-107	D, see ¹⁰⁰ Pd	3E+4 LLI wall	2E+4 Kidneys	9E-6	-	-	-
			(4E+4)	(2E+4)	-	3E-8	5E-4	5E-3
		W, see ¹⁰⁰ Pd	-	7E+3	3E-6	iE-8	-	-
		Y, see ¹⁰⁰ Pd	-	4E+2	2E-7	6E-10	-	-
46	Palladium-109	D, see 100Pd	2E+3	6E+3	3E-6	9E-6	3E-5	3E-4
		W, see 100Pd	-	5E+3	2E-6	8E-9	-	-
		Y, see ¹⁰⁰ Pd	-	5E+3	2E-6	6E-9	-	-
47	Silver-102 ⁽²⁾	D, all compounds except those given for W and Y	5E+4 St. wall	2E+5	8E-5	2E-7	-	-
			(6E+4)	-	-	-	9E-4	9E-3
		W, nitrates and sulfides	-	2E+5	9E-5	3E-7	-	-
		Y, oxides and hydroxides	-	2E+5	8E-5	3E-7	-	-
47	Silver-103 ⁽²⁾	D, see 102Ag	4E+4	1E+5	4E-5	1E-7	5E-4	5E-3
		W, see 102Ag	-	1E+5	5E-5	2E-7	-	-
		Y, see 102Ag	-	1E+5	5E-5	2E-7	-	-
47	Silver-104m ⁽²⁾	D, see 102Ag	3E+4	9E+4	4E-5	1E-7	4E-4	4E-3
		W, see 102Ag	-	1E+5	5E-5	2E-7	-	-
		Y, see 102Ag	-	1E+5	5E-5	2E-7	-	-
47	Silver-104(2)	D, see ¹⁰² Ag	2E+4	7E+4	3E-5	1E-7	3E-4	3E-3
		W, see 102Ag	-	1E+5	6E-5	2E-7	-	-
		Y, see 102Ag	-	1E+5	6E-5	2E-7	-	-
47	Silver-105	D, see 103Ag	3E+3	IE+3	4E-7	1E-9	4E-5	4E-4
		W, see 102Ag	- 1	2E+3	7E-7	2E-9	-	
		Y, see 102Ag	-	2E+3	7E-7	2E-9	-	-
47	Silver-106m	D, see 102 Ag	8E+2	7E+2	3E-7	1E-9	1E-5	1E-4
		W, see 102Ag	-	9E+2	4E-7	1E-9	-	-
		Y, see 102Ag	-	9E+2	4E-7	1E-9	-	-
47	Silver-106 ⁽²⁾	D, see ¹⁰² Ag	6E+4 St. wall	2E+5	8E-5	3E-7	-	-

B-30

NUREG-1736

				Table 1 upational Va		Effl Concen	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average Concentration (μCi/ml)
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	
·			(6E+4)	-	-	-	9E-4	9E-3
		W, see 102Ag	-	2E+5	9E-5	3E-7		
		Y, see 102 Ag	-	2E+5	8E-5	3E-7	-	-
47	Silver-108m	D, see 102Ag	6E+2	2E+2	8E-8	3E-10	9E-6	9E-5
		W, see 102Ag	-	3E+2	1E-7	4E-10	-	-
		Y, see ¹⁰² Ag	-	2E+1	1E-8	3E-11	-	-
47	Silver-110m	D, see 102Ag	5E+2	1E+2	5E-8	2E-10	6E-6	6E-5
		W, see 102Ag	-	2E+2	8E-8	3E-10	-	-
		Y, see 102Ag	-	9E+1	4E-8	1E-10	-	-
47	Silver-111	D, see ¹⁰² Ag	9E+2 LLI wail	2E+3 Liver	6E-7	-	-	-
			(1E+3)	(2E+3)	-	2E-9	2E-5	2E-4
		W, see 102Ag	-	9E+2	4E-7	1E-9	-	- '
		Y, see 102Ag	-	9E+2	4E-7	1E-9	-	-
47	Silver-112	D, see 102Ag	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4
		W, see 102Ag	-	1E+4	4E-6	1E-8	-	-
		Y, see 102Ag	-	9E+3	4E-6	1E-8	-	-
47	Silver-115 ⁽²⁾	D, see ¹⁰² Ag	3E+4 St. wall	9E+4	4E-5	1E-7	-	-
			(3E+4)	-	-	-	4E-4	4E-3
		W, see 102Ag	-	9E+4	4E-5	1E-7	-	-
		Y, see ¹⁰² Ag	-	8E+4	3E-5	1E-7	-	-
48	Cadmium-104 ⁽²⁾	D, all compounds except those given for W and Y	2E+4	7E+4	3E-5	9E-8	3E-4	3E-3
		W, sulfides, halides, and nitrates	-	1E+5	5E-5	2E-7	-	-
		Y, oxides and hydroxides	-	1E+5	5E-5	2E-7	-	-
48	Cadmium-107	D, see ¹⁰⁴ Cd	2E+4	5 E +4	2E-5	8E-8	3E-4	3E-3
		W, see 104Cd		6E+4	2E-5	8E-8	-	-
		Y, see 104Cd	-	5E+4	2E-5	7E-8	-	-

NUREG-1736

			Occ	Table 1 cupational V	alues	Table 2 Effluent Concentrations		Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Water (µCi/ml)	
			Oral Ingestion	Inha	lation			Monthly
Atomic No. Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)			
48	Cadmium-109	D, see ¹⁰⁴ Cd	3E+2 Kidneys	4E+1 Kidneys	1E-8	-	-	-
			(4E+2)	(5E+1)	-	7E-11	6E-6	6E-5
		W, see ¹⁰⁴ Cd	-	1E+2 Kidneys	5E-8	-	-	•
			-	(1E+2)	-	2E-10	-	-
		Y, see 104Cd	-	1E+2	5E-8	2E-10	-	
48	Cadmium-113m	D, see ¹⁰⁴ Cd	2E+1 Kidneys	2E+0 Kidneys	1E-9	-	-	-
			(4E+1)	(4E+0)	-	5E-12	5E-7	5E-6
		W, see ¹⁰⁴ Cd	-	8E+0 Kidneys	4E-9	-	-	Monthly Average Concentration (μCi/ml) 6E-5
			-	(1E+1)	-	2E-11	-	-
		Y, see 104Cd	-	1E+1	5E-9	2E-11	-	-

			Occ	Table 1 upational Va		Effl Concen	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	
48	Cadmium-113	D, see ¹⁰⁴ Cd	2E+1 Kidneys	2E+0 Kidneys	9E-10	-	-	-
			(3E+1)	(3E+0)	-	5E-12	4E-7	4E-6
		W, see ¹⁰⁴ Cd	-	8E+0 Kidneys	3E-9	-	-	-
			-	(1E+1)	-	2E-11	•	-
		Y, see 104Cd	-	1E+1	6E-9	2E-11	-	-
48	Cadmium-115m	D, see ¹⁰⁴ Cd	3E+2	5E+1 Kidneys	2E-8	-	4E-6	4E-5
			-	(8E+1)	-	1E-10	-	Monthly Average Concentration (μCi/ml) - 4E-6 - 4E-5 - 1E-4 - 6E-4 - 3E-3
		W, see ¹⁰⁴ Cd	-	1E+2	5E-8	2E-10	-	-
		Y, see 104Cd	-	1E+2	6E-8	2E-10	-	-
48	Cadmium-115	D, see ¹⁰⁴ Cd	9E+2 LLI wall	1E+3	6E-7	2E-9	-	-
			(1E+3)	-	-	-	1E-5	1E-4
		W, see 104Cd	-	1E+3	5E-7	2E-9	-	-
		Y, see 104Cd	-	1E+3	6E-7	2E-9	-	-
48	Cadmium-117m	D, see ¹⁰⁴ Cd	5E+3	1E+4	5E-6	2E-8	6E-5	6E-4
		W, see 104Cd	-	2E+4	7E-6	2E-8	-	-
		Y, see ¹⁰⁴ Cd	-	1E+4	6E-6	2E-8		-
48	Cadmium-117	D, see 104Cd	5E+3	1E+4	5E-6	2E-8	6E-5	6E-4
		W, see 104Cd	-	2E+4	7E-6	2E-8	-	-
		Y, see 104Cd	-	IE+4	6E-6	2E-8		-
49	Indium-109	D, all compounds except those given for W	2E+4	4E+4	2E-5	6E-8	3E-4	3E-3
		W, oxides, hydroxides, halides, and nitrates	-	6E+4	3E-5	9E-8	-	-
49	Indium-110 ⁽²⁾	D, see 109In	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
	(69.1min)	W, see 109In	-	6E+4	2E-5	8E-8	-	-
49	Indium-110	D, see 109In	5E+3	2E+4	7E-6	2E-8	7E-5	7E-4
	(4.9h)	W, see 109In	-	2E+4	8E-6	3E-8	-	_

B-33 NUREG-1736

			Occ	Table 1 cupational V	'alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
49	Indium-111	D, see 109In	4E+3	6E+3	3E-6	9E-9	6E-5	6E-4
		W, see 109In	-	6E+3	3E-6	9E-9	-	-
49	Indium-112(2)	D, see ¹⁰⁹ In	2E+5	6E+5	3E-4	9E-7	2E-3	2E-2
		W, see 109In		7E+5	3E-4	1E-6	-	-
49	Indium-113m ⁽²⁾	D, see 109In	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3
		W, see 109In	-	2E+5	8E-5	3E-7	-	-
49	Indium-114m	D, see ¹⁰⁹ In	3E+2 LLI wall	6E+1	3E-8	9E-11	-	-
			(4E+2)	-	-	-	5E-6	5E-5
		W, see ¹⁰⁹ In	-	1E+2	4E-8	1E-10	-	-
49	Indium-115m	D, see 109In	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see 109In	-	5E+4	2E-5	7E-8	-	
49	Indium-115	D, see 109In	4E+1	1E+0	6E-10	2E-12	5E-7	5E-6
		W, see 109In	-	5E+0	2E-9	8E-12	-	-
49	Indium-116m ⁽²⁾	D, see 109In	2E+4	8E+4	3E-5	IE-7	3E-4	3E-3
		W, see 109In	-	1E-5	5E-5	2E-7	-	-
49	Indium-117m ⁽²⁾	D, see 109In	1E+4	3E+4	1E-5	5E-8	2E-4	2E-3
		W, see 109In	-]	4E+4	2E-5	6E-8	-	=
49	Indium-117 ⁽²⁾	D, see 109In	6E+4	2E+5	7E-5	2E-7	8E-4	8E-3
		W, see 109In	-	2E+5	9E-5	3E-7	-	-
49	Indium-119m ⁽²⁾	D, see ¹⁰⁹ In	4E+4 St. wall	1E+5	5E-5	2E-7	-	-
			(5E+4)		-	-	7E-4	7E-3
		W, see 109In	-	1E+5	6E-5	2E-7	-	-
50	Tin-110	D, all compounds except those given for W	4E+3	1E+4	5E-6	2E-8	5E-5	5E-4
		W, sulfides, oxides, hydroxides, halides, nitrates, and stannic phosphate	-	1E+4	5E-6	2E-8	-	-

<u> </u>			Occ	Table 1 upational Va	lues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
50	Tin-111(2)	D, see 110Sn	7E+4	2E+5	9E-5	3E-7	1E-3	1 E -2
		W, see 110Sn	-	3E+5	1E-4	4E-7	-	-
50	Tin-113	D, see 110Sn	2E+3 LLI wall	1E+3	5E-7	2E-9	-	-
		(2E+3)	-	-	<u> </u>	3E-5	3E-4	
		W, see 110Sn	-	5E+2	2E-7	8E-10	-	-
50	Tin-117m	D, see 110Sn	2E+3 LLI wall	1E+3 Bone Surf	5E-7	-	-	-
			(2E+3)	(2E+3)	-	3E-9	3E-5	3E-4
	1	W, see 110Sn	-	1E+3	6E-7	2E-9	-	-
50	Tin-119m	D, see 110Sn	3E+3 LLI wall	2E+3	1E-6	3E-9	-	-
			(4E+3)	-	-		6E-5	6E-4
		W, see 110Sn	-	1E+3	4E-7	1E-9	-	
50	Tin-121m	D, see 110Sn	3E+3 LLI wall	9E+2	4E-7	1E-9	-	-
			(4E+3)	-		-	5E-5	5E-4
		W, see 110Sn	-	5E+2	2E-7	8E-10	-	-
58	Т121	D, յու i Թնո	6lī i i LLI wall	?F ≛ 4	ńF⊪ń	2E-8	-	-
			(6E+3)	-	-	-	8E-5	8E-4
		W, see 110Sn	-	1E+4	5E-6	2E-8		-
50	Tin-123m(2)	D, see 110Sn	5E+4	1E+5	5E-5	2E-7	7E-4	7E-3
		W, see ¹¹⁰ Sn	-	1E+5	6E-5	2E-7	-	
50	Tin-123	D, see ¹¹⁰ Sn	5E+2 LLI wall	6E+2	3E-7	9E-10	-	-
			(6E+2)	-	-	-	9E-6	9E-5
		W, see 110Sn	-	2E+2	7E-8	2E-10		-

B-35 NUREG-1736

_				Table 1 cupational V		Eff Conce	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
50	Tin-125	D, see ¹¹⁰ Sn	4E+2 LLI wall	9E+2	4E-7	1E-9	-	-
			(5E+2)	-	-	-	6E-6	6E-5
		W, see 110Sn	-	4E+2	1E-7	5E-10		-
50	Tin-126	D, see 110Sn	3E+2	6E+1	2E-8	8E-11	4E-6	4E-5
		W, see 110Sn	-	7E+1	3E-8	9E-11	-	-
50	Tin-127	D, see 110Sn	7E+3	2E+4	8E-6	3E-8	9E-5	9E-4
		W, see 110Sn	-	2E+4	8E-6	3E-8	-	-
50	Tin-128 ⁽²⁾	D, see 110Sn	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		W, see 110Sn	-	4E+4	1E-5	5E-8	-	-
51	Antimony-115 ⁽²⁾	D, all compounds except those given for W	8E+4	2E+5	1E-4	3E-7	1E-3	1E-2
		W, oxides, hydroxides, halides, sulfides, sulfates, and nitrates	-	3E+5	1E-4	4E-7	-	-
51	Antimony-	D, see 115Sb	2E+4	7E+4	3E-5	1E-7	3E-4	3E-3
	116m ⁽²⁾	W, see 115Sb	-	1E+5	6E-5	2E-7	-	-
51	Antimony-116 ⁽²⁾	D, see ¹¹⁵ Sb	7E+4 St. wall	3E+5	1E-4	4E-7	-	
			(9E+4)	-	-	-	1E-3	1E-2
		W, see 115Sb	-	3E+5	1E-4	5E-7	-	
51	Antimony-117	D, see 115Sb	7E+4	2E+5	9E-5	3E-7	9E-4	9E-3
		W, see 115Sb	-	3E+5	1E-4	4E-7	-	-
51	Antimony-118m	D, see 115Sb	6E+3	2E+4	8E-6	3E-8	7E-5	7E-4
		W, see 115Sb	5E+3	2E+4	9E-6	3E-8	-	-
51	Antimony-119	D, see 115Sb	2E+4	5E+4	2E-5	6E-8	2E-4	2E-3
		W, see 115Sb	2E+4	3E+4	1E-5	4E-8	-	
51	Antimony-120 (16min)	D, see 115Sb	1E+5 St. wall	4E+5	2E-4	6E-7	-	-
			(2E+5)	-	-	-	2E-3	2E-2
		W, see 115Sb	-	5E+5	2E-4	7E-7	-	-

			Occ	Table 1 upational V	alues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic		Clare	Ingestion ALI	ALI	DAC	Air (μCi/ml)	Water	Average Concentration (µCi/ml)
No.	Radionuclide	Class D, see 115Sb	(μCi)	(μ Ci) 2E+3	(μ Ci/ml) 9 E -7	3E-9	(μ Ci/ml) 1E-5	1E-4
51	Antimony-120 (5.76 d)	W, see 115Sb	9E+2	1E+3	5E-7	2E-9	-	112-4
51	Antimony-122	D, see 115Sb	8E+2 LLI wall	2E+3	1E-6	3E-9	-	-
			(8E+2)	-	-	-	1E-5	1E-4
		W, see 115Sb	7E+2	1E+3	4E-7	2E-9	-	-
51	Antimony-	D, see 115Sb	3E+5	8E+5	4E-4	1E-6	3E-3	3E-2
	124m ⁽²⁾	W, see 115Sb	2E+5	6E+5	2E-4	8E-7	-	-
51	Antimony-124	D, see 115Sb	6E+2	9E+2	4E-7	1E-9	7E-6	7E-5
		W, see 115Sb	5E+2	2E+2	1E-7	3E-10	-	-
51	Antimony-125	D, see 115Sb	2E+3	2E+3	1E-6	3E-9	3E-5	3E-4
		W, see 115Sb	-	5E+2	2E-7	7E-10	-	-
51	Antimony- 126m ⁽²⁾	D, see 115Sb	5E+4 St. wall	2E+5	8E-5	3E-7	-	-
			(7E+4)	-	-	-	9E-4	9E-3
		W, see 115Sb	-	2E+5	8E-5	3E-7	-	•
51	Antimony-126	D, see 115Sb	6E+2	1E+3	5E-7	2E-9	7E-6	7E-5
		W, see 115Sb	5E+2	5E+2	2E-7	7E-10	-	
51	Antimony-127	D, see 115Sb	8E+2 LLI wall	2E+3	9E-7	3E-9	-	-
			(8E+2)	-	-	-	1E-5	1E-4
		W, see 115Sb	7E+2	9E+2	4E-7	1E-9	-	-
51	Antimony-128 ⁽²⁾ (10.4min)	D, see 115Sb	8E+4 St. wall	4E+5	2E-4	5E-7	-	-
			(1E+5)	-	-	-	1E-3	1E-2
		W, see 115Sb	-	4E+5	2E-4	6E-7	-	-
51	Antimony-128	D, see 115Sb	1E+3	4E+3	2E-6	6E-9	2E-5	2E-4
	(9.01h)	W, see 115Sb	-	3E+3	IE-6	5E-9	-	-
51	Antimony-129	D, see 115Sb	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		W, see 115Sb	-	9E+3	4E-6	1E-8	-	

B-37 NUREG-1736

			Oc	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
Atomic			Oral Ingestion		Inhalation			Monthly Average
No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
51	Antimony-130(2)	D, see 115Sb	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		W, see 115Sb	-	8E+4	3E-5	1E-7	-	-
51	Antimony-131 ⁽²⁾	D, see 115Sb	1E+4 Thyroid	2E+4 Thyroid	1E-5	-		-
			(2E+4)	(4E+4)	-	6E-8	2E-4	Releases to Sewers 1. 2 Monthly Average Concentration (\(\(\mu\)Ci/ml) -4 3E-3
		W, see 115Sb	-	2E+4 Thyroid	1E-5	-	-	
			-	(4E+4)	-	6E-8	-	-
52	Tetlurium-116	D, all compounds except those given for W	8E+3	2E+4	9E-6	3E-8	1E-4	1E-3
		W, oxides, hydroxides, and nitrates	-	3E+4	1E-5	4E-8	-	-
52	Tellurium-121m	D, see ¹¹⁶ Te	5E+2 Bone Surf	2E+2 Bone Surf	8E-8	-	-	-
			(7E+2)	(4E+2)	-	5E-10	1E-5	1E-4
		W, see 116Te	-	4E+2	2E-7	6E-10	-	-
52	Tellurium-121	D, see 116Te	3E+3	4E+3	2E-6	6E-9	4E-5	4E-4
		W, see 116Te	-	3E+3	1E-6	4E-9	-	-
52	Tellurium-123m	D, see ¹¹⁶ Te	6E+2 Bone Surf	2E+2 Bone Surf	9E-8	-	-	-
			(1E+3)	(5E+2)	-	8E-10	1E-5	1E-4
		W, see 116Te	-	5E+2	2E-7	8E-10	-	-
52	Tellurium-123	D, see 116Te	5E+2 Bone Surf	2E+2 Bone Surf	8E-8	-	-	-
			(1E+3)	(5E+2)	-	7E-10	2E-5	2E-4
		W, see 116Te	-	4E+2 Bone Surf	2E-7	-	-	-
			-	(1E+3)	-	2E-9	-	-

NUREG-1736

			Occ	Table 1 upational Va	lues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
52	Tellurium-125m	D, see ¹¹⁶ Te	1E+3 Bone Surf	4E+2 Bone Surf	2E-7	-	•	-
			(1E+3)	(1E+3)	-	1E-9	2E-5	2E-4
		W, see 116Te	-	7E+2	3E-7	1E-9	-	-
52	Tellurium-127m	D, see 116Te	6E+2	3E+2 Bone Surf	1E-7	-	9E-6	9E-5
			-	(4E+2)		6E-10	-	-
	1	W, see 116Te	-	3E+2	1 E -7	4E-10	-	-
52	Tellurium-127	D, see 116Te	7E+3	2E+4	9E-6	3E-8	1E-4	1E-3
		W, see 116Te	-	2E+4	7E-6	2E-8	-	-
52	Tellurium-129m	D, see 116Te	5E+2	6E+2	3E-7	9E-10	7E-6	7E-5
		W, see 116Te	-	2E+2	1E-7	3E-10	-	-
52	Tellurium-129(2)	D, see "6Te	3E+4	6E+4	3E-5	9E-8	4E-4	4E-3
		W, see 116Te	-	7E+4	3E-5	1E-7	-	-
52	Tellurium-131m	D, see 116Te	3E+2 Thyroid	4E+2 Thyroid	2E-7	-	-	-
			(6E+2)	(1E+3)	-	2E-9	8E-6	8E-5
		W, see 116Te	-	4E+2 Thyroid	2E-7	-	-	-
				(9E+2)	-	1E-9	-	-
52	Tellurium-131 ⁽²⁾	D, see ¹¹⁶ Te	3E+3 Thyroid	5E+3 Thyroid	2E-6	-		-
			(6E+3)	(1E+4)	-	2E-8	8E-5	Monthly Average Concentration (μCi/ml)
		W, see 116Te	_	5E+3 Thyroid	2E-6	-	-	-
			-	(1E+4)	-	2E-8	-	-
52	Tellurium-132	D, see 116Te	2E+2 Thyroid	2E+2 Thyroid	9E-8	-	-	-
			(7E+2)	(8E+2)	-	1E-9	9E-6	9E-5
		W, see ¹¹⁶ Te	-	2E+2 Thyroid	9E-8	-	-	
			-	(6E+2)	-	9E-10	-	

B-39 NUREG-1736

			Oc	Table 1 cupational V	/alues	En	ble 2 luent ntrations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 9E-4 - 4E-3 - 3E-3 - 2E-3
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	
			Ingestion	Inh	alation			
Atomic No.	Radionuclide		ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration
52	Tellurium- 133m ⁽²⁾	D, see 116Te	3E+3 Thyroid	5E+3 Thyroid	2E-6	-	-	
			(6E+3)	(1E+4)	-	2E-8	9E-5	9E-4
		W, see 116Te	-	5E+3 Thyroid	2E-6	-	-	-
				(1E+4)	-	2E-8	-	-
52	Tellurium-133 ⁽²⁾	D, see 116Te	lE+4 Thyroid	2E+4 Thyroid	9E-6	-	-	-
			(3E+4)	(6E+4)	-	8E-8	4E-4	4E-3
		W, see 116Te		2E+4 Thyroid	9E-6	-		-
			-	(6E+4)	-	8E-8	-	-
52	Tellurium-134 ⁽²⁾	D. see ¹¹⁶ Te	2E+4 Thyroid	2E+4 Thyroid	1E-5	-	-	-
			(2E+4)	(5E+4)	-	7E-8	3E-4	3E-3
		W, see 116Te	-	2E+4 Thyroid	1E-5	-	-	-
			-	(5E+4)	-	7E-8	-	
53	Iodine-120m ⁽²⁾	D, all compounds	1E+4 Thyroid	2E+4	9E-6	3E-8	-	-
			(IE+4)	-	-	-	2E-4	2E-3
53	Iodine-120 ⁽²⁾	D, all compounds	4 E+3 Thyroid	9E+3 Thyroid	4E-6	-	-	
			(8E+3)	(lE+4)	-	2E-8	IE-4	1E-3
53	Iodine-121	D, all compounds	1E+4 Thyroid	2E+4 Thyroid	8E-6	-	-	-
			(3E+4)	(5E+4)	_	7E-8	4E-4	4E-3
53	Iodine-123	D, all compounds	3E+3 Thyroid	6E+3 Thyroid	3E-6	-	-	
			(1E+4)	(2E+4)	-	2E-8	1E-4	1E-3
53	Iodine-124	D, all compounds	5E+1 Thyroid	8E+1 Thyroid	3E-8	-	-	-
			(2E+2)	(3E+2)	-	4E-10	2E-6	2E-5

NUREG-1736

			Occ	Table 1 upational Va	llues	Effi	ole 2 uent strations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) - 2E-5 - 1E-5 - 2E-6 - 2E-4 - 1E-5 - 1E-3 - 7E-5
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration
53	Iodine-125	D, all compounds	4E+1 Thyroid	6E+1 Thyroid	3E-8	-	-	-
			(1E+2)	(2E+2)	-	3E-10	2E-6	2E-5
53	Iodine-126	D, all compounds	2E+1 Thyroid	4E+1 Thyroid	1E-8	-	-	-
			(7E+1)	(1E+2)	-	2E-10	1E-6	1E-5
53	Iodine-128 ⁽²⁾	D, all compounds	4E+4 St. wall	1E+5	5E-5	2E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
53	Iodine-129	D, all compounds	5E+0 Thyroid	9E+0 Thyroid	4E-9	-	-	-
			(2E+1)	(3E+1)	-	4E-11	2E-7	2E-6
53	Iodine-130	D, all compounds	4E+2 Thyroid	7E+2 Thyroid	3E-7	-	-	-
			(1E+3)	(2E+3)	-	3E-9	2E-5	2E-4
53	Iodine-131	D, all compounds	3E+1 Thyroid	5E+1 Thyroid	2E-8	-	-	-
			(9E+1)	(2E+2)	-	2E-10	1E-6	1E-5
53	lodine-132m ⁽²⁾	D, all compounds	4E+3 Thyroid	8E+3 Thyroid	4E-6	-	-	-
			(1E+4)	(2E+4)	-	3E-8	1E-4	1E-3
53	Iodine-132	D, all compounds	4E+3 Thyroid	8E+3 Thyroid	3E-6	-	-	-
			(9E+3)	(1E+4)	-	2E-8	1E-4	1E-3
53	Iodine-133	D, all compounds	1E+2 Thyroid	3E+2 Thyroid	1E-7	-	-	-
			(5E+2)	(9E+2)	-	1E-9	7E-6	7E-5
53	Iodine-134 ⁽²⁾	D, all compounds	2E+4 Thyroid	5E+4	2E-5	6E-8	-	
			(3E+4)	-	-	-	4E-4	4E-3
53	lodine-135	D, all compounds	8E+2 Thyroid	2E+3 Thyroid	7E-7	-	-	
			(3E+3)	(4E+3)	-	6E-9	3E-5	3E-4

B-41 NUREG-1736

			Occ	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Average Concentration (µCi/ml)
54	Xenon-120 ⁽²⁾	Submersion ⁽¹⁾	-	-	1E-5	4E-8	-	-
54	Xenon-121(2)	Submersion ⁽¹⁾	-	-	2E-6	1E-8	-	-
54	Xenon-122	Submersion ⁽¹⁾	-	-	7E-5	3E-7	-	-
54	Xenon-123	Submersion ⁽¹⁾	-	-	6E-6	3E-8	-	
54	Xenon-125	Submersion ^(t)	-	-	2E-5	7E-8	-	-
54	Xenon-127	Submersion(1)	-	-	1E-5	6E-8	-	-
54	Xenon-129m	Submersion ⁽¹⁾	-	-	2E-4	9E-7	-	-
54	Xenon-131m	Submersion ⁽¹⁾	-	-	4E-4	2E-6	-	-
54	Xenon-133m	Submersion ⁽¹⁾	-	-	1E-4	6E-7	-	-
54	Xenon-133	Submersion ⁽¹⁾	-	-	1E-4	5E-7	-	-
54	Xenon-135m ⁽²⁾	Submersion ⁽¹⁾	-	-	9E-6	4E-8	-	-
54	Xenon-135	Submersion ⁽¹⁾	-	-	1E-5	7E-8	-	-
54	Xenon-138(2)	Submersion ⁽¹⁾	-	-	4E-6	2E-8	-	-
55	Cesium-125 ⁽²⁾	D, all compounds	5E+4 St. wali	1E+5	6E-5	2E-7	-	-
			(9E+4)	-	-	-	1E-3	1E-2
55	Cesium-127	D, all compounds	6E+4	9E+4	4E-5	1E-7	9E-4	9E-3
55	Cesium-129	D, all compounds	2E+4	3E+4	1E-5	5E-8	3E-4	3E-3
55	Cesium-130 ⁽²⁾	D, all compounds	6E+4 St. wall	2E+5	8E-5	3E-7	-	-
			(1E+5)	-	-	-	1E-3	1E-2
55	Cesium-131	D, all compounds	2E+4	3E+4	1E-5	4E-8	3E-4	3E-3
55	Cesium-132	D, all compounds	3E+3	4E+3	2E-6	6E-9	4E-5	4E-4
55	Cesium-134m	D. all compounds	1E+5 St. wall	lE+5	6E-5	2E-7		-
			(1E+5)	-	-	-	2E-3	2E-2
55	Cesium-134	D, all compounds	7E+1	1E+2	4E-8	2E-10	9E-7	9E-6
55	Cesium-135m ⁽²⁾	D, all compounds	1E+5	2E+5	8E-5	3E-7	1E-3	1E-2
55	Cesium-135	D, all compounds	7E+2	1E+3	5E-7	2E-9	1E-5	1E-4
55	Cesium-136	D, all compounds	4E+2	7E+2	3E-7	9E-10	6E-6	6E-5

NUREG-1736

		-	Occ	Table 1 upational Va	alues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion		Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	water (μCi/ml)	Concentration (μCi/ml)
55	Cesium-137	D, all compounds	1E+2	2E+2	6E-8	2E-10	1E-6	1E-5
55	Cesium-138 ⁽²⁾	D, all compounds	2E+4 St. wall	6E+4	2E-5	8E-8	-	-
			(3E+4)	-	-		4E-4	4E-3
56	Barium-126 ⁽²⁾	D, all compounds	6E+3	2E+4	6E-6	2E-8	8E-5	8E-4
56	Barium-128	D, all compounds	5E+2	2E+3	7E-7	2E-9	7E-6	7E-5
56	Barium-131m ⁽²⁾	D, all compounds	4E+5 St. wall	1E+6	6E-4	2E-6	-	-
			(5E+5)	-	-	-	7E-3	7E-2
56	Barium-131	D, all compounds	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4
56	Barium-133m	D, all compounds	2E+3 LLI wall	9E+3	4E-6	1E-8	-	-
	İ		(3E+3)	-	-	-	4E-5	4E-4
56	Barium-133	D, all compounds	2E+3	7E+2	3E-7	9E-10	2E-5	2E-4
56	Barium-135m	D, all compounds	3E+3	1E+4	5E-6	2E-8	4E-5	4E-4
56	Barium-139(2)	D, all compounds	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
56	Barium-140	D, all compounds	5E+2 LLI wall	1E+3	6E-7	2E-9	-	-
	1		(6E+2)	-	-	-	8E-6	8E-5
56	Barium-141 ⁽²⁾	D, all compounds	2E+4	7E+4	3E-5	1E-7	3E-4	3E-3
56	Barium-142(2)	D, all compounds	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3
57	Lanthanum- 131 ⁽²⁾	D, all compounds except those given for W	5E+4	1E+5	5E-5	2E-7	6E-4	6E-3
		W, oxides and hydroxides	-	2E+5	7E-5	2E-7	_	-
57	Lanthanum-132	D, see 131La	3E+3	1E+4	4E-6	1E-8	4E-5	4E-4
		W, see 131La	-	1E+4	5E-6	2E-8	-	-
57	Lanthanum-135	D, see 131La	4E+4	IE+5	4E-5	1E-7	5E-4	5E-3
		W, see 131La	T .	9E+4	4E-5	1E-7	-	-

			Occ	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 2E-3
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (µCi)	ALI (μCi)	DAC (\(\(\alpha\)Ci/ml)	Air (μCi/ml)	Water (µCi/ml)	Average Concentration (μCi/ml) 2E-3
57	Lanthanum-137	D, see ¹³¹ La	1E+4	6E+1 Liver	3E-8	-	2E-4	2E-3
			-	(7E+1)	-	1E-10	-	-
		W, see 131La	-	3E+2 Liver	1E-7	-	-	-
			-	(3E+2)	-	4E-10	-	-
57	Lanthanum-138	D, see 131La	9E+2	4E+0	1E-9	5E-12	1E-5	1E-4
		W, see 131La	-	1E+1	6E-9	2E-11	-	-
57	Lanthanum-140	D, see 131La	6E+2	1E+3	6E-7	2E-9	9E-6	9E-5
		W, see 131La	-	1E+3	5E-7	2E-9	-	-
57	Lanthanum-141	D, see 131La	4E+3	9E+3	4E-6	1E-8	5E-5	5E-4
		W, see 131La	-	1E+4	5E-6	2E-8	-	-
57	Lanthanum-	D, see 131 La	8E+3	2E+4	9E-6	3E-8	1E-4	1E-3
	142	W, see 131La	-	3E+4	1E-5	5E-8	-	-
57	Lanthanum- 143 ⁽²⁾	D, see ¹³¹ La	4E+4 St. wall	1E+5	4E-5	1E-7	-	-
			(4E+4)	-	-	-	5E-4	5E-3
		W, see 131La	-	9E+4	4E-5	1E-7	-	-
58	Cerium-134	W, all compounds except those given for Y	5E+2 LLI wall	7E+2	3E-7	1E-9	-	-
			(6E+2)	-	-	-	8E-6	8E-5
		Y, oxides, hydroxides, and fluorides		7E+2	3E-7	9E-10	-	-
58	Cerium-135	W, see 134Ce	2E+3	4E+3	2E-6	5E-9	2E-5	2E-4
		Y, see ¹³⁴ Ce	-	4E+3	1E-6	5E-9	-	-
58	Cerium-137m	W, see ¹³⁴ Ce	2E+3 LLI wall	4E+3	2E-6	6E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
		Y, see ¹³⁴ Ce	-	4E+3	2E-6	5E-9	-	-
58	Cerium-137	W, see 134Ce	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3
		Y, see 134Ce	-	1E+5	5E-5	2E-7	-	

NUREG-1736 B-44

1

			Occ	Table 1 upational V	alues	EM	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
58	Cerium-139	W, see ¹³⁴ Ce	5E+3	8E+2	3E-7	1E-9	7E-5	7E-4
		Y, see ¹³⁴ Ce	-	7E+2	3E-7	9E-10	-	-
58	Cerium-141	W, see ¹³⁴ Ce	2E+3 LLI wall	7E+2	3E-7	1E-9	-	-
	ĺ		(2E+3)	-	-	-	3E-5	3E-4
		Y, see ¹³⁴ Ce	-	6E+2	2E-7	8E-10	-	-
58	Cerium-143	W, see ¹³⁴ Ce	1E+3 LLI wall	2E+3	8E-7	3E-9	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see ¹³⁴ Ce	-	2E+3	7E-7	2E-9	-	-
58	Cerium-144	W, see ¹³⁴ Ce	2E+2 LLI wall	3E+1	1E-8	4E-11	-	-
			(3E+2)	-	-	-	3E-6	3E-5
		Y, see ¹³⁴ Ce	-	1E+1	6E-9	2E-11	-	_
59	Praseodymium- 136 ⁽²⁾	W, all compounds except those given for Y	5E+4 St. wall	2E+5	1E-4	3E-7	-	-
			(7E+4)	-	-	-	1E-3	1E-2
		Y, oxides, hydroxides, carbides, and fluorides	-	2E+5	9E-5	3E-7	-	-
59	Praseodymium-	W, see 136Pr	4E+4	2E+5	6E-5	2E-7	5E-4	5E-3
	137 ⁽²⁾	Y, see ¹³⁶ Pr	-	1E+5	6E-5	2E-7	-	-
59	Praseodymium-	W, see ¹³⁶ Pr	1E±4	5E±4	2E-5	8E-8	1E-4	1E-3
	138m	Y, see ¹³⁶ Pr	-	4E+4	2E-5	6E-8	-	-
59	Praseodymium-	W, see 136Pr	4E+4	1E+5	5E-5	2E-7	6E-4	6E-3
	139	Y, see ¹³⁶ Pr	-	IE+5	5E-5	2E-7	-	-
59	Praseodymium-	W, see ¹³⁶ Pr	8E+4	2E+5	7E-5	2E-7	1E-3	1E-2
	142m ⁽²⁾	Y, see ¹³⁶ Pr	-	1E+5	6E-5	2E-7	-	-
59	Praseodymium-	W, see 136Pr	1E+3	2E+3	9E-7	3E-9	1E-5	1E-4
	142	Y, see ¹³⁶ Pr	-	2E+3	8E-7	3E-9	-	-

			Oc	Table 1 cupational	Values	Ef	ible 2 fluent ntrations	Table 3 Releases to Sewers
	-		Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation				Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Average Concentration (μCi/ml)
59	Praseodymium- 143	W, see ¹³⁶ Pr	9E+2 LLI wall	8E+2	3E-7	1E-9	-	-
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see ¹³⁶ Pr	-	7E+2	3E-7	9E-10	-	-
59	Praseodymium- 144 ⁽²⁾	W, see ¹³⁶ Pr	3E+4 St. wall	1E+5	5E-5	2E-7	-	-
			(4E+4)	-	-	-	6E-4	6E-3
		Y, see 136Pr	-	1E+5	5E-5	2E-7	-	-
59	Praseodymium- 145	W, see 136Pr	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
	143	Y, see ¹³⁶ Pr	-	8E+3	3E-6	1E-8	-	-
59	Praseodymium- 147 ⁽²⁾	W, see ¹³⁶ Pr	5E+4 St. wall	2E+5	8E-5	3E-7	-	-
	-		(8E+4)	•	-	-	1E-3	1E-2
		Y, see 136Pr	-	2E+5	8E-5	3E-7	-	-
60	Neodymium- 136 ⁽²⁾	W, all compounds except those given for Y	1E+4	6E+4	2E-5	8E-8	2E-4	2E-3
		Y, oxides, hydroxides, carbides, and fluorides	-	5E+4	2E-5	8E-8	-	-
60	Neodymium-138	W, see ¹³⁶ Nd	2E+3	6E+3	3E-6	9E-9	3E-5	3E-4
		Y, see ¹³⁶ Nd	-	5E+3	2E-6	7E-9	-	
60	Neodymium- 139m	W, see ¹³⁶ Nd	5E+3	2E+4	7E-6	2E-8	7E-5	7E-4
	13911	Y, see 136Nd	- 1	1E+4	6E-6	2E-8	-	-
60	Neodymium- 139 ⁽²⁾	W, see ¹³⁶ Nd	9E+4	3E+5	1E-4	5E-7	1E-3	1E-2
	139	Y, see ¹³⁶ Nd	-	3E+5	IE-4	4E-7	-	-
60	Neodymium-141	W, see 136Nd	2E+5	7E+5	3E-4	1E-6	2E-3	2E-2
		Y, see ¹³⁶ Nd	-	6E+5	3E-4	9E-7	-	
60	Neodymium-147	W, see ¹³⁶ Nd	1E+3 LLI wall	9E+2	4E-7	1E-9	-	
			(1E+3)	-	-	-	2E-5	2E-4
		Y, see ¹³⁶ Nd	. 1	8E+2	4E-7	1E-9	-	-

			Occ	Table 1 upational Va	alues	Em	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
60	Neodymium-	W, see 136Nd	1E+4	3E+4	1E-5	4E-8	1E-4	1E-3
	149(2)	Y, see 136Nd	-	2E+4	1E-5	3E-8	-	-
60	Neodymium-	W, see 136Nd	7E+4	2E+5	8E-5	3E-7	9E-4	9E-3
	151 ⁽²⁾	Y, see 136Nd	-	2E+5	8E-5	3E-7	-	-
61	Promethium- 141 ⁽²⁾	W, all compounds except those given for Y	5E+4 St. wall	2E+5	8E-5	3E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
		Y, oxides, hydroxides, carbides, and fluorides	-	2E+5	7E-5	2E-7	-	-
61	Promethium-143	W, see 141Pm	5E+3	6E+2	2E-7	8E-10	7E-5	7E-4
		Y, see 141Pm	-	7E+2	3E-7	1E-9		-
61	Promethium-144	W, see 141Pm	1E+3	1E+2	5E-8	2E-10	2E-5	2E-4
		Y, see 141Pm	-	1E+2	5E-8	2E-10		-
61	Promethium-145	W, see ¹⁴¹ Pm	1E+4	2E+2 Bone Surf	7E-8	-	1E-4	1E-3
			-	(2E+2)	-	3E-10	-	-
		Y, see 141Pm	-	2E+2	8E-8	3E-10	-	-
61	Promethium-146	W, see 141Pm	2E+3	5E+1	2E-8	7E-11	2E-5	2E-4
		Y, see 141Pm	-	4E+1	2E-8	6E-11		· .
61	Promethium-147	W, see ¹⁴¹ Pm	4E+3 LLI wall	tE+2 Bone Surf	5E-8	-	-	-
			(5E+3)	(2E+2)	-	3E-10	7E-5	7E-4
		Y, see 141Pm	-	1E+2	6E-8	2E-10	-	_
61	Promethium-	W, see 141Pm	7E+2	3E+2	1E-7	4E-10	1E-5	1E-4
	148m	Y, see 141Pm	-	3E+2	1E-7	5E-10	-	-
61	Promethium-148	W, see ¹⁴¹ Pm	4E+2 LLI wall	5E+2	2E-7	8E-10	-	-
			(5E+2)	-	-	-	7E-6	7E-5
		Y, see ¹⁴¹ Pm	T -	5E+2	2E-7	7E-10	-	-

B-47 NUREG-1736

			Oc	Table 1 cupational V	Т	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
61	Promethium-149	W, see ⁽⁴⁾ Pm	1E+3 LLI wall	2E+3	8E-7	3E-9	-	-
	1		(1E+3)	-	-	-	2E-5	2E-4
		Y, see 141Pm	-	2E+3	8E-7	2E-9	-	-
61	Promethium-150	W, see 141Pm	5E+3	2E+4	8E-6	3E-8	7E-5	7E-4
		Y, see ^[4] Pm	-	2E+4	7E-6	2E-8	-	-
16	Promethium-151	W, see 141Pm	2E+3	4E+3	1E-6	5E-9	2E-5	2E-4
		Y, see 141Pm	-	3E+3	1E-6	4E-9	-	-
62	Samarium- 141 m ⁽²⁾	W, all compounds	3E+4	1E+5	4E-5	1E-7	4E-4	4E-3
62	Samarium-141 ⁽²⁾	W, all compounds	5E+4 St. wall	2E+5	8E-5	2E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
62	Samarium-142 ⁽²⁾	W, all compounds	8E+3	3E+4	1E-5	4E-8	1E-4	1E-3
62	Samarium-145	W, all compounds	6E+3	5E+2	2E-7	7E-10	8E-5	8E-4
62	Samarium-146	W, all compounds	1E+1 Bone Surf	4E-2 Bone Surf	1E-11	-	-	-
			(3E+1)	(6E-2)	-	9E-14	3E-7	3E-6
62	Samarium-147	W, all compounds	2E+1 Bone Surf	4E-2 Bone Surf	2E-11		-	-
			(3E+1)	(7E-2)	-	IE-13	4E-7	4E-6
62	Samarium-151	W, all compounds	1E+4 LLI wall	1E+2 Bone Surf	4E-8	-	-	-
			(1E+4)	(2E+2)		2E-10	2E-4	2E-3
62	Samarium-153	W, all compounds	2E+3 LLI wali	3E+3	1E-6	4E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
62	Samarium-155 ⁽²⁾	W, all compounds	6E+4 St. wall	2E+5	9E-5	3E-7	-	-
			(8E+4)	-	-	-	1E-3	1E-2
62	Samarium-156	W, all compounds	5E+3	9E+3	4E-6	1E-8	7E-5	7E-4
63	Europium-145	W, all compounds	2E+3	2E+3	8E-7	3E-9	2E-5	2E-4

NUREG-1736

			Occ	Table I cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly
Atomic			ALI	ALI	DAC	Air	Water	Average Concentration
No.	Radionuclide	Class	(μCi)	(μCi)	(μCi/ml)	(μCi/ml)	(μCi/ml)	(μCi/ml)
63	Europium-146	W, all compounds	1E+3	1E+3	5E-7	2E-9	1E-5	1E-4
63	Europium-147	W, all compounds	3E+3	2E+3	7E-7	2E-9	4E-5	4E-4
63	Europium-148	W, all compounds	1E+3	4E+2	1E-7	5E-10	1E-5	1E-4
63	Europium-149	W, all compounds	1E+4	3E+3	1E-6	4E-9	2E-4	2E-3
63	Europium-150 (12.62h)	W, all compounds	3E+3	8E+3	4E-6	1E-8	4E-5	4E-4
63	Europium-150 (34.2y)	W, all compounds	8E+2	2E+1	8E-9	3E-11	1E-5	1E-4
63	Europium-152m	W, all compounds	3E+3	6E+3	3E-6	9E-9	4E-5	4E-4
63	Europium-152	W, all compounds	8E+2	2E+1	1E-8	3E-11	1E-5	1E-4
63	Europium-154	W, all compounds	5E+2	2E+1	8E-9	3E-11	7E-6	7E-5
63	Europium-155	W, all compounds	4E+3	9E+1 Bone Surf	4E-8	-	5E-5	5E-4
			-	(1E+2)	-	2E-10	-	-
63	Europium-156	W, all compounds	6E+2	5E+2	2E-7	6E-10	8E-6	8E-5
63	Europium-157	W, all compounds	2E+3	5E+3	2E-6	7E-9	3E-5	3E-4
63	Europium-158(2)	W, all compounds	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
64	Gadolinium- 145 ⁽²⁾	D, all compounds except those given for W	5E+4 St. wall	2E+5	6E-5	2E-7	-	~
			(5E+4)	-	-	-	6E-4	6E-3
		W, oxides, hydroxides, and fluorides	-	2E+5	7E-5	2E-7	-	-
64	Gadolinium-146	D, see ¹⁴⁵ Gd	1E+3	1E+2	5E-8	2E-10	2E-5	2E-4
		W, see 145Gd	-	3E+2	1E-7	4E-10	-	-
64	Gadolinium-147	D, see 145Gd	2E+3	4E+3	2E-6	6E-9	3E-5	3E-4
		W, see 145Gd	-	4E+3	1E-6	5E-9	-	-

B-49 NUREG-1736

			Occ	Table 1 upational Va	alues	EM	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Cot. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
64	Gadolinium-148	D, see ¹⁴⁵ Gd	1E+1 Bone Surf	8E+3 Bone Surf	3E-12	-	-	-
			(2E+1)	(2E+2)	-	2E-14	3E-7	3E-6
		W, see 145Gd	-	3E-2 Bone Surf	1E-11	-	-	-
			-	(6E-2)	-	8E-14	-	-
64	Gadolinium-149	D, see 145Gd	3E+3	2E+3	9E-7	3E-9	4E-5	4E-4
		W, see 145Gd	-	2E+3	1E-6	3E-9	-	-
64	Gadolinium-151	D, see ¹⁴⁵ Gd	6E+3	4E+2 Bone Surf	2E-7	-	9E-5	9E-4
			-	(6E+2)	-	9E-10	-	-
		W, see 145Gd	-	1E+3	5E-7	2E-9	-	-
64	Gadolinium-152	D, see ¹⁴⁵ Gd	2E+1 Bone Surf	1E-2 Bone Surf	4E-12	-	-	-
			(3E+1)	(2E-2)	-	3E-14	4E-7	4E-6
		W, see 145Gd	-	4E-2 Bone Surf	2E-11	-	-	-
			-	(8E-2)	-	1E-13	-	-
64	Gadolinium-153	D, see ¹⁴⁵ Gd	5E+3	1E+2 Bone Surf	6E-8	-	6E-5	6E-4
			-	(2E+2)	-	3E-10	-	-
		W, see 145Gd	-	6E+2	2E-7	8E-10		-
64	Gadolinium-159	D, see 145Gd	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4
		W, see 145Gd	-	6E+3	2E-6	8E-9	+	-
65	Terbium-147 ⁽²⁾	W, all compounds	9E+3	3E+4	1E-5	5E-8	IE-4	1E-3
65	Terbium-149	W, all compounds	5E+3	7E+2	3E-7	1E-9	7E-5	7E-4
65	Terbium-150	W, all compounds	5E+3	2E+4	9E-6	3E-8	7E-5	7E-4
65	Terbium-151	W, all compounds	4E+3	9E+3	4E-6	1E-8	5E-5	5E-4
65	Terbium-153	W, all compounds	5E+3	7E+3	3E-6	1E-8	7E-5	7E-4
65	Terbium-154	W, all compounds	2E+3	4E+3	2E-6	6E-9	2E-5	2E-4
65	Terbium-155	W, all compounds	6E+3	8E+3	3E-6	1E-8	8E-5	8E-4

1

			Occ	Table 1 upational Va	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
	,		Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
65	Terbium-156m (5.0h)	W, all compounds	2E+4	3E+4	1E-5	4E-8	2E-4	2E-3
65	Terbium-156m (24.4h)	W, all compounds	7E+3	8E+3	3E-6	1E-8	1E-4	1E-3
65	Terbium-156	W, all compounds	1E+3	1E+3	6E-7	2E-9	1E-5	1E-4
65	Terbium-157	W, all compounds	5E+4 LLI wall	3E+2 Bone Surf	1E-7	-	-	-
			(5E+4)	(6E+2)	-	8E-10	7E-4	7E-3
65	Terbium-158	W, all compounds	1E+3	2E+1	8E-9	3E-11	2E-5	2E-4
65	Terbium-160	W, all compounds	8E+2	2E+2	9E-8	3E-10	1E-5	1E-4
65	Terbium-161	W, all compounds	2E+3 LLI wall	2E+3	7E-7	2E-9	-	-
			(2E+3)	-	- '	-	3E-5	3E-4
66	Dysprosium-155	W, all compounds	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
66	Dysprosium-157	W, all compounds	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
66	Dysprosium-159	W, all compounds	1E+4	2E+3	1E-6	3E-9	2E-4	2E-3
66	Dysprosium-165	W, all compounds	1E+4	5E÷4	2E-5	6E-8	2E-4	2E-3
66	Dysprosium-166	W, all compounds	6E+2 LLI wall	7E+2	3E-7	1E-9	-	-
			(8E+2)	-	-	-	1E-5	1E-4
67	Holmium-155 ⁽²⁾	W, all compounds	4E+4	2E+5	6E-5	2E-7	6E-4	6E-3
67	Holmium-157 ⁽²⁾	W, all compounds	3E+5	1E+6	6E-4	2E-6	4E-3	4E-2
67	Holmium-159 ⁽²⁾	W, all compounds	2E+5	1E+6	4E-4	1E-6	3E-3	3E-2
67	Holmium-161	W, all compounds	1E+5	4E+5	2E-4	6E-7	1E-3	1E-2
67	Holmium- 162m ⁽²⁾	W, all compounds	5E+4	3E+5	1E-4	4E-7	7E-4	7E-3
67	Holmium-162 ⁽²⁾	W, all compounds	5E+5 St. wall	2E+6	1E-3	3E-6	-	-
			(8E+5)	-	-	-	1E-2	1E-1
67	Holmium- 164m ⁽²⁾	W, all compounds	1E+5	3E+5	1E-4	4E-7	1E-3	1E-2

B-51 NUREG-1736

			Oe	Table 1 cupational V	alues	Eff	ble 2 tuent ntrations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	Ingestion ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (\(\mu\)Ci/ml)
67	Holmium-164 ⁽²⁾	W, all compounds	2E+5 St. wall	6E+5	3E-4	9E-7	-	-
			(2E+5)	-	-	-	3E-3	3E-2
67	Holmium-166m	W, all compounds	6E+2	7E+0	3E-9	9E-12	9E-6	9E-5
67	Holmium-166	W, all compounds	9E+2 LLI wail	2E+3	7E-7	2E-9	-	-
			(9E+2)	-	-	-	1E-5	1E-4
67	Holmium-167	W, all compounds	2E+4	6E+4	2E-5	8E-8	2E-4	2E-3
68	Erbium-161	W, all compounds	2E+4	6E+4	3E-5	9E-8	2E-4	2E-3
68	Erbium-165	W, all compounds	6E+4	2E+5	8E-5	3E-7	9E-4	9E-3
68	Erbium-169	W, all compounds	3E+3 LLI wall	3E+3	1E-6	4E-9	-	-
			(4E+3)	-	-	-	5E-5	5E-4
68	Erbium-171	W, all compounds	4E+3	1E+4	4E-6	1E-8	5E-5	5E-4
68	Erbium-172	W, all compounds	1E+3 LLI wall	1E+3	6E-7	2E-9	1	•
			(1E+3)	-	-	-	2E-5	2E-4
69	Thulium-162 ⁽²⁾	W, all compounds	7E+4 St. wall	3E+5	1E-4	4E-7	-	-
			(7E+4)	-		-	1E-3	1E-2
69	Thulium-166	W, all compounds	4E+3	1E+4	6E-6	2E-8	6E-5	6E-4
69	Thulium-167	W, all compounds	2E+3 LLI wall	2E+3	8E-7	3E-9	-	-
			(2E+3)	-	•	-	3E-5	3E-4
69	Thulium-170	W, all compounds	8E+2 LLI wail	2E+2	9E-8	3E-10	-	-
			(1E+3)		-		1E-5	1E-4
69	Thulium-171	W, all compounds	1E+4 LLI wall	3E+2 Bone Surf	1E-7	-	-	-
			(1E+4)	(6E+2)	-	8E-10	2E-4	2E-3

			Occ	Table 1 upational V	alues	Eff	ole 2 uent strations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Col. 3		Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
69	Thulium-172	W, all compounds	7E+2 LLI wall	1E+3	5E-7	. 2E-9	-	-
			(8E+2)	-	-	-	1E-5	1E-4
69	Thulium-173	W, all compounds	4E+3	1E+4	5E-6	2E-8	6E-5	6E-4
69	Thulium-175 ⁽²⁾	W, all compounds	7E+4 St. wall	3E+5	1E-4	4E-7	-	-
			(9E+4)	-	-	-	1E-3	1E-2
70	Ytterbium-162(2)	W, all compounds except those given for Y	7E+4	3E+5	1E-4	4E-7	1E-3	1E-2
		Y, oxides, hydroxides, and fluorides	-	3E+5	1E-4	4E-7	-	-
70	Ytterbium-166	W, see 162Yb	1E+3	2E+3	8E-7	3E-9	2E-5	2E-4
		Y, see 162Yb	-	2E+3	8E-7	3E-9	-	-
70	Ytterbium-167(2)	W, see 162Yb	3E+5	8E+5	3E-4	1E-6	4E-3	4E-2
		Y, see 162Yb	-	7E+5	3E-4	1E-6	-	•
70	Ytterbium-169	W, see 162Yb	2E+3	8E+2	4E-7	1E-9	2E-5	2E-4
		Y, see 162Yb	-	7E+2	3E-7	1E-9	-	-
70	Ytterbium-175	W, see ¹⁶² Yb	3E+3 LLI wall	4E+3	1E-6	5E-9	-	-
			(3E+3)	-	-	-	4E-5	4E-4
		Y, see 162Yb	-	3E+3	1E-6	5E-9	-	-
70	Ytterbium-177(2)	W, see 162Yb	2E+4	5E+4	2E-5	7E-8	2E-4	2E-3
		Y, see 162Yb	-	5E+4	2E-5	6E-8	-	-
70	Ytterbium-178 ⁽²⁾	W, see 162Yb	lE+4	4E+4	2E-5	6E-8	2E-4	2E-3
		Y, see 162Yb	-	4E+4	2E-5	5E-8	-	-
71	Lutetium-169	W, all compounds except those given for Y	3E+3	4E+3	2E-6	6E-9	3E-5	3E-4
		Y, oxides, hydroxides, and fluorides	-	4E+3	2E-6	6E-9	-	-
71	Lutetium-170	W, see 169Lu	1E+3	2E+3	9E-7	3E-9	2E-5	2E-4
		Y, see 169Lu	-	2E+3	8E-7	3E-9	1	-

B-53 NUREG-1736

•			Occ	Table 1 cupational V	alues	Eff	ble 2 luent atrations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion		Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
71	Lutetium-171	W, see 169Lu	2E+3	2E+3	8E-7	3E-9	3E-5	3E-4
		Y, see 169Lu		2E+3	8E-7	3E-9	-	-
71	Lutetium-172	W, see 169Lu	1E+3	1E+3	5E-7	2E-9	1E-5	1E-4
		Y, see 169Lu		1E+3	5E-7	2E-9	-	-
71	Lutetium-173	W, see 169Lu	5E+3	3E+2 Bone Surf	1E-7	-	7E-5	7E-4
			-	(5E+2)	-	6E-10	-	-
		Y, see 169Lu	-	3E+2	1E-7	4E-10	-	-
71	Lutetium-174m	W, see 169Lu	2E+3 LLI wall	2E+2 Bone Surf	1E-7	-	-	-
			(3E+3)	(3E+2)	-	5E-10	4E-5	4E-4
		Y, see 169Lu	-	2E+2	9E-8	3E-10	-	-
71	Lutetium-174	W, see 169Lu	5E+3	1E+2 Bone Surf	5E-8	-	7E-5	7E-4
	İ		-	(2E+2)		3E-10	-	-
		Y, see 169Lu	-	2E+2	6E-8	2E-10	-	-
71	Lutetium-176m	W, see 169Lu	8E+3	3E+4	1E-5	3E-8	1E-4	1E-3
		Y, see 169Lu	-	2E+4	9E-6	3E-8	-	-
71	Lutetium-176	W, see 169 Lu	7E+2	5E+0 Bone Surf	2E-9	-	1E-5	1E-4
			-	(1E+1)	-	2E-11	-	-
		Y, see 169Lu		8E+0	3E-9	1E-11	-	-
71	Lutetium-177m	W, see ¹⁶⁹ Lu	7E+2	1E+2 Bone Surf	5E-8	-	1E-5	1E-4
			-	(1E+2)		2E-10		-
		Y, see 169Lu	-	8E+1	3E-8	1E-10	-	-
71	Lutetium-177	W, see ¹⁶⁹ Lu	2E+3 LLI wall	2E+3	9E-7	3E-9	-	-
			(3E+3)	-	-		4E-5	4E-4
		Y, see 169Lu	-	2E+3	9E-7	3E-9	-	-

			Occ	Table 1 cupational V	alues	Eff	ble 2 luent itrations	Table 3 Releases to Sewers
	İ		Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
71	Lutetium-178m ⁽²⁾	W, see 169Lu	5E+4 St. wall	2E+5	8E-5	3E-7	-	-
			(6E+4)	-	-	-	8E-4	8E-3
		Y, see 169Lu	-	2E+5	7E-5	2E-7	-	-
71	Lutetium-178 ⁽²⁾	W, see 169Lu	4E+4 St. wali	1E+5	5 E -5	2E-7	-	*
			(4E+4)	-	-	-	6E-4	6E-3
		Y, see 169Lu	-	1E+5	5E-5	2E-7	-	-
71	Lutetium-179	W, see 169Lu	6E+3	2E+4	8E-6	3E-8	9E-5	9E-4
		Y, see 169Lu	-	2E+4	6E-6	3E-8	-	-
72	Hafnium-170	D, all compounds except those given for W	3E+3	6E+3	2E-6	8E-9	4E-5	4E-4
		W, oxides, hydroxides, carbides, and nitrates	-	5E+3	2E-6	6E-9	,	-
72	Hafnium-172	D, see ¹⁷⁰ Hf	1E+3	9E+0 Bone Surf	4E-9	-	2E-5	2E-4
			-	(2E+1)	-	3E-11	-	-
		W, see ¹⁷⁰ Hf	-	4E+1 Bone Surf	2E-8	-	-	-
			-	(6E+1)	-	8E-11		-
72	Hafnium-173	D, see ¹⁷⁰ Hf	5E+3	1E+4	5E-6	2E-8	7E-5	7E-4
		W, see 170Hf	-	1E+4	5E-6	2E-8	-	-
72	Hafnium-175	D, see ¹⁷⁰ Hf	3E+3	9E+2 Bone Surf	4E-7	. -	4E-5	4 <u>E</u> -4
			-	(1E+3)	-	1E-9	-	-
		W, see 170Hf	-	1E+3	5E-7	2E-9	-	-
72	Hafnium-177m ⁽²⁾	D, see ¹⁷⁰ Hf	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
		W, see 170Hf	-	9E+4	4E-5	1E-7	-	-

B-55 NUREG-1736

			Occ	Table 1 cupational V	alues	Em	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 3E-5
			Col. 1	Col, 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			*
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μ Ci/ml)	Water (µCi/ml)	1
72	Hafnium-178m	D, see ¹⁷⁰ Hf	3E+2	1E+0 Bone Surf	5E-10	-	3E-6	3E-5
			-	(2E+0)	-	3E-12	-	-
		W, see 170Hf	-	5E+0 Bone Surf	2E-9	-	-	-
			-	(9E+0)	-	1E-11	-	-
72	Hafnium-179m	D, see ¹⁷⁰ Hf	1E+3	3E+2 Bone Surf	1E-7	-	1E-5	1E-4
			-	(6E+2)	-	8E-10	•	-
		W, see 170Hf	-	6E+2	3E-7	8E-10	-	_
72	Hafnium-180m	D, see ¹⁷⁰ Hf	7E+3	2E+4	9E-6	3E-8	1E-4	1E-3
		W, see 170Hf	-	3E+4	1E-5	4E-8		-
72	Hafnium-181	D, see ¹⁷⁰ Hf	1E+3	2E+2 Bone Surf	7E-8	-	2E-5	2E-4
			-	(4E+2)	-	6E-10	-	-
	·	W, see 170Hf	_	4E+2	2E-7	6E-10	-	-
72	Hafnium-182m ⁽²⁾	D, see ¹⁷⁶ Hf	4E+4	9E+4	4E-5	1E-7	5E-4	5E-3
		W, see ¹⁷⁰ Hf	-	1E+5	6E-5	2E-7	-	•
72	Hafnium-182	D, see ¹⁷⁰ Hf	2E+2 Bone Surf	8E-1 Bone Surf	3E-10	-	•	-
			(4E+2)	(2E+0)	-	2E-12	1E-5	5E-5
		W, see ¹⁷⁰ Hf	-	3E+0 Bone Surf	1E-9	-	-	•
			-	(7E+0)		1E-11	-	-
72	Hafnium-183 ⁽²⁾	D, see ¹⁷⁰ Hf	2E+4	5E+4	2E-5	6E-8	3E-4	3E-3
		W, see 170Hf	-	6E+4	2E-5	8E-8	•	
72	Hafnium-184	D, see ¹⁷⁰ Hf	2E+3	8E+3	3E-6	1E-8	3E-5	3E-4
		W, see 170Hf	-	6E+3	3E-6	9E-9	-	-

			Occ	Table 1 upational V	alues	Em	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 5E-3 9E-4 - 4E-3 - 8E-4 - 5E-4 - 2E-3 - 2E-3 - 3E-3 - 3E-3 - 2E-4
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration
73	Tantalum-172(2)	W, all compounds except those given for Y	4E+4	1E+5	5E-5	2E-7	5E-4	5E-3
		Y, elemental Ta, oxides, hydroxides, halides, carbides, nitrates, and nitrides	-	1E+5	4E-5	1E-7		-
73	Tantalum-173	W, see 172Ta	7E+3	2E+4	8E-6	3E-8	9E-5	9E-4
		Y, see 172Ta	-	2E+4	7E-6	2E-8	-	-
73	Tantalum-174(2)	W, see 172Ta	3E+4	1E+5	4E-5	IE-7	4E-4	4E-3
		Y, see 173Ta	-	9E+4	4E-5	IE-7	-	-
73	Tantalum-175	W, see 172Ta	6E+3	2E+4	7E-6	2E-8	8E-5	8E-4
		Y, see 172 Ta	-	1E+4	6E-6	2E-8	-	-
73	Tantalum-176	W, see 172Ta	4E+3	1E+4	5E-6	2E-8	5E-5	5E-4
	İ	Y, see 172Ta	-	1E+4	5E-6	2E-8	-	-
73	Tantalum-177	W, see 172Ta	1E+4	2E+4	8E-6	3E-8	2E-4	2E-3
		Y, see 172Ta	-	2E+4	7E-6	2E-8	-	-
73	Tantalum-178	W, see 172Ta	2E+4	9E+4	4E-5	1E-7	2E-4	2E-3
		Y, see 173Ta	-	7E+4	3E-5	1E-7	-	-
73	Tantalum-179	W, see 172Ta	2E+4	5E+3	2E-6	8E-9	3E-4	3E-3
		Y, see 172Ta	-	9E+2	4E-7	1E-9	-	-
73	Tantalum-180m	W, see 173Ta	2E+4	7E+4	3E-5	9E-8	3E-4	3E-3
		Υ, see 173 Ta	-	6E+4	2E-5	8E-8	-	-
73	Tantalum-180	W, see 173 Ta	1E+3	4E+2	2E-7	6E-10	2E-5	2E-4
		Y, see 172Ta	-	2E+1	1E-8	3E-11	-	-
73	Tantalum- 182m ⁽²⁾	W, see 172Ta	2E+5 St. wall	5E+5	2E-4	8E-7	-	-
			(2E+5)	-	-	-	3E-3	3E-2
		Y, see 172Ta		4E+5	2E-4	6E-7	-	-
73	Tantalum-182	W, see 172Ta	8E+2	3E+2	1E-7	5E-10	1E-5	1E-4
		Y, see 172Ta	-	1E+2	6E-8	2E-10	-	-

B-57 NUREG-1736

			Occ	Table 1 upational V	alues	Eff	ble 2 luent itrations	Table 3 Releases to Sewers
					Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
73	Tantalum-183	W, see ¹⁷² Ta	9E+2 LLI wall	1E+3	5E-7	2E-9	-	-
			(1E+3)	-		-	2E-5	2E-4
		Y, see 172Ta	-	1E+3	4E-7	1E-9	-	-
73	Tantalum-184	W, see 172 Ta	2E+3	5E+3	2E-6	8E-9	3E-5	3E-4
		Y, see 172Ta	-	5E+3	2E-6	7E-9	-	-
73	Tantalum-185 ⁽²⁾	W, see 172 Ta	3E+4	7E+4	3E-5	IE-7	4E-4	4E-3
	<u> </u>	Y, see ¹⁷² Ta	-	6E+4	3E-5	9E-8		-
73	Tantalum-186 ⁽²⁾	W, see 172Ta	5E+4 St. wall	2E+5	1E-4	3E-7	-	-
	l		(7E+4)	-	-	-	1E-3	1E-2
		Y, see 172Ta	-	2E+5	9E-5	3E-7	-	-
74	Tungsten-176	D, all compounds	1E+4	5E+4	2E-5	7E-8	1E-4	1E-3
74	Tungsten-177	D, all compounds	2E+4	9E+4	4E-5	1E-7	3E-4	3E-3
74	Tungsten-178	D, all compounds	5E+3	2E+4	8E-6	3E-8	7E-5	7E-4
74	Tungsten-179(2)	D, all compounds	5E+5	2E+6	7E-4	2E-6	7E-3	7E-2
74	Tungsten-181	D, all compounds	2E+4	3E+4	1E-5	5E-8	2E-4	2E-3
74	Tungsten-185	D, all compounds	2E+3 LLI wall	7E+3	3E-6	9E-9	-	
			(3E+3)	-	-	-	4E-5	4E-4
74	Tungsten-187	D, all compounds	2E+3	9E+3	4E-6	1E-8	3E-5	3E-4
74	Tungsten-188	D, all compounds	4E+2 LLI wall	1E+3	5E-7	2E-9	-	-
			(5E+2)	-	-	-	7E-6	7E-5
75	Rhenium-177 ¹²¹	D, all compounds except those given for W	9E+4 St. wall	3E+5	IE-4	4E-7	-	•
			(1E+5)	-	-	-	2E-3	2E-2
		W, oxides, hydroxides, and nitrates	-	4E+5	1E-4	5E-7	-	-

<u> </u>			Oec	Table 1 upational Va	alues	Em	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (μCi/ml)
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	i .
75	Rhenium-178 ⁽²⁾	D, see ¹⁷⁷ Re	7E+4 St. wall	3E+5	1E-4	4E-7	-	-
			(1E+5)	-	-	-	1E-3	1E-2
		W, see 177Re	-	3E+5	1E-4	4E-7		-
75	Rhenium-181	D, see ¹⁷⁷ Re	5E+3	9E+3	4E-6	1E-8	7E-5	7E-4
		W, see 177Re	-	9E+3	4E-6	1E-8	-	-
75	Rhenium-182	D, see 177Re	7E+3	1E+4	5E-6	2E-8	9E-5	9E-4
	(12.7h)	W, see 177Re	-	2E+4	6E-6	2E-8	-	-
75	Rhenium-182	D, see 177Re	1E+3	2E+3	1E-6	3E-9	2E-5	2E-4
	(64.0h)	W, see 177Re	-	2E+3	9E-7	3E-9	-	-
75	Rhenium-184m	D, see 177Re	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4
		W, see 177Re	-	4E+2	2E-7	6E-10	-	-
75	Rhenium-184	D, see 177Re	2E+3	4E+3	1E-6	5E-9	3E-5	Monthly Average Concentration (μCi/ml) 1E-2 7E-4 9E-4 3E-4 3E-4 3E-4 1E-2 1E-2 1E-2 2E-4 4E-4
		W, see 177Re	-	1E+3	6E-7	2E-9	-	-
75	Rhenium-186m	D, see 177Re	1E+3 St. wall	2E+3 St. wall	7E-7	-	-	-
			(2E+3)	(2E+3)	-	3E-9	2E-5	2E-4
		W, see 177Re	-	2E+2	6E-8	2E-10	-	-
75	Rhenium-186	D, see 177Re	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4
		W, see 177Re	-	2E+3	7E-7	2E-9	-	-
75	Rhenium-187	D, see 177Re	6E+5	8E+5 St. wall	4E-4	-	8E-3	8E-2
			-	(9E+5)	-	1E-6	-	-
		W, see 177Re	-	1E+5	4E-5	1E-7	-	-
75	Rhenium-188m ⁽²⁾	D, see 177Re	8E+4	1E+5	6E-5	2E-7	1E-3	1E-2
		W, see 177Re	-	1E+5	6E-5	2E-7	-	-
75	Rhenium-188	D, see 177Re	2E+3	3E+3	1E-6	4E-9	2E-5	2E-4
		W, 000 ¹⁷⁷ Ro		3F#3	1F-fi	4E-9	-	-
75	Rhenium-189	D, see 177Re	3E+3	5E+3	2E-6	7E-9	4E-5	4E-4
		W, see 177Re	-	4E+3	2E-6	6E-9	-	-

B-59 NUREG-1736

			Occ	Table 1 upational V	alues	Eff	ble 2 luent strations	Table 3 Releases to Sewers Monthly Average Concentration (μCi/ml) 1E-2
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1 Col. 2		1 '
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration
76	Osmium-180 ⁽²⁾	D, all compounds except those given for W and Y	1E+5	4E+5	2E-4	5E-7	1E-3	1E-2
		W, halides and nitrates	-	5E+5	2E-4	7E-7	·: -	-
		Y, oxides and hydroxides	-	5E+5	2E-4	6E-7		+
76	Osmium-181 ⁽²⁾	D, see ¹⁸⁰ Os	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see 180Os	-	5E+4	2E-5	6E-8	-	-
		Y, see ¹⁸⁰ Os	-	4E+4	2E-5	6E-8	-	-
76	Osmium-182	D, see ¹⁸⁰ Os	2E+3	6E+3	2E-6	8E-9	3E-5	3E-4
		W, see 180Os	-	4E+3	2E-6	6E-9	-	-
		Y, see 180Os	-	4E+3	2E-6	6E-9	-	-
76	Osmium-185	D, see ¹⁸⁰ Os	2E+3	5E+2	2E-7	7E-10	3E-5	3E-4
		W, see 180Os	-	8E+2	3E-7	1E-9	-	-
		Y, see ¹⁸⁰ Os	-	8E+2	3E-7	1E-9	-	-
76	Osmium-189m	D, see 180Os	8E+4	2E+5	1E-4	3E-7	1E-3	1E-2
		W, see 180Os	-	2E+5	9E-5	3E-7	-	3E-4
		Y, see 180Os		2E+5	7E-5	2E-7	-	-
76	Osmium-191m	D, see ¹⁸⁰ Os	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
		W, see INOOs	-	2E+4	8E-6	3E-8	-	-
		Y, see 180Os	-	2E+4	7E-6	2E-8	-	
76	Osmium-191	D, see ¹⁸⁰ Os	2E+3 LLI wall	2E+3	9E-7	3E-9		-
			(3E+3)	-	-	-	3E-5	3E-4
		W, see 180Os		2E+3	7E-7	2E-9	-	
		Y, see 180Os	-	1E+3	6E-7	2E-9	-	-
76	Osmium-193	D, see ¹⁸⁰ Os	2E+3 LLI wall	5E+3	2E-6	6E-9	-	-
			(2E+3)	-	-	-	2E-5	2E-4
		W, see ¹⁸⁰ Os	-	3E+3	1E-6	4E-9	-	-
		Y, see INOOs	-	3E+3	1E-6	4E-9	-	

			Occ	Table 1 upational V	alues	Effi	ole 2 uent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Ingestion Inhalation				Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (μCi/ml)
76	Osmium-194	D, see ¹⁸⁰ Os	4E+2 LLI wall	4E+1	2E-8	6E-11	-	-
			(6E+2)	-	-	-	8E-6	8E-5
	,	W, see 180Os	-	6E+1	2E-8	8E-11	-	-
		Y, see ¹⁸⁰ Os	-	8E+0	3E-9	1E-11	-	-
77	Iridium-182 ⁽²⁾	D, all compounds except those given for W and Y	4E+4 St. wall	1E+5	6E-5	2E-7	-	-
			(4E+4)	-	-	-	6E-4	6E-3
		W, halides, nitrates, and metallic iridium		2E+5	6E-5	2E-7	-	-
		Y. oxides and hydroxides	-	1E+5	5E-5	2E-7	-	-
. 77	Iridium-184	D, see 182Ir	8E+3	2E+4	1E-5	3E-8	1E-4	1E-3
		W, see 182Ir	-	3E+4	1E-5	5E-8	-	-
		Y, see 182Ir	-	3E+4	1E-5	4E-8	-	-
77	Iridium-185	D, see 182 fr	5E+3	1E+4	5E-6	2E-8	7E-5	7E-4
		W, see 182Ir		IE+4	5E-6	2E-8	-	-
		Y, see 182 Ir	-	1E+4	4E-6	1E-8		-
77	Iridium-186	D, see 182 Ir	2E+3	8E+3	3E-6	1E-8	3E-5	3E-4
		W, see 182Ir	-	6E+3	3E-6	9E-9	-	-
		Y, see 182 Ir	-	6E+3	2E-6	8E-9	-	-
77	Iridium-187	D, see 182Ir	1E+4	3E+4	1E-5	5E-8	1E-4	1E-3
		W, see 1821r	-	3E+4	1E-5	4E-8	-	_
		Y, see 182Ir	-	3E+4	1E-5	4E-8	-	•
77	Iridium-188	D, see 182 Ir	2E+3	5E+3	2E-6	6E-9	3E-5	3E-4
		W, see 1821r	-	4E+3	1E-6	5E-9	-	-
		Y, see 182Ir	-	3E+3	1E-6	5E-9	-	-

B-61 NUREG-1736

			Occ	Table 1 upational V	alues	Eff	ole 2 uent itrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	alation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
77	Iridium-189	D, see 182Ir	5E+3 LLI wall	5E+3	2E-6	7E-9	-	-
			(5E+3)	-	-	-	7E-5	7E-4
		W, see 182Ir	-	4E+3	2E-6	5E-9	-	-
		Y, see 182 Ir	-	4E+3	1E-6	5E-9	-	-
77	Iridium-190m ⁽²⁾	D, see 182 Ir	2E+5	2E+5	8E-5	3E-7	2E-3	2E-2
		W, see 182Ir	-	2E+5	9E-5	3E-7	-	-
	1	Y, see 182 Ir	-	2E+5	8E-5	3E-7	-	-
77	Iridium-190	D, see 182 Ir	1E+3	9E+2	4E-7	1E-9	1E-5	1E-4
		W, see 182 Ir	-	1E+3	4E-7	1E-9	-	-
		Y, see 182 Ir	-	9E+2	4 E -7	1E-9	-	-
77	Iridium-192m	D, see 182 Ir	3E+3	9E+1	4E-8	1E-10	4E-5	4E-4
		W, see 182Ir	-	2E+2	9E-8	3E-10	-	-
		Y, see 182Ir	-	2E+1	6E-9	2E-11	-	-
77	Iridium-192	D, see 182 Ir	9E+2	3E+2	IE-7	4E-10	1E-5	1E-4
		W, see 182 Ir	-	4E+2	2E-7	6E-10	-	-
	·	Y, see 1×2 Ir	-	2E+2	9E-8	3E-10	-	-
77	Iridium-194m	D, see 182Ir	6E+2	9E+1	4E-8	1E-10	9E-6	9E-5
		W, see 182 Ir	-	2E+2	7E-8	2E-10	-	-
		Y, see 182Ir	-	1E+2	4E-8	1E-10	-	-
77	Iridium-194	D, see 182 Ir	1E+3	3E+3	1E-6	4E-9	1E-5	1E-4
		W, see 182 Ir	-	2E+3	9E-7	3E-9	-	-
		Y, see 182 Ir	-	2E+3	8E-7	3E-9	-	-
77	Iridium-195m	D, see ¹⁸² lr	8E+3	2E+4	1E-5	3E-8	1E-4	1E-3
		W, see 182 Ir	-	3E+4	1E-5	4E-8	-	-
		Y, see 182 Ir	-	2E+4	9E-6	3E-8	-	-
77	Iridium-195	D, see 182 Ir	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see 182 Ir	-	5E+4	2E-5	7E-8	- 1	-
i		Y, see 182 Ir	-	4E+4	2E-5	6E-8	-	-

			Occ	Table 1 upational Va	alues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion		lation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
78	Platinum-186	D, all compounds	1E+4	4E+4	2E-5	5E-8	2E-4	2E-3
78	Platinum-188	D, all compounds	2E+3	2E+3	7E-7	2E-9	2E-5	2E-4
78	Platinum-189	D, all compounds	1E+4	3E+4	1E-5	4E-8	1E-4	1E-3
78	Platinum-191	D, all compounds	4E+3	8E+3	4E-6	1E-8	5E-5	5E-4
78	Platinum-193m	D, all compounds	3E+3 LLI wall	6E+3	3E-6	8E-9	-	-
			(3E+4)	-	-	-	4E-5	4E-4
78	Platinum-193	D, all compounds	4E+4 LLI wall	2E+4	1E-5	3E-8	-	-
			(5E+4)	-	-	-	6E-4	6E-3
78	Platinum-195m	D, all compounds	2E+3 LLI wall	4E+3	2E-6	6E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
78	Platinum-197m(2)	D, all compounds	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
78	Platinum-197	D, all compounds	3E+3	1E+4	4E-6	1E-8	4E-5	4E-4
78	Platinum-199 ⁽²⁾	D, all compounds	5E+4	1E+5	6E-5	2E-7	7E-4	7E-3
78	Platinum-200	D, all compounds	1E+3	3E+3	1E-6	5E-9	2E-5	2E-4
79	Gold-193	D, all compounds except those given for W and Y	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
		W, halides and nitrates	-	2E+4	9E-6	3E-8		
		Y, oxides and hydroxides	-	2E+4	8E-6	3E-8	-	-
79	Gold-194	D, see 193Au	3E+3	8E+3	3E-6	1E-8	4E-5	4E-4
		W, see ¹⁹³ Au	-	5E+3	2E-6	8E-9	-	-
		Y, see 193Au	-	5E+3	2E-6	7E-9	-	-
79	Gold-195	D, see 193Au	5E+3	1E+4	5E-6	2E-8	7E-5	7E-4
		W, see 193Au	-	1E+3	6E-7	2E-9		-
		Y, see 193Au	-	4E+2	2E-7	6E-10	-	-

			Occ	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inhalation			-	Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (μCi/ml)
79	Gold-198m	D, see 193Au	1E+3	3E+3	IE-6	4E-9	1E-5	1E-4
		W, see 193Au	-	1E+3	5E-7	2E-9		_
		Y, see 193Au	-	1E+3	5E-7	2E-9	-	-
79	Gold-198	D, see 193Au	1E+3	4E+3	2E-6	5E-9	2E-5	2E-4
		W, see 193Au	-	2E+3	8E-7	3E-9	-	-
		Y, see 193Au	-	2E+3	7E-7	2E-9	-	-
79	Gold-199	D, see ¹⁹³ Au	3E+3 LLI wall	9E+3	4E-6	1E-8	-	-
			(3E+3)	-	-	-	4E-5	4E-4
		W, see 193Au	-	4E+3	2E-6	6E-9	-	-
		Y, see 193Au	-	4E+3	2E-6	5E-9	-	-
79	Gold-200m	D, see 193Au	1E+3	4E+3	1E-6	5E-9	2E-5	2E-4
		W, see 193Au	-	3E+3	1E-6	4E-9	-	
		Y, see 193Au	-	2E+4	1E-6	3E-9	-	-
79	Gold-200 ⁽²⁾	D, see 193Au	3E+4	6E+4	3E-5	9E-8	4E-4	4E-3
		W, see 193Au	-	8E+4	3E-5	1E-7	-	-
		Y, see 193Au	-	7E+4	3E-5	1E-7	-	-
79	Gold-201 ⁽²⁾	D, see ¹⁹³ Au	7E+4 St. wall	2E+5	9E-5	3E-7	-	-
			(9E+4)	-	-	-	1E-3	1E-2
		W, see 193Au	-	2E+5	1E-4	3E-7	-	-
		Y, see 193Au	-	2E+5	9E-5	3E-7	-	-
80	Mercury-193m	Vapor	-	8E+3	4E-6	1E-8	-	-
		Organic D	4E+3	1E+4	5E-6	2E-8	6E-5	6E-4
ĺ		D, sulfates	3E+3	9E+3	4E-6	1E-8	4E-5	4E-4
		W, oxides, hydroxides, halides, nitrates, and sulfides	-	8E+3	3E-6	1E-8	-	-

NUREG-1736

			Occ	Table 1 upational Va	ilues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion Inhalation				Monthly Average	
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
80	Mercury-193	Vapor	-	3E+4	1E-5	4E-8	-	-
		Organic D	2E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		D, see ^{193m} Hg	2E+4	4E+4	2E-5	6E-8	2E-4	2E-3
		W, see 193mHg	-	4E+4	2E-5	6E-8	-	-
80	Mercury-194	Vapor	-	3E+1	1E-8	4E-11	-	
		Organic D	2E+1	3E+1	1E-8	4E-11	2E-7	2E-6
		D, see ^{193m} Hg	8E+2	4E+1	2E-8	6E-11	1E-5	1E-4
		W, see 193mHg	-	1E+2	5E-8	2E-10	-	-
80	Mercury-195m	Vapor	-	4E+3	2E-6	6E-9	-	-
		Organic D	3E+3	6E+3	3E-6	8E-9	4E-5	4E-4
		D, see 193mHg	2E+3	5E+3	2E-6	7E-9	3E-5	3E-4
		W, see 193mHg	-	4E+3	2E-6	5E-9	-	-
80	Mercury-195	Vapor	-	3E+4	1E-5	4E-8	-	-
		Organic D	2E+4	5E+4	2E-5	6E-8	2E-4	2E-3
		D, see 193mHg	1E+4	4E+4	1E-5	5E-8	2E-4	2E-3
		W, see 193mHg	-	3E+4	1E-5	5E-8	-	-
80	Mercury-197m	Vapor	-	5E+3	2E-6	7E-9	-	-
		Organic D	4E+3	9E+3	4E-6	1E-8	5E-5	5E-4
		D, see 193mHg	3E+3	7E+3	3E-6	1E-8	4E-5	4E-4
		W, see 193mHg	-	5E+3	2E-6	7E-9	-	-
80	Mercury-197	Vapor	-	8E+3	4E-6	1E-8	-	-
		Organic D	7E+3	1E+4	6E-6	2E-8	9E-5	9E-4
		D, see ^{193m} Hg	6E+3	1E+4	5E-6	2E-8	8E-5	8E-4
		W, see 193mHg	T -	9E+3	4E-6	1E-8	-	-

-			Occ	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inh	alation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
80	Mercury-199m ⁽²⁾	Vapor	-	8E+4	3E-5	1E-7	-	-
		Organic D	6E+4 St. wall	2E+5	7E-5	2E-7	-	-
			(1E+5)	-	-		1E-3	1E-2
		D, see 193mHg	6E+4	1E+5	6E-5	2 E -7	8E-4	8E-3
		W, see 193mHg	-	2E+5	7E-5	2E-7	-	-
80	Mercury-203	Vapor	-	8E+2	4E-7	1E-9	-	-
		Organic D	5E+2	8E+2	3E-7	1E-9	7E-6	7E-5
		D, see ^{193m} Hg	2E+3	1E+3	5E-7	2E-9	3E-5	3E-4
		W, see 193mHg	-	1E+3	5E-7	2E-9	-	-
81	Thallium-194m ⁽²⁾	D, all compounds	5E+4 St. wall	2E+5	6E-5	2E-7	-	-
-,.			(7E+4)	-	-	-	1E-3	1E-2
81	Thallium-194 ⁽²⁾	D, all compounds	3E+5 St. wall	6E+5	2E-4	8E-7	-	-
			(3E+5)	-	-	-	4E-3	4E-2
81	Thallium-195 ⁽²⁾	D, all compounds	6E+4	1E+5	5E-5	2E-7	9E-4	9E-3
81	Thallium-197	D, all compounds	7E+4	1E+5	5E-5	2E-7	1E-3	1E-2
81	Thallium-198m ⁽²⁾	D, all compounds	3E+4	5E+4	2E-5	8E-8	4E-4	4E-3
81	Thallium-198	D, all compounds	2E+4	3E+4	1E-5	5E-8	3E-4	3E-3
81	Thallium-199	D, all compounds	6E+4	8E+4	4E-5	IE-7	9E-4	9E-3
81	Thallium-200	D, all compounds	8E+3	1E+4	5E-6	2E-8	1E-4	1E-3
81	Thallium-201	D. all compounds	2E+4	2E+4	9E-6	3E-8	2E-4	2E-3
81	Thallium-202	D, all compounds	4E+3	5E+3	2E-6	7E-9	5E-5	5E-4
81	Thallium-204	D, all compounds	2E+3	2E+3	9E-7	3E-9	2E-5	2E-4
82	Lead-195m ⁽²⁾	D, all compounds	6E+4	2E+5	8E-5	3E-7	8E-4	8E-3
82	Lead-198	D, all compounds	3E+4	6E+4	3E-5	9E-8	4E-4	4E-3
82	Lead-199 ⁽²⁾	D, all compounds	2E+4	7E+4	3E-5	1E-7	3E-4	3E-3
82	Lead-200	D, all compounds	3E+3	6E+3	3E-6	9E-9	4E-5	4E-4
82	Lead-201	D, all compounds	7E+3	2E+4	8E-6	3E-8	1E-4	1E-3

			Occ	Table 1 upational Va	alues	Effi	ole 2 uent trations	Table 3 Releases to Sewers
			Col. 1 Oral Ingestion	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
82	Lead-202m	D, all compounds	9E+3	3E+4	1E-5	4E-8	1E-4	1E-3
82	Lead-202	D, all compounds	1E+2	5E+1	2E-8	7E-11	2E-6	2E-5
82	Lead-203	D, all compounds	5E+3	9E+3	4E-6	1E-8	7E-5	7E-4
82	Lead-205	D, all compounds	4E+3	1E+3	6E-7	2E-9	5E-5	5E-4
82	Lead-209	D, all compounds	2E+4	6E+4	2E-5	8E-8	3E-4	3E-3
82	Lead-210	D, all compounds	6E+1 Bone Surf	2E+1 Bone Surf	1E-10	-		-
			(1E+0)	(4E-1)	-	6E-13	1E-8	1E-7
82	Lead-211(2)	D, all compounds	1E+4	6E+2	3E-7	9E-10	2E-4	2E-3
82	Lead-212	D, all compounds	8E+1 Bone Surf	3E+1	1E-8	5E-11	-	-
			(1E+2)	-	-	-	2E-6	2E-5
82	Lead-214(2)	D, all compounds	9E+3	8E+2	3E-7	1E-9	1E-4	1E-3
83	Bismuth-200(2)	D, nitrates	3E+4	8E+4	4E-5	1E-7	4E-4	4E-3
		W, all other compounds	-	1E+5	4E-5	1E-7	-	-
83	Bismuth-201(2)	D, see ²⁰⁰ Bi	1E+4	3E+4	1E-5	4E-8	2E-4	2E-3
		W, see 200Bi	-	4E+4	2E-5	5E-8	-	
83	Bismuth-202(2)	D, see 200Bi	1E+4	4E+4	2E-5	6E-8	2E-4	2E-3
	1	W, see ²⁰⁰ Bi	T -	8E+4	3E-5	1E-7	-	-
83	Bismuth-203	D, see 200 Bi	2E+3	7E+3	3E-6	9E-9	3E-5	3E-4
		W, see ²⁰⁰ Bi	-	6E+3	3E-6	9E-9	-	-
83	Bismuth-205	D, see 200Bi	1E+3	3E+3	1E-6	3E-9	2E-5	2E-4
		W, see 200Bi	-	1E+3	5E-7	2E-9	-	-
83	Bismuth-206	D, see ²⁰⁰ Bi	6E+2	1E+3	6 E -7	2E-9	9E-6	9E-5
		W, see 300Bi	-	9E+2	4E-7	1E-9	-	-
83	Bismuth-207	D, see ²⁰⁰ Bi	1E+3	2E+3	7E-7	2E-9	1E-5	1E-4
		W, see ²⁰⁰ Bi		4E+2	1E-7	5E-10	-	

			Occ	Table 1 cupational V	alues	Eff	ble 2 luent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	alation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
83	Bismuth 210m	D, see ²⁰⁰ Bi	4E+1 Kidneys	5E+8 Kidneys	2E-9	-	-	•
			(6E+1)	(6E+0)	-	9E-12	8E-7	8E-6
		W, see 200Bi	-	7E-1	3E-10	9E-13	-	-
83	Bismuth-210	D, see ²⁰⁰ Bi	8E+2	2E+2 Kidneys	1E-7	-	1E-5	1E-4
			-	(4E+2)	-	5E-10	-	-
		W, see 200Bi	-	3E+1	1E-8	4E-11	-	-
83	Bismuth-212(2)	D, see ²⁰⁰ Bi	5E+3	2E+2	1E-7	3E-10	7E-5	7E-4
		W, see 200Bi	-	3E+2	1E-7	4E-10	-	-
83	Bismuth-213(2)	D, see ²⁰⁰ Bi	7E+3	3E+2	1E-7	4E-10	1E-4	1E-3
		W, see 200Bi	-	4E+2	1E-7	5E-10	-	-
83	Bismuth-214 ⁽²⁾	D, see ³⁰⁰ Bi	2E+4 St. wall	8E+2	3E-7	1E-9	-	-
			(2E+4)	•	-	-	3E-4	3E-3
		W, see 200Bi	-	9E-2	4E-7	1E-9	-	_
84	Polonium-203 ⁽²⁾	D, all compounds except those given for W	3E+4	6E+4	3E-5	9E-8	3E-4	3E-3
		W, oxides, hydroxides, and nitrates	-	9E+4	4E-5	IE-7	-	_
84	Polonium-205(2)	D, see 203Po	2E+4	4E+4	2E-5	5E-8	3E-4	3E-3
		W, see ²⁰³ Po	-	7E+4	3E-5	1E-7	-	<u>-</u> .
84	Polonium-207	D, see ²⁰³ Po	8E+3	3E+4	1E-5	3E-8	1E-4	1E-3
		W, see 203Po	-	3E+4	1E-5	4E-8	-	-
84	Polonium-210	D, see ²⁰³ Po	3E+0	6E-1	3E-10	9E-13	4E-8	4E-7
		W, see ²⁰³ Po	-	6E-1	3E-10	9E-13	-	-
85	Astatine-207 ⁽²⁾	D, halides	6E+3	3E+3	1E-6	4E-9	8E-5	8E-4
		w		2E+3	9E-7	3E-9	-	-
85	Astatine-211	D, halides	1E+2	8E+1	3E-8	1E-10	2E-6	2E-5
		w	-	5E+1	2E-8	8E-11	-	-

			Occ	Table 1 upational Va	lues	Effi	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 3E-4 8E-5 - 1E-6 - 2E-6
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration
86	Radon-220	With daughters removed	-	2E+4	7E-6	2E-8	-	-
		With daughters present	-	2E+1 (or 12 working level months)	9E-9 (or 1.0 working level)	3E-11	· -	-
86	Radon-222	With daughters removed	-	1E+4	4E-6	1E-8	-	-
		With daughters present	-	1E+2 (or 4 working level months)	3E-8 (or 0.33 working level)	1E-10	-	-
87	Francium-222(2)	D, all compounds	2E+3	5E+2	2E-7	6E-10	3E-5	3E-4
87	Francium-223(2)	D, all compounds	6E+2	8E+2	3E-7	1E-9	8E-6	8E-5
88	Radium-223	W, all compounds	5E+0 Bone Surf	7E-1	3E-10	9E-13	-	-
	1		(9E+0)	-	-	-	1E-7	1E-6
88	Radium-224	W, all compounds	8E+0 Bone Surf	2E+0	7E-10	2E-12	-	-
			(2E+1)	-		-	2E-7	2E-6
88	Radium-225	W, all compounds	8E+0 Bone Surf	7E-1	3E-10	9E-13	-	-
			(2E+1)	-	-	-	2E-7	2E-6
88	Radium-226	W, all compounds	2E+0 Bone Surf	6E-1	3E-10	9E-13	-	-
			(5E+0)	-	-	-	6E-8	6E-7
88	Radium-227 ⁽²⁾	W, all compounds	2E+4 Bone Surf	1E+4 Bone Surf	6E-6	-	-	_
			(2E+4)	(2E+4)	-	3E-8	3E-4	3E-3
88	Radium-228	W, all compounds	2E+0 Bone Surf	1E+0	5E-10	2E-12	-	-
			(4E+0)	-	-	-	6E-8	6E-7

			Oc	Table 1 cupational V	alues	Eff	ble 2 luent ntrations	Table 3 Releases to Sewers
			Col. 1	Col. 2 Col. 3	Col. 1	Col. 2		
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)			Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
89	Actinium-224	D, all compounds except those given for W and Y	2E+3 LLI wall		1E-8	-	-	-
			(2E+3)	(4E+1)	-	5E-11	3E-5	3E-4
		W, halides and nitrates	-	5E+1	2E-8	7E-11	-	-
		Y, oxides and hydroxides	-	5E+1	2E-8	6E-11	-	-
89	Actinium-225	D, see ²²⁴ Ac	5E+1 LLI wall		1E-10	-	-	-
			(5E+1)	(5E-1)	-	7E-13	7E-7	7E-6
		W, see ²²⁴ Ac	-	6E-1	3E-10	9E-13	-	-
		Y, see ²²⁴ Ac	-	6E-1	3E-10	9E-13	-	-
89	Actinium-226	D, see ²²⁴ Ac	1E+2 LLI wall		1E-9	-	7	-
-			(1E+2)	(4E+0)	-	5E-12	2E-6	2E-5
		W, see ²²⁴ Ac	-	5E+0	2E-9	7E-12	-	-
		Y, see ²²⁴ Ac	-	5E+0	2E-9	6E-12	-	
89	Actinium-227	D, see ²²⁴ Ac	2E-1 Bone Surf		2E-13	-	-	. •
			(4E-1)	(8E-4)	-	IE-15	5E-9	5E-8
		W, see ²²⁴ Ac	-		7E-13	-	-	-
			-	(3E-3)	-	4E-15	-	-
		Y, see ²²⁴ Ac	-	4E-3	2E-12	6E-15	-	-
89	Actinium-228	D, see ²²⁴ Ac	2E+3	9E+0 Bone Surf	4E-9	-	3E-5	3E-4
			-	(2E+1)	-	2E-11	-	_
		W, see ²²⁴ Ac	-	4E+1 Bone Surf	2E-8	-		-
			-	(6E+1)	-	8E-11	-	-
		Y, see 224Ac	-	4E+1	2E-8	6E-11	-	-

			Occ	Table 1 upational Va	lues	Effi Concen	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 7E-4 2E-5 2E-6 2E-7 - 1E-6 - 3E-7
Atomic			Col. 1 Oral Ingestion ALI	Col. 2 Inha	Col. 3	Col. 1	Col. 2	Average
No.	Radionuclide	Class	(μCi)	(μCi)	(μCi/ml)	(μCi/ml)	(μCi/ml)	(μCi/ml)
90	Thorium-226 ⁽²⁾	W, all compounds except those given for Y	5E+3 St. wali	2E+2	6E-8	2E-10	-	-
			(5E+3)		-	-	7E-5	7E-4
		Y, oxides and hydroxides	-	1E+2	6E-8	2E-10	-	-
90	Thorium-227	W, see ²²⁶ Th	1E+2	3E-1	1E-10	5E-13	2E-6	2E-5
	ŀ	Y, see ²²⁶ Th	-	3E-1	1E-10	5E-13	-	-
90	Thorium-228	W, see 226Th	6E+0 Bone Surf	1E-2 Bone Surf	4E-12		-	-
			(1E+1)	(2E-2)	-	3E-14	2E-7	Monthly Average Concentration (μCi/ml) 7E-4 2E-5 2E-6 2E-7 1E-6 5E-4
		Y, see ²²⁶ Th	-	2E-2	7E-12	2E-14	-	-
90	Thorium-229	W, see ²²⁶ Th	6E-1 Bone Surf	9E-4 Bone Surf	4E-13	-	-	-
			(1E+0)	(2E-3)	-	3E-15	2E-8	2E-7
		Y, see ²²⁶ Th	-	2E-3 Bone Surf	1E-12	-	-	Average Concentration (μCi/ml) 7E-4
			-	(3E-3)	-	4E-15	-	-
90	Thorium-230	W, see 226Th	4E+0 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(9E+0)	(2E-2)	-	2E-14	1E-7	1E-6
		Y, see ²²⁶ Th	-	2E-2 Bone Surf	6E-12	-	-	-
			-	(2E-2)	-	3 E -14	-	-
90	Thorium-231	W, see 226 Th	4E+3	6E+3	3E-6	9E-9	5E-5	5E-4
		Y, see ²²⁶ Th	-	6E+3	3E-6	9E-9	-	-
90	Thorium-232	W, see 256Th	7E-1 Bone Surf	1E-3 Bone Surf	5E-13	-	-	-
			(2E+0)	(3E-3)	-	4E-15	3E-8	3E-7
		Y, see 226Th	-	3E-3 Bone Surf	1E-12	-	-	1
			-	(4E-3)	-	6E-15	-	-

			0	Table 1 ccupational	Values	Ea	ible 2 fluent ntrations	Table 3 Releases to Sewers
			Col. 1	Oral ngestion Inhalation Air (μCi) Wate (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) Air (μCi/ml) A	Col. 2			
			Oral Ingestion	Inhalation				Monthly Average
Atomic No.	Radionuclide	Class					Water (µCi/ml)	Concentration (µCi/ml)
90	Thorium-234	W, see ²²⁶ Th	3E+2 LLI wall	2E+2	8E-8	3E-10	-	
			(4E+2)	-	-	-	5E-6	5E-5
		Y, see 226Th	-	2E+2	6E-8	2E-10	-	-
91	Protactinium- 227 ⁽²⁾	W, all compounds except those given for Y	4E+3	1E+2	5E-8	2E-10	5E-5	5E-4
		Y, oxides and hydroxides	-	1E+2	4E-8	1E-10		-
91	Protactinium-228	W, see ²²⁷ Pa	1E+3		5E-9	-	2E-5	2E-4
			-	(2E+1)	-	3E-11	-	-
		Y, see ²²⁷ Pa	-	1E+1	5E-9	2E-11	-	-
91	Protactinium-230	W, see ²²⁷ Pa	6E+2 Bone Surf	5E+0	2E-9	7 E -12	-	-
			(9E+2)	-	-	-	1E-5	1E-4
		Y, see ³²⁷ Pa	· .	4E+0	IE-9	5E-12	-	-
91	Protactinium-231	W, see ²²⁷ Pa	2E-1 Bone Surf		6E-13	-	-	-
			(5E-1)	(4E-3)	-	6E-15	6E-9	6E-8
		Y, see ²²⁷ Pa			2E-12	-	-	-
			-	(6E-3)	-	8E-15	-	-
91	Protactinium-232	W, see ²²⁷ Pa	1E+3	2E+1 Bone Surf	9E-9	-	2E-5	2E-4
- 1	ļ		-	(6E+1)	-	8E-11	-	
		Y, see ²²⁷ Pa	-	6E+1 Bone Surf	2E-8	-	-	-
			-	(7E+1)	-	1E-10	-	
91	Protactinium-233	W, see ²²⁷ Pa	1E+3 LLI wall	7E+2	3E-7	1E-9	-	-
			(2E+3)	-	-	-	2E-5	2E-4
		Y, see 227Pa	-	6E+2	2E-7	8E-10	-	
91 1	Protactinium-234	W, see 227Pa	2E+3	8E+3	3E-6	1E-8	3E-5	3E-4

NUREG-1736

			Occ	Table 1 upational Va	lues	Effi	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml)
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	I
		Y, see 227Pa	-	7E+3	3E-6	9E-9	-	
92	Uranium-230	D, UF ₆ , UO ₂ F ₂ , UO ₂ (NO ₃) ₂	4E+0 Bone Surf	4E-1 Bone Surf	2E-10	-	-	-
			(6E+0)	(6E-1)	-	8E-13	8E-8	8E-7
		W, UO ₃ , UF ₄ , UCI ₄	-	4E-1	1E-10	5E-13	-	-
		Y, UO ₂ , U ₃ O ₈	-	3E-1	1E-10	4E-13	<u>.</u>	<u>.</u>
92	Uranium-231	D, see ²³⁰ U	5E+3 LLI wall	8E+3	3E-6	1E-8	-	-
			(4E+3)	-	-	-	6E-5	6E-4
		W, see ²³⁰ U	-	6E+3	2E-6	8E-9	-	-
		Y, see ²³⁰ U	-	5E+3	2E-6	6E-9	-	
92	Uranium-232	D, see ²³⁰ U	2E+0 Bone Surf	2E-1 Bone Surf	9E-11	-	-	-
			(4E+0)	(4E-1)	-	6E-13	6E-8	6E-7
		W, see ²³⁰ U	-	4E-1	2E-10	5E-13	_	-
		Y, see ²³⁰ U	-	8E-3	3E-12	1E-14	-	-
92	Uranium-233	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	5E-10	-	-	-
			(2E±1)	(2E+9)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	7E-1	3E-10	1E-12	-	-
		Y, see ²⁸⁰ U	-	4E-2	2E-11	5E-14	-	-
92	Uranium-234(3)	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	5E-10	-	^	-
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	7E-1	3E-10	1E-12	_	-
		Y, see ²³⁰ U	-	4E-2	2E-11	5E-14	-	-

B-73

			Occ	Table 1 upational Va	alues	Eff		Table 3 Releases to Sewers Monthly Average Concentration (μCi/ml) 3E-6 3E-6 3E-6 3E-6 - 3E-6
			Col. 1	Col. 2	Col. 3	Col. 1	Value Val	
			Oral Ingestion	Inha	lation			
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)		Concentration (µCi/ml)
92	Uranium-235 ⁽³⁾	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	6E-10	-	-	-
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	8E-1	3E-10	1E-12	-	-
		Y, see ²³⁰ U	-	4E-2	2E-11	6E-14	-	-
92	Uranium-236	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	5E-10	-	-	
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	8E-1	3E-10	1E-12	-	-
		Y, see ²³⁰ U	-	4E-2	2E-11	6E-14	-	-
92	Uranium-237	D, see ²³⁰ U	2E+3 LLI wałl	3E+3	1E-6	4E-9	-	-
			(2E+3)	-	-	-	3E-5	3E-4
		W, see ²³⁰ U		2E+3	7E-7	2E-9	-	
		Y, see ²³⁰ U	-	2E+3	6E-7	2E-9		-
92	Uranium-238 ⁽³⁾	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	6E-10	-	-	-
	İ		(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	8E-1	3E-10	1E-12	-	-
		Y, see ²³⁰ U	-	4E-2	2E-11	6E-14	-	-
92	Uranium-239 ⁽²⁾	D, see ²³⁰ U	7E+4	2E+5	8E-5	3E-7	9E-4	9E-3
		W, see ²³⁰ U	-	2E+5	7E-5	2E-7	-	-
		Y, see ²³⁰ U	-	2E+5	6E-5	2E-7	-	-
92	Uranium-240	D, see ²³⁰ U	1E+3	4E+3	2E-6	5E-9	2E-5	2E-4
		W, see ²³⁰ U	-	3E+3	1E-6	4E-9	-	-
		Y, see ²³⁰ U	-	2E+3	IE-6	3E-9	-	-

			Table 1 Occupational Values			Effi	ole 2 uent trations	Table 3 Releases to Sewers Monthly Average Concentration (µCi/ml) 3E-6
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion		lation			Releases to Sewers Monthly Average Concentration (µCi/ml) 3E-6 2E-2 1E-1 3E-4 3E-3 9E-7 5E-4 2E-7 2E-4
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (µCi/ml)	Water (μCi/ml)	I
92	Uranium- natural ⁽³⁾	D, see ²³⁰ U	1E+1 Bone Surf	1E+0 Bone Surf	5E-10	-	-	-
			(2E+1)	(2E+0)	-	3E-12	3E-7	3E-6
		W, see ²³⁰ U	-	8E-1	3E-10	9E-13	-	-
		Y, see 230U	-	5E-2	2E-11	9E-14	-	-
93	Neptunium-232(2)	W, all compounds	1E+5	2E+3 Bone Surf	7E-7	-	2E-3	2E-2
			-	(5E+2)	-	6E-9	-	
93	Neptunium-233(2)	W, all compounds	8E+5	3E+6	1E-3	4E-6	1E-2	1E-1
93	Neptunium-234	W, all compounds	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4
93	Neptunium-235	W, all compounds	2E+4 LLI wall	8E+2 Bone Surf	3E-7	-	-	-
			(2E+4)	(1E+3)	-	2E-9	3E-4	3E-3
93	Neptunium-236 (1.15E+5y)	W, all compounds	3E+0 Bone Surf	2E-2 Bone Surf	9E-12	-	-	-
			(6E+0)	(5E-5)	-	8E-14	9E-8	9E-7
93	Neptunium- 236m (22.5h)	W, all compounds	3E+3 Bone Surf	3E+1 Bone Surf	1E-8	-	-	
			(4E+3)	(7E+1)	-	1E-10	5E-5	5E-4
93	Neptunium-237	W, all compounds	5E-1 Bone Surf	4E-3 Bone Surf	2E-12	-	-	-
			(1E+0)	(1E-2)	-	1E-14	2E-8	2E-7
93	Neptunium-238	W, all compounds	1E+3	6E+1 Bone Surf	3E-8	-	2E-5	2E-4
			-	(2E+2)	-	2E-10		-
93	Neptunium-239	W, all compounds	2E+3 LLI wall	2E+3	9E-7	3E-9	-	-
			(2E+3)	-	-	-	2E-5	2E-4
93	Neptunium-240 ⁽²⁾	W, all compounds	2E+4	8E+4	3E-5	1E-7	3E-4	3E-3

			Oc	Table 1 cupational V	alues	Eff	ble 2 luent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2]
Atomic No.	Radionuclide	G.	Oral Ingestion ALI	ALI	DAC	Air	Water	Monthly Average Concentration
94		Class	(μCi)	(μCi)	(μCi/ml)	(μCi/ml)	(μCi/ml)	(μCi/ml)
94	Plutonium-234	W, all compounds except PuO ₂	8E+3	2E+2	9E-8	3E-10	IE-4	IE-3
		Y, PuO ₂		2E+2	8E-8	3E-10	-	-
94	Plutonium-235(2)	W, see 234Pu	9E+5	3E+6	1E-3	4E-6	1E-2	1E-1
		Y, see ²³⁴ Pu	-	3E+6	1E-3	3E-6	-	-
94	Plutonium-236	W, see ²³⁴ Pu	2E+0 Bone Surf	2E-2 Bone Surf	8E-12	-	-	_
			(4E+0)	(4E-2)	-	5E-14	6E-8	6E-7
		Y, see ²³⁴ Pu	-	4E-2	2E-11	6E-14	-	-
94	Plutonium-237	W, see ²³⁴ Pu	1E+4	3E+3	1E-6	5E-9	2E-4	2E-3
		Y, see ²³⁴ Pu	-	3E+3	1E-6	4E-9	-	-
94	Plutonium-238	W, see ²³⁴ Pu	9E-1 Bone Surf	7E-3 Bone Surf	3E-12	-	-	-
			(2E+0)	(1E-2)		2E-14	2E-8	2E-7
		Y, see ²³⁴ Pu	-	2E-2	8E-12	2E-14	-	-
94	Plutonium-239	W, see ²³⁴ Pu	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
		Y, see ³³⁴ Pu	-	2E-2 Bone Surf	7E-12	-	-	•
			-	(2E-2)	-	2E-14	-	-
94	Plutonium-240	W, see ²³⁴ Pu	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
		Y, see ²³⁴ Pu	-	2E-2 Bone Surf	7E-12	-	-	-
			-	(2E-2)	-	2E-14	-	-

NUREG-1736

			Occ	Table 1 upational Va		Effi Concen	ole 2 uent tratisns	Table 3 Releases to £aware
			Col. 1 Oral Ingestion	Col. 2	Col. 3	Col. 1	Col. 2	Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration (µCi/ml)
94	Plutonium-241	W, see ²³⁴ Pu	4E+1 Bone Surf	3E-1 Bone Surf	1E-10	-	-	-
			(7E+1)	(6E-1)	-	8E-13	1E-6	1E-5
		Y, see ²³⁴ Pu	-	8E-1 Bone Surf	3E-10	-	-	-
			-	(1E+0)	-	1E-12	-	
94	Plutonium-242	W, see ²³⁴ Pu	8E-1 Bone Surf	7E-3 Bone Surf	3E-12	-	-	-
	ł		(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
		Y, see ²³⁴ Pu	-	2E-2 Bone Surf	7E-12	-	-	-
1			-	(2E-2)	-	2E-14	-	-
94	Plutonium-243	W, see 234Pu	2E+4	4E+4	2E-5	5E-8	2E-4	2E-3
		Y, see ²³⁴ Pu	-	4E+4	2E-5	5E-8	-	-
94	Plutonium-244	W, see ²³⁴ Pu	8E-1 Bone Surf	7E-3 Bone Surf	3E-12	-	-	-
			(2E+0)	(IE-2)	-	2E-14	2E-8	2E-7
		Y, see ²³⁴ Pu	-	2E-2 Bone Surf	7E-12	-	-	-
				(2E-2)	-	2E-14	-	<u> </u>
94	Plutonium-245	W, see ²³⁴ Pu	2E+3	5E+3	2E-6	6E-9	3E-5	3E-4
		Y, see ²³⁴ Pu	-	4E+3	2E-6	6E-9	-	-
94	Plutonium-246	W, see ²³⁴ Pu	4E+2 LLI wall	3E+2	1E-7	4E-10	-	-
			(4E+2)	-	-	-	6E-6	6E-5
		Y, see ²³⁴ Pu	-	3E+2	1E-7	4E-10	-	-
95	Americium- 237 ⁽²⁾	W, all compounds	8E+4	3E+5	IE-4	4E-7	1E-3	1E-2
95	Americium- 238 ⁽²⁾	W, all compounds	4E+4	3E+3 Bone Surf	1E-6	-	5E-4	5E-3
		_	-	(6E+3)	-	9E-9	-	
95	Americium-239	W, all compounds	5E+3	1E+4	5E-6	2E-8	7E-5	7E-4

B-77 NUREG-1736

			Occ	Table 1 cupational V	alues	Eff	ole 2 uent strations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	Ingestion ALI (μCi)	ALI (µCi)	DAC (µCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (µCi/ml)
95	Americium-240	W, all compounds	2E+3	3E+3	1E-6	4E-9	3E-5	3E-4
95	Americium-241	W, all compounds	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
95	Americium- 242m	W, all compounds	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
95	Americium-242	W, all compounds	4E+3	8E+1 Bone Surf	4E-8	-	5E-5	5E-4
	ļ		-	(9E+1)		1E-10	-	-
95	Americium-243	W, all compounds	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
95	Americium- 244m ⁽²⁾	W, all compounds	6E+4 St. wall	4E+3 Bone Surf	2E-6	-	•	-
			(8E+4)	(7E+3)	-	1E-8	1E-3	1E-2
95	Americium-244	W, all compounds	3E+3	2E+2 Bone Surf	8E-8	-	4E-5	4E-4
			-	(3E+2)	-	4E-10	-	-
95	Americium-245	W, all compounds	3E+4	8E+4	3E-5	1E-7	4E-4	4E-3
95	Americium- 246m ⁽²⁾	W, all compounds	5E+4 St. wall	2E+5	8E-5	3E-7	-	,
			(6E+4)	-	-	-	8E-4	8E-3
95	Americium- 246 ⁽²⁾	W, all compounds	3E+4	1E+5	4E-5	1E-7	4E-4	4E-3
96	Curium-238	W, all compounds	2E+4	1E+3	5E-7	2E-9	2E-4	2E-3
96	Curium-240	W, all compounds	6E+1 Bone Surf	6E-1 Bone Surf	2E-10	-	-	-
			(8E+1)	(6E-1)	-	9E-13	1E-6	1E-5
96	Curium-241	W, all compounds	1E+3	3E+1 Bone Surf	1E-8	-	2E-5	2E-4
			-	(4E+1)	-	5E-11	-	+

			Oce	Table 1 cupational Va	alues	Em	ble 2 luent strations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Average Concentration (μCi/ml)
96	Curium-242	W, all compounds	3E+1 Bone Surf	3E-1 Bone Surf	1E-10	-	-	-
			(5E+1)	(3E-1)	-	4E-13	7E-7	7E-6
96	Curium-243	W, all compounds	1E+0 Bone Surf	9E-3 Bone Surf	4E-12	-	-	-
			(2E+0)	(2E-2)	-	2E-14	3E-8	3E-7
96	Curium-244	W, all compounds	1E+0 Bone Surf	1E-2 Bone Surf	5E-12	-	-	-
			(3E+0)	(2E-2)	-	3E-14	3E-8	3E-7
96	Curium-245	W, all compounds	7E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1E+0)	(1E-2)	-	2E-14	2E-8	2E-7
96	Curium-246	W, all compounds	7E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
	ĺ		(1E+0)	(IE-2)	-	2E-14	2E-8	2E-7
96	Curium-247	W, all compounds	8E-1 Bone Surf	6E-3 Bone Surf	3E-12	-	-	-
			(1 E +0)	(1E-2)	-	2E-14	2E-8	2E-7
96	Curium-248	W, all compounds	2E-1 Bone Surf	2E-3 Bone Surf	7E-13	-		-
			(4E-1)	(3E-3)	-	4E-15	5E-9	5E-8
96	Curium-249 ⁽²⁾	W, all compounds	5E+4	2E+4 Bone Surf	7E-6		7E-4	7E-3
			-	(3E+4)	-	4E-8	•	-
96	Curium-250	W, all compounds	4E-2 Bone Surf	3E-4 Bone Surf	1E-13	-	•	-
			(6E-2)	(5E-4)	-	8E-16	9E-10	9E-9
97	Berkelium-245	W, all compounds	2E+3	1E+3	5E-7	2E-9	3E-5	3E-4
97	Berkelium-246	W, all compounds	3E+3	3E+3	1E-6	4E-9	4E-5	4E-4
97	Berkelium-247	W, all compounds	5E-1 Bone Surf	4E-3 Bone Surf	2E-12	-	-	-
			(1E+0)	(9E-3)	-	1E-14	2E-8	2E-7

B-79 NUREG-1736

			Oce	Table 1 Occupational Values			ble 2 luent strations	Table 3 Releases to Sewers
			Col. 1 Oral	Col. 2	Col. 3	Col. 1	Col. 2	Monthly
Atomic No.	Radionuclide	Class	Ingestion ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Average Concentration (\(\alpha\)Ci/ml)
97	Berkelium-249	W, all compounds	2E+2 Bone Surf	2E+0 Bone Surf	7E-10	-	-	-
			(5E+2)	(4E+0)	-	5E-12	6E-6	6E-5
97	Berkelium-250	W, all compounds	9E+3	3E+2 Bone Surf	1E-7	-	1E-4	1E-3
			-	(7E+2)	-	1 E -9	-	-
98	Californium- 244 ⁽²⁾	W, all compounds except those given for Y	3E+4 St. wall	6E+2	2E-7	8E-10	_	-
			(3E+4)	-	-	-	4E-4	4E-3
		Y, oxides and hydroxides	-	6E+2	2E-7	8E-10	-	-
98	Californium-246	W, see ²⁴⁴ Cf	4E+2	9E+0	4E-9	1E-11	5E-6	5E-5
		Y, see ²⁴⁴ Cf	-	9E+0	4E-9	1E-11	-	-
98	Californium-248	W, see ²⁴⁴ Cf	8E+0 Bone Surf	6E-2 Bone Surf	3E-11	-	-	-
			(2E+1)	(1E-1)	-	2E-13	2E-7	2E-6
		Y, see 244Cf	-	1E-1	4E-11	1E-13	-	-
98	Californium-249	W, see ²⁴⁴ Cf	5E-1 Bone Surf	4E-3 Bone Surf	2E-12	-	-	-
			(1E+0)	(9E-3)	-	1E-14	2E-8	2E-7
		Y, see ²⁴⁴ Cf	-	1E-2 Bone Surf	4E-12	-	-	-
			-	(1E-2)	-	2E-14	-	-
98	Californium-250	W, see ²⁴⁴ Cf	1E+0 Bone Surf	9E-3 Bone Surf	4E-12	-	-	-
			(2E+0)	(2E-2)	-	3E-14	3E-8	3E-7
		Y, see ²¹⁴ Cf	-	3E-2	1E-11	4E-14	-	-
98	Californium-251	W, see ²⁴⁴ Cf	5E-1 Bone Surf	4E-3 Bone Surf	2E-12	-	-	-
			(1E+0)	(9E-3)	-	1E-14	2E-8	2E-7
		Y, see 244Cf	-	1E-2 Bone Surf	4E-12	-	-	-
			-	(1E-2)	-	2E-14	-	-

				Table 1 Occupational Values			ble 2 luent atrations	Table 3 Releases to Sewers
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (μCi/ml)	Concentration
98	Californium-252	W, see ²⁴⁴ Cf	2E+0	2E-2	8E-12	(actini)	(делии)	(μCi/ml)
			Bone Surf	Bone Surf				
			(5E+0)	(4E-2)	-	5E-14	7E-8	7E-7
		Y, see ²⁴⁴ Cf	-	3E-2	1E-11	5E-14	-	-
98	Californium-253	W, see ²⁴⁴ Cf	2E+2 Bone Surf	2E+0	8E-10	3E-12	-	-
			(4E+2)	-	-	-	5E-6	5E-5
		Y, see ²⁴⁴ Cf	-	2E+0	7E-10	2E-12		-
98	Californium-254	W, see 244Cf	2E+0	2E-2	9E-12	3E-14	3E-8	3E-7
		Y, see ²⁴⁴ Cf	-	2E-2	7E-12	2E-14	-	-
99	Einsteinium-250	W, all compounds	4E+4	5E+2 Bone Surf	2E-7	-	6E-4	6E-3
			-	(1E+3)	-	2E-9	-	-
99	Einsteinium-251	W, all compounds	7E+3	9E+2 Bone Surf	4E-7	-	1E-4	1E-3
			-	(1E+3)	-	2E-9	-	-
99	Einsteinium-253	W, all compounds	2E+2	1E+0	6E-10	2E-12	2E-6	2E-5
99	Einsteinium- 254m	W, all compounds	3E+2 LLI wall	iE+1	4E-9	1E-11	-	-
			(3E+2)	-	-	-	4E-6	4E-5
99	Einsteinium-254	W, all compounds	8E+0 Bone Surf	7E-2 Bone Surf	3E-11	-	-	-
			(2E+1)	(1E-1)	-	2E-13	2E-7	2E-6
100	Fermium-252	W, all compounds	5E+2	1E+1	5E-9	2E-11	6E-6	6E-5
100	Fermium-253	W, all compounds	1E+3	lE+l	4E-9	1E-11	1E-5	1E-4
100	Fermium-254	W, all compounds	3E+3	9E+1	4E-8	1E-10	4E-5	4E-4
100	Fermium-255	W, all compounds	5E+2	2E+1	9E-9	3E-11	7E-6	7E-5
100	Fermium-257	W, all compounds	2E+1 Bone Surf	2E-1 Bone Surf	7E-11	-	-	-
			(4E+1)	(2E-1)	-	3E-13	5E-7	5E-6

B-81 NUREG-1736

			Occupational Values Effluent Rele				Table 3 Releases to Sewers	
			Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
			Oral Ingestion	Inha	lation			Monthly Average
Atomic No.	Radionuclide	Class	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (μCi/ml)
101	Mendelevium- 257	W, all compounds	7E+3	8E+1 Bone Surf	4E-8	-	1E-4	1E-3
			-	(9E+1)	-	1E-10	-	-
101	Mendelevium- 258	W, all compounds	3E+1 Bone Surf	2E-1 Bone Surf	1E-10	-	-	-
			(5E+1)	(3E-1)	-	5E-13	6E-7	6E-6
-	Any single radionulisted above with dother than alpha en spontaneous fission radioactive half-life 2 hours	ecay mode nission or n and with		2E+2	1 E -7	1 E -9	-	-
-	Any single radionuclide not listed above with decay mode other than alpha emission or spontaneous fission and with radioactive half-life greater than 2 hours		-	2E-1	1E-10	1E-12	1E-8	1E-7
-	Any single radionulisted above that de emission or sponta or any mixture for the identity or the of any radionuclide is not known	ecays by alpha neous fission, which either concentration	_	4E-4	2E-13	1E-15	2E-9	2E-8

FOOTNOTES:

^{(1) &}quot;Submersion" means that values given are for submission in a hemispherical semi-infinite cloud of airborne material.

¹²⁾ These radionuclides have radiological half-lives of less than 2 hours. The total effective dose equivalent received during operations with these radionuclides might include a significant contribution from external exposure. The DAC values for all radionuclides, other than those designated Class "Submersion," are based upon the committed effective dose equivalent due to the intake of the radionuclide into the body and do NOT include potentially significant contributions to dose equivalent from external exposures. The licensee may substitute 1E-7μCi/ml for the listed DAC to account for the submersion dose prospectively, but should use individual monitoring devices or other radiation measuring instruments that measure external exposure to demonstrate compliance with the limits. (See section 20.1203.)

⁽³⁾ For soluble mixtures of U-238, U-234, and U-235 in air, chemical toxicity may be the limiting factor (see section 20.1201(e)). If the percent by weight (enrichment) of U-235 is not greater than 5, the concentration value for a 40-hour workweek is 0.2 milligrams uranium per cubic meter of air average. For any enrichment, the product of the average concentration and time of exposure during a 40-hour workweek shall not exceed 8E-3 (SA) μ Ci-hr/ml, where SA is the specific activity of the uranium inhaled. The specific activity for natural uranium is 6.77E-7 curies per gram U. The specific activity for other mixtures of U-236, U-235, and U-234, if not known, shall be:

SA = 3.6E-7 curies/gram U U-depleted

SA = $[0.4 + 0.38 \text{ (enrichment)} + 0.0034 \text{ (enrichment)}^2]$ E-6, enrichment ≥ 0.72

where enrichment is the percentage by weight of U-235, expressed in percent.

NOTE:

- If the identity of each radionuclide in a mixture is known but the concentration of one or more of the radionuclides in the mixture is not known, the DAC for the mixture shall be the most restrictive DAC of any radionuclide in the mixture.
- If the identity of each radionuclide in the mixture is not known, but it is known that certain radionuclides specified in the appendix are not
 present in the mixture, the inhalation ALI, DAC, and effluent and sewage concentration for the mixture are the lowest values specified in this
 appendix for any radionuclide that is not known to be absent from the mixture; or

	Table 1 Occupational Values			Table 2 Effluent Concentrations		Table 3 Releases to Sewers
	Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
	Oral Ingestion	Inha	lation			Monthly Average
Radionuclide	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
If it is known that Ac-227-D and Cm-250-W are not present	-	7E-4	3E-13	-	-	-
If, in addition, it is known that Ac-227-W, Y, Th-229-W, Y, Th-230-W, Th-232-W, Y, Pa-231-W, Y, Np-237-W, Pu-239-W, Pu-240-W, Pu-242-W, Am-241-W, Am-242m-W, Am-243-W, Cm-245-W, Cm-246-W, Cm-247-W, Cm-248-W, Bk-247-W, Cf-249-W, and Cf-251-W are not present	-	7E-3	3E-12		-	-
If, in addition, it is known that Sm-146-W, Sm-147-W, Gd-148-D, W, Gd-152-D, W, Th-228-W, Y, Th-230-Y, U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, Np-236-W, Pu-236-W, Y, Pu-238-W, Y, Pu-239-Y, Pu-240-Y, Pu-242-Y, Pu-244-W, Y, Cm-243-W, Cm-244-W, Cf-248-W, Cf-249-Y, Cf-250-W, Y, Cf-251-Y, Cf-252-W, Y, and Cf-254-W, Y are not present	-	7E-2	3E-11	-	-	-
If, in addition, it is known that Pb-210-D, Bi-210m-W, Po-210-D, W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D, W, Y, Th-227-W, Y, U-230-D, W, Y, U-232-D, W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-Y, Es-254-W, Fm-257-W, and Md-258-W are not present		7E-1	3E-10	-	-	-
If, in addition, it is known that Si-32-Y, Ti-44-Y, Fe-60-D, Sr-90-Y, Zr-93-D, Cd-113m-D, Cd-113-D, In-115-D, W, La-138-D, Lu-176-W, Hf-178m-D, W, Hf-182-D, W, Bi-210m-D, Ra-224-W, Ra-228-W, Ac-226-D, W, Y, Pa-230-W, Y, U-233-D, W; U-234-D, W, U-235-D, W, U-236-D, W, U-238-D, W, Pu-241-Y, Bk-249-W, Cf-253-W, Y, and Es-253-W are not present	-	7E+0	3E-9	_	-	-

B-83 NUREG-1736

	Table 1 Occupational Values			Table 2 Effluent Concentrations		Table 3 Releases to Sewers
	Col. 1	Col. 2	Col. 3	Col. 1	Col. 2	
	Oral Ingestion	Inhal	ation			Monthly Average
Radionuclide	ALI (μCi)	ALI (μCi)	DAC (μCi/ml)	Air (μCi/ml)	Water (µCi/ml)	Concentration (µCi/ml)
If it is known that Ac-227-D, W, Y, Th-229-W, Y, Th-232-W, Y, Pa-231-W, Y, Cm-248-W, and Cm-250-W are not present	-	-	-	1E-14	-	-
If, in addition, it is known that Sm-146-W, Gd-148-D, W, Gd-152-D, Th-228-W, Y, Th-230-W, Y, U-232-Y, U-233-Y, U-234-Y, U-235-Y, U-236-Y, U-238-Y, U-Nat-Y, Np-236-W, Np-237-W, Pu-236-W, Y, Pu-238-W, Y, Pu-239-W, Y, Pu-240-W, Y, Pu-242-W, Y, Pu-244-W, Y, Am-241-W, Am-242m-W, Am-243-W, Cm-243-W, Cm-244-W, Cm-245-W, Cm-246-W, Cm-247-W, Bk-247-W, Cf-249-W, Y, Cf-250-W, Y, Cf-251-W, Y, Cf-252-W, Y, and Cf-254-W, Y are not present				1E-13		-
If, in addition, it is known that Sm-147-W, Gd-152-W, Pb-210-D, Bi-210m-W, Po-210-D, W, Ra-223-W, Ra-225-W, Ra-226-W, Ac-225-D, W, Y, Th-227-W, Y, U-230-D, W, Y, U-232-D, W, U-Nat-W, Pu-241-W, Cm-240-W, Cm-242-W, Cf-248-W, Y, Es-254-W, Fm-257-W, and Md-258-W are not present	-	-	-	1E-12	-	-
If, in addition, it is known that Fe-60, Sr-90, Cd-113m, Cd-113, In-115, I-129, Cs-134, Sm-145, Sm-147, Gd-148, Gd-152, Hg-194 (organic), Bi-210m, Ra-223, Ra-224, Ra-225, Ac-225, Th-228, Th-230, U-233, U-234, U-235, U-236, U-238, U-Nat, Cm-242, Cf-248, Es-254, Fm-257, and Md-258 are not present	_			-	1E-6	1E-5

- 3. If a mixture of radionuclides consists of uranium and its daughters in ore dust (10μm AMAD particle distribution assumed) prior to chemical separation of the uranium from the ore, the following values may be used for the DAC of the mixture; 6E-11μCi of gross alpha activity from uranium-238, uranium-234, thorium-230, and radium-226 per milliliter of air; 3E-11μCi of natural uranium per milliliter of air; or 45 micrograms of natural uranium per cubic meter of air.
- 4. If the identity and concentration of each radionuclide in a mixture are known, the limiting values should be derived as follows: determine, for each radionuclide in the mixture, the ratio between the concentration present in the mixture and the concentration otherwise established in Appendix B for the specific radionuclide when not in a mixture. The sum of such ratios for all of the radionuclides in the mixture may not exceed "1" (i.e., "unity").

Example: If radionuclides "A," "B," and "C" are present in concentrations C_A , C_B , and C_C , and if the applicable DACs are DAC_A, DAC_B, and DAC_C, respectively, then the concentrations shall be limited so that the following relationship exists:

3

$\underline{\mathbf{C}}_{A}$	+	<u>C</u> _B	+	$\underline{\mathbf{C}}_{\mathbf{c}}$	
DAC.		DAC_n		DAC_c	< 1

Discussion:

The data tabulated in this appendix is intended to be used to show compliance with a number of sections of Part 20 that refer to one or more of the tables in the appendix. For example, monitoring of workers for intakes is required when annual intakes may exceed specified fractions of Columns (2) and (3) of Table (1). Licensees may show compliance, in part, with public dose limits for doses resulting from effluents by referring to the concentrations listed in Columns (1) and (2) of Table (2). Compliance with sewer release limits is shown, in part, by using the values in Table (3). In addition, certain requirements such as area posting, respiratory protection, and incident reporting use Appendix B values as triggers for these actions. Table (1) is based on occupational dose limits, Table (2) on dose limits to members of the public, and Table (3) is a special case of exposure to members of the public.

The values tabulated in Appendix B are all secondary limits or derived quantities, and each column in the appendix is based on a primary limit, which in this case is a dose. A secondary limit, such as the DAC, is derived from a primary limit. The difference is that the primary limit is absolute in that it is not to be exceeded in any routine situation. The secondary limit is not absolute in the sense that it is applicable only if certain conditions are met. It is not valid as a limit if these conditions are not met. For example, the ALI is a limit if there are no external exposures during the monitoring year and the only source of exposure is internal. If there are external exposures, limiting annual intakes to an ALI will lead to exceeding the primary dose limit, and hence a violation of NRC requirements. The ALI is also not a limit if the ingested eximhaled radioactive material contains more than one type of radionuclide. In such cases, the ALIs of each of the components must be adjusted to take account of the presence of the other components.

A derived quantity, such as the DAC, is not a limit at all, and may be exceeded at any time provided certain restrictions apply. The DAC is tabulated for convenience and because it is an easily measured quantity. It is easily calculated from the ALI by assuming a suitable breathing rate and exposure time. Part 20 does not limit airborne concentrations at any given time to values below the DAC, and requirements in Part 20 that are specified in terms of airborne concentrations generally use only time-averaged concentrations and not instantaneous values.

In this appendix, the daughter products of the radionuclides listed were not included in the intake when calculating the tabulated values of ALI and DAC for the parent. However, the effects of the daughters that are produced in the body after intake of the parent are included in the calculations. For example, uranium decays in a long decay chain that includes many radioactive daughter products. When considering the inhalation of uranium, the calculations of ALIs and DACs for the tables assume that only the parent uranium isotope is inhaled, and no daughters are considered with the uranium inhalation. The daughters produced in the body after the uranium is taken into the body are included in estimating the dose resulting from the intake. To properly account for the dose from a parent that produces one or more daughters, the parent and each of the daughters must be treated as separately inhaled or ingested radionuclides, and the dose from each added to produce a total dose. The parent and its daughters that may be in the inhaled air or

B-85 NUREG-1736

in the ingested material are considered as a mixture of radionuclides and not as members of one chain.

One exception to this rule is the case in which the half-life of the daughter is very short (usually less than about 20 minutes) and much shorter than that of the parent. In this case, the tabulated values assume that the daughter is in secular equilibrium with the parent and that both are always inhaled or ingested together. The daughter in this case need not be considered separately in determining the ALI from the table, because it has been already included in calculating the ALI for the parent. In such situations, you will not find data in the table pertaining to short-lived daughters of tabulated radionuclides. In such cases, assume that the data for the missing daughter has been included in the data for the parent.

Column (1) in the appendix is the ALI for ingestion by occupationally exposed workers. Ingestion means taking in the material by mouth via food or drink or as solid or liquid contamination in the workplace. The values are based on an annual dose limit of 5 rem effective dose equivalent (called the stochastic dose limit) or 50 rem organ dose equivalent (called the non-stochastic, or deterministic, dose limit), whichever is more limiting. Internal dose models described in ICRP Publication 30 were used to calculate the effective and organ doses that would result from intake of unit activity of each of the radionuclides listed in the table. The intakes that would lead to an effective dose of 5 rem or an organ dose of 50 rem are then calculated. The highest intake that does not result in exceeding any organ limit or the effective dose equivalent limit is then selected as the ALI and tabulated in Column (1). If the ALI is based on an organ dose, the organ is specified under the tabulated ALI, and the ALI that would result in an effective dose equivalent of 5 rem is listed in parentheses under that organ name. The stochastic ALI is specified in parentheses because it is sometimes needed to show compliance when several radionuclides are present in the ingested material. If the ALI is based on the effective dose equivalent, then only that value is listed, with no other information.

Column (2) in Table (1) is calculated in the same manner as that used for Column (1), except that the intake is by inhalation of airborne material rather than ingestion. The methods of calculation are the same, but the dosimetric models are those for inhalation rather than for ingestion. In addition, inhaled material is classified into one of three classes, called D, W, or Y, depending on how rapidly the material is cleared from the lungs after it is inhaled. Class D is cleared most rapidly, within a matter of days, and Class Y is cleared most slowly, within months or years. Class W is intermediate. The same radionuclide may exist in one or more classes depending on its chemical and physical characteristics. For example, uranium as a fluoride is a Class D material, but some of its oxide forms are Class W, and other oxide forms are Class Y. Licensees should make a concerted effort to accurately classify the airborne material present at their sites because such classification will determine the ALI and the dose received by a worker following an intake.

The first step in classification is to know the chemical form of the airborne radioactive material. With that knowledge, the licensee may refer to the listing in Appendix B, which specifies the classification of the most frequently encountered compounds of each radionuclide. If the specific

compound is not listed, then other references may be used, such as the tabulations by the ICRP. See Reference {1} listed below.

Note also that the values of the ALI are based on the assumption that the airborne radioactive material is in the form of particles with an activity median aerodynamic diameter of 1 micrometer, or micron. If the median particle size on site is known and is substantially different from 1 micron, for example 5 microns, then the ALIs may be adjusted accordingly, but only after obtaining approval from NRC. The method of adjustment is described in References {1} and {2}, listed below. If the particle size is not known, then 1 micron is assumed.

The values in Column (3), Table (1), the derived air concentrations (DACs), are calculated directly from Column (2) by dividing the respective ALIs by the breathing rate of a standard person (1.2 m³/hr) and the number of working hours per year, taken to be 2,000 hr/yr. Exceptions to this method are those airborne radionuclides that pose an external rather than an internal hazard, and for which ALIs are not given, such as the isotopes of xenon and krypton. In such cases, the DACs are calculated directly from the external doses, assuming immersion in a semi-infinite cloud of the gas.

The values in Table (2) differ from those in Table (1) in two major respects: they do not include values that are based on non-stochastic radiation effects, because the public dose limits are so low that such effects are no longer of concern; and they are based on a stochastic dose limit of 100 mrem/yr effective dose equivalent rather than 5 rem/yr. The concentrations in Column (1) of Table (2) were obtained by dividing the stochastic ALIs in Table (1) by the breathing rate of 2,400 m³/yr, then dividing by 3 to take into account the fact that members of the public breathe the air 24 hours per day all year, rather than 8 hr/day during work days, as is assumed for occupational exposure, and also to adjust for differences in inhalation rates between persons at work and members of the public. The result is then divided by 50 to adjust the values from a dose limit of 5,000 mrem/yr to 100 mrem/yr. Because the occupational ALIs were calculated for healthy adult workers, but members of the public include groups that may be of varying health conditions as well as children, the results are again divided by a safety factor of 2 to allow for this effect.

In the case of radionuclides that pose an external hazard, the concentrations in Column (1) of Table (2) were obtained by adjusting the occupational DACs in Table (1) for the difference in dose limits, that is, by dividing by a factor of 50, and then adjusting for differences in exposure duration from 8 hours per day during work days to 24 hours per day every day.

The concentrations for liquid effluents in Column (2) of Table (2) were obtained by using the most restrictive value in Column (1) of Table (1) and then adjusting it in the same manner as that used to adjust the air values.

The monthly average concentrations in Table (3) were obtained by assuming that a person obtains all of his water from the licensee's sewer outfall, and then calculating the average concentration that would result in an annual ingestion dose of 500 mrem. Averaging the

B-87 NUREG-1736

concentrations over a month rather than a year avoids excessive short-term peak discharges by seasonal discharges.

References:

- International Commission on Radiological Protection, Publication 30 and addenda, Pergamon Press, Fairview Park, Elmsford, NY 10523.
- 2. NRC Regulatory Guide 8.9, Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program.

Appendix C

Quantities of Licensed Material Requiring Labeling

Statement of Requirement:

Table C.1. Appendix C to Part 20 – Quantities¹ of Licensed Material Requiring Labeling

Radionuclide	Abbreviation	Quantity (μCi)
Hydrogen-3	H-3	1,000
Beryllium-7	Be-7	1,000
Beryllium-10	Be-10	1
Carbon-11	C-11	1,000
Carbon-14	C-14	100
Fluorine-18	F-18	1,000
Sodium-22	Na-22	10
Sodium-24	Na-24	100
Magnesium-28	Mg-28	100
Aluminum-26	Al-26	10
Silicon-31	Si-31	1,000
Silicon-32	Si-32	1
Phosphorus-32	P-32	10
Phosphorus-33	P-33	100
Sulfur-35	S-35	100
Chlorine-36	Cl-36	10
Chlorine-38	Cl-38	1,000
Chlorine-39	Cl-39	1,000
Argon-39	Ar-39	1,000
Argon-41	Ar-41	1,000
Potassium-40	K-40	100

The quantities listed above were derived by taking ½10th of the most restrictive ALI listed in Table 1, columns 1 and 2, of Appendix B to 10 CFR 20.1001-20.2401 of this part, rounding to the nearest factor of 10, and arbitrarily constraining the values listed between 0.001 and 1,000 μCi. Values of 100 μCi have been assigned for radionuclides having a radioactive half-life in excess of 10° years (except rhenium, 1,000 μCi) to take into account their low specific activity.

C-1 NUREG-1736

Radionuclide	Abbreviation	Quantity (μCi)
Potassium-42	K-42	1,000
Potassium-43	K-43	1,000
Potassium-44	K-44	1,000
Potassium-45	K-45	1,000
Calcium-41	Ca-41	100
Calcium-45	Ca-45	100
Calcium-47	Ca-47	100
Scandium-43	Sc-43	1,000
Scandium-44m	Sc-44m	100
Scandium-44	Sc-44	100
Scandium-46	Sc-46	10
Scandium-47	Sc-47	100
Scandium-48	Sc-48	100
Scandium-49	Sc-49	1,000
Titanium-44	Ti-44	1
Titanium-45	Ti-45	1,000
Vanadium-47	V-47	1,000
Vanadium-48	V-48	100
Vanadium-49	V-49	1,000
Chromium-48	Cr-48	1,000
Chromium-49	Cr-49	1,000
Chromium-51	Cr-51	1,000
Manganese-51	Mn-51	1,000
Manganese-52m	Mn-52m	1,000
Manganese-52	Mn-52	100
Manganese-53	Mn-53	1,000

Radionuclide	Abbreviation	Quantity (μCi)
Manganese-54	Mn-54	100
Manganese-56	Mn-56	1,000
Iron-52	Fe-52	100
Iron-55	Fe-55	100
Iron 50	Fe₌59	10
Iron-60	Fe-60	1
Cobalt-55	Co-55	100
Cobalt-56	Co-56	10
Cobalt-57	Co-57	100
Cobalt-58m	Co-58m	1,000
Cobalt-58	Co-58	100
Cobalt-60m	Co-60m	1,000
Cobalt-60	Co-60	1
Cobalt-61	Co-61	1,000
Cobalt-62m	Co-62m	1,000
Nickel-56	Ni-56	100
Nickel-57	Ni-57	100
Nickel-59	Ni-59	100
Nickel-63	Ni-63	100
Nickel-65	Ni-65	1,000
Nickel-66	Ni-66	10
Copper-60	Cu-60	1,000
Copper-61	Cu-61	1,000
Copper-64	Cu-64	1,000
Copper-67	Cu-67	1,000
Zinc-62	Zn-62	100

C-3 NUREG-1736

Radionuclide	Abbreviation	Quantity (μCi)
Zinc-63	Zn-63	1,000
Zinc-65	Zn-65	10
Zinc-69m	Zn-69m	100
Zinc-69	Zn-69	1,000
Zinc-71m	Zn-71m	1,000
Zinc-72	Zn-72	100
Gallium-65	Ga-65	1,000
Gallium-66	Ga-66	100
Gallium-67	Ga-67	1,000
Gallium-68	Ga-68	1,000
Gallium-70	Ga-70	1,000
Gallium-72	Ga-72	100
Gallium-73	Ga-73	1,000
Germanium-66	Ge-66	1,000
Germanium-67	Ge-67	1,000
Germanium-68	Ge-68	10
Germanium-69	Ge-69	1,000
Germanium-71	Ge-71	1,000
Germanium-75	Ge-75	1,000
Germanium-77	Ge-77	1,000
Germanium-78	Ge-78	1,000
Arsenic-69	As-69	1,000
Arsenic-70	As-70	1,000
Arsenic-71	As-71	100
Arsenic-72	As-72	100
Arsenic-73	As-73	100

Radionuclide	Abbreviation	Quantity (µCi)
Arsenic-74	As-74	100
Arsenic-76	As-76	100
Arsenic-77	As-77	100
Arsenic-78	As-78	1,000
Selenium-70	Se-70	1,000
Selenium-73m	Se-73m	1,000
Selenium-73	Se-73	100
Selenium-75	Se-75	100
Selenium-79	Se-79	100
Selenium-81m	Se-81m	1,000
Selenium-81	Se-81	1,000
Selenium-83	Se-83	1,000
Bromine-74m	Br-74m	1,000
Bromine-74	Br-74	1,000
Bromine-75	Br-75	1,000
Bromine-76	Br-76	100
Bromine-77	Br-77	1,000
Bromine-80m	Br-80m	1,000
Bromine-80	Br-80	1,000
Bromine-82	Br-82	100
Bromine-83	Br-83	1,000
Bromine-84	Br-84	1,000
Krypton-74	Kr-74	1,000
Krypton-76	Kr-76	1,000
Krypton-77	Kr-77	1,000
Krypton-79	Kr-79	1,000

Radionuclide	Abbreviation	Quantity (µCi)
Krypton-81	Kr-81	1,000
Krypton-83m	Kr-83m	1,000
Krypton-85m	Kr-85m	1,000
Krypton-85	Kr-85	1,000
Krypton-87	Kr-87	1,000
Krypton-88	Kr-88	1,000
Rubidium-79	Rb-79	1,000
Rubidium-81m	Rb-81m	1,000
Rubidium-81	Rb-81	1,000
Rubidium-82m	Rb-82m	1,000
Rubidium-83	Rb-83	100
Rubidium-84	Rb-84	100
Rubidium-86	Rb-86	100
Rubidium-87	Rb-87	100
Rubidium-88	Rb-88	1,000
Rubidium-89	Rb-89	1,000
Strontium-80	Sr-80	100
Strontium-81	Sr-81	1,000
Strontium-83	Sr-83	100
Strontium-85m	Sr-85m	1,000
Strontium-85	Sr-85	100
Strontium-87m	Sr-87m	1,000
Strontium-89	Sr-89	10
Strontium-90	Sr-90	0.1
Strontium-91	Sr-91	100
Strontium-92	Sr-92	100

NUREG-1736

Radionuclide	Abbreviation	Quantity (μCi)
Yttrium-86m	Y-86m	1,000
Yttrium-86	Y-86	100
Yttrium-87	Y-87	100
Yttrium-88	Y-88	10
Yttrium-90m	Y-90m	1,000
Yttrium-90	Y-90	10
Yttrium-91m	Y-91m	1,000
Yttrium-91	Y -91	10
Yttrium-92	Y-92	100
Yttrium-93	Y-93	100
Yttrium-94	Y-94	1,000
Yttrium-95	Y-95	1,000
Zirconium-86	Zr-86	100
Zirconium-88	Zr-88	10
Zirconium-89	Zr-89	100
Zirconium-93	Zr-93	1
Zirconium-95	Zr-95	10
Zirconium-97	Zr-97	100
Niobium-88	Nb-88	1,000
Niobium-89m (66 min)	Nb-89m	1,000
Niobium-89 (122 min)	Nb-89	1,000
Niobium-90	Nb-90	100
Niobium-93m	Nb-93m	10
Niobium-94	Nb-94	1
Niobium-95m	Nb-95m	100
Niobium-95	Nb-95	100

Radionuclide	Abbreviation	Quantity (µCi)
Niobium-96	Nb-96	100
Niobium-97	Nb-97	1,000
Niobium-98	Nb-98	1,000
Molybdenum-90	Mo-90	100
Molybdenum-93m	Mo-93m	100
Molybdenum-93	Mo-93	10
Molybdenum-99	Mo-99	100
Molybdenum-101	Mo-101	1,000
Technetium-93m	Tc-93m	1,000
Technetium-93	Tc-93	1,000
Technetium-94m	Tc-94m	1,000
Technetium-94	Tc-94	1,000
Technetium-96m	Tc-96	1,000
Technetium-96	Tc-96	100
Technetium-97m	Tc-97m	100
Technetium-97	Tc-97	1,000
Technetium-98	Tc-98	10
Technetium-99m	Tc-99m	1,000
Technetium-99	Tc-99	100
Technetium-101	Tc-101	1,000
Technetium-104	Tc-104	1,000
Ruthenium-94	Ru-94	1,000
Ruthenium-97	Ru-97	1,000
Ruthenium-103	Ru-103	100
Ruthenium-105	Ru-105	1,000
Ruthenium-106	Ru-106	1

Radionuclide	Abbreviation	Quantity (μCi)
Rhodium-99m	Rh-99m	1,000
Rhodium-99	Rh-99	100
Rhodium-100	Rh-100	100
Rhodium-101m	Rh-101m	1,000
Rhodium-101	Rh-101	10
Rhodium-102m	Rh-102m	10
Rhodium-102	Rh-102	10
Rhodium-103m	Rh-103m	1,000
Rhodium-105	Rh-105	100
Rhodium-106m	Rh-106m	1,000
Rhodium-107	Rh-107	1,000
Palladium-100	Pd-100	100
Palladium-101	Pd-101	1,000
Palladium-103	Pd-103	100
Palladium-107	Pd-107	10
Palladium-109	Pd-109	100
Silver-102	Ag-102	1,000
Silver-103	Ag-103	1,000
Silver-104m	Ag-104m	1,000
Silver-104	Ag-104	1,000
Silver-105	Ag-105	100
Silver-106m	Ag-106m	100
Silver-106	Ag-106	1,000
Silver-108m	Ag-108m	1
Silver-110m	Ag-110m	10
Silver-111	Ag-111	100

C-9 NUREG-1736

APPENDIX-C

Radionuclide	Abbreviation	Quantity (µCi)
Silver-112	Ag-112	100
Silver-115	Ag-115	1,000
Cadmium-104	Cd-104	1,000
Cadmium-107	Cd-107	1,000
Cadmium-109	Cd-109	1
Cadmium-113m	Cd-113m	0.1
Cadmium-113	Cd-113	100
Cadmium-115m	Cd-115m	10
Cadmium-115	Cd-115	100
Cadmium-117m	Cd-117m	1,000
Cadmium-117	Cd-117	1,000
Indium-109	In-109	1,000
Indium-110 (69.1 min.)	In-110	1,000
Indium-110 (4.9h)	In-110	1,000
Indium-111	In-111	100
Indium-112	In-112	1,000
Indium-113m	In-113m	1,000
Indium-114m	In-114m	10
Indium-115m	In-115m	1,000
Indium-115	In-115	100
Indium-116m	In-116m	1,000
Indium-117m	In-117m	1,000
Indium-117	In-117	1,000
Indium-119m	In-119m	1,000
Tin-110	Sn-110	100
Tin-111	Sn-111	1,000

Radionuclide	Abbreviation	Quantity (µCi)
Tin-113	Sn-113	100
Tin-117m	Sn-117m	100
Tin-119m	Sn-119m	100
Tin-121m	Sn-121m	100
Tin-121	Sn-121	1,000
Tin-123m	Sn-123m	1,000
Tin-123	Sn-123	10
Tin-125	Sn-125	10
Tin-126	Sn-126	10
Tin-127	Sn-127	1,000
Tin-128	Sn-128	1,000
Antimony 115	Sh±115	1,000
Antimony-116m	Sb-116m	1,000
Antimony-116	Sb-116	1,000
Antimony-117	Sb-117	1,000
Antimony-118m	Ab-118m	1,000
Antimony-119	Ab-119	1,000
Antimony-120 (16 min.)	Ab-120	1,000
Antimony-120 (5.76d)	Ab-120	100
Antimony-122	Ab-122	100
Antimony-124m	Ab-124m	1,000
Antimony-124	Ab-124	10
Antimony-125	Ab-125	100
Antimony-126m	Ab-126m	1,000
Antimony-126	Ab-126	100
Antimony-127	Ab-127	100

Radionuclide	Abbreviation	Quantity (µCi)
Antimony-128 (10.4 min.)	Ab-128	1,000
Antimony-128 (9.01h)	Ab 128	100
Antimony-129	Ab-129	100
Antimony-130	Ab-130	1,000
Antimony-131	Ab-131	1,000
Tellurium-116	Te-116	1,000
Tellurium-121m	Te-121m	10
Tellurium-121	Te-121	100
Tellurium-123m	Te-123m	10
Tellurium-123	Te-123	100
Tellurium-125m	Te-125m	10
Tellurium-127m	Te-127m	10
Tellurium-127	Te-127	1,000
Tellurium-129m	Te-129m	10
Tellurium-129	Te-129	1,000
Tellurium-131m	Te-131m	10
Tellurium-131	Te-131	100
Tellurium-132	Te-132	10
Tellurium-133m	Te-133m	100
Tellurium-133	Te-133	1,000
Tellurium-134	Te-134	1,000
Iodine-120m	I-120m	1,000
Iodine-120	I-120	100
Iodine-121	I-121	1,000
Iodine-123	I-123	100
Iodine-124	I-124	10

Radionuclide	Abbreviation	Quantity (μCi)
Iodine-125	I-125	1
Iodine-126	I-126	1
Iodine-128	I-128	1,000
Iodine-129	I-129	1
Iodine-130	I-130	10
Iodine-131	I-131	1
Iodine-132m	I-132m	100
Iodine-132	I-132	100
Iodine-133	I-133	10
Iodine-134	I-134	1,000
Iodine-135	I-135	100
Xenon-120	Xe-120	1,000
Xenon-121	Xe-121	1,000
Xenon-122	Xe-122	1,000
Xenon-123	Xe-123	1,000
Xenon-125	Xe-125	1,000
Xenon-127	Xe-127	1,000
Xenon-129m	Xe-129m	1,000
Xenon-131m	Xe-131m	1,000
Xenon-133m	Xe-133m	1,000
Xenon-133	Xe-133	1,000
Xenon-135m	Xe-135m	1,000
Xenon-135	Xe-135	1,000
Xenon-138	Xe-138	1,000
Cesium-125	Cs-125	1,000
Cesium-127	Cs-127	1,000

C-13 NUREG-1736

Radionuclide	Abbreviation	Quantity (μCi)
Cesium-129	Cs-129	1,000
Cesium-130	Cs-130	1,000
Cesium-131	Cs-131	1,000
Cesium-132	Cs-132	100
Cesium-134m	Cs-134m	1,000
Cesium-134	Cs-134	10
Cesium-135m	Cs-135m	1,000
Cesium-135	Cs-135	100
Cesium-136	Cs-136	10
Cesium-137	Cs-137	10
Cesium-138	Cs-138	1,000
Barium-126	Ba-126	1,000
Barium-128	B-128	100
Barium-131m	Ba-131m	1,000
Barium-131	Ba-131	100
Barium-133m	Ba-133m	100
Barium-133	Ba-133	100
Barium-135m	Ba-135m	100
Barium-139	Ba-139	1,000
Barium-140	Ba-140	100
Barium-141	Ba-141	1,000
Barium-142	Ba-142	1,000
Lanthanum-131	La-131	1,000
Lanthanum-132	La-132	100
Lanthanum-135	La-135	1,000
Lanthanum-137	La-137	10

Radionuclide	Abbreviation	Quantity (µCi)
Lanthanum-138	La-138	100
Lanthanum-140	La-140	100
Lanthanum-141	La-141	100
Lanthanum-142	La-142	1,000
Lanthanum-143	La-143	1,000
Cerium-134	Ce-134	100
Cerium-135	Ce-135	100
Cerium-137m	Ce-137m	100
Cerium-137	Ce-137	1,000
Cerium-139	Ce-139	100
Cerium-141	Ce-141	100
Cerium-143	Ce-143	100
Cerium-144	Ce-144	1
Praseodymium-136	Pr-136	1,000
Praseodymium-137	Pr-137	1,000
Praseodymium-138m	Pe-138m	1,000
Praseodymium-139	Pe-139	1,000
Praseodymium-142m	Pe-142m	1,000
Praseodymium-142	Pe-142	100
Praseodymium-143	Pe-143	100
Praseodymium-144	Pe-144	1,000
Praseodymium-145	Pe-145	100
Praseodymium-147	Pe-147	1,000
Neodymium-136	Nd-136	1,000
Neodymium-138	Nd-138	100
Neodymium-139m	Nd-139m	1,000

Radionuclide	Abbreviation	Quantity (μCi)
Neodymium-139	Nd-139	1,000
Neodymium-141	Nd-141	1,000
Neodymium-147	Nd-147	100
Neodymium-149	Nd-149	1,000
Neodymium-151	Nd-151	1,000
Promethium-141	Pm-141	1,000
Promethium-143	Pm-143	100
Promethium-144	Pm-144	10
Promethium-145	Pm-145	10
Promethium-146	Pm-146	1
Promethium-147	Pm-147	10
Promethium-148m	Pm-148m	10
Promethium-148	Pm-148	10
Promethium-149	Pm-149	100
Promethium-150	Pm-150	1,000
Promethium-151	Pm-151	100
Samarium-141m	Sm-141m	1,000
Samarium-141	Sm-141	1,000
Samarium-142	Sm-142	1,000
Samarium-145	Sm-145	100
Samarium-146	Sm-146	1
Samarium-147	Sm-147	100
Samarium-151	Sm-151	10
Samarium-153	Sm-153	100
Samarium-155	Sm-155	1,000
Samarium-156	Sm-156	1,000

Radionuclide	Abbreviation	Quantity (μCi)
Europium-145	Eu-145	100
Europium-146	Eu-146	100
Europium-147	Eu-147	100
Europium-148	Eu-148	10
Europium-149	Eu-149	100
Europium-150 (12.62h)	Eu-150	100
Europium-150 (34.2y)	Eu-150	1
Europium-152m	Eu-152m	100
Europium-152	Eu-152	1
Europium-154	Eu-154	1
Europium-155	Eu-155	10
Europium-156	Eu-156	100
Europium-157	Eu-157	100
Europium-158	Eu-158	1,000
Gadolinium-145	Gd-145	1,000
Gadolinium-146	Gd-146	10
Gadolinium-147	Gd-147	100
Gadolinium-148	Gd-148	0.001
Gadolinium-149	Gd-149	100
Gadolinium-151	Gd-151	10
Gadolinium-152	Gd-152	100
Gadolinium-153	Gd-153	10
Gadolinium-159	Gd-159	100
Terbium-147	Tb-147	1,000
Terbium-149	Tb-149	100
Terbium-150	Tb-150	1,000

Radionuclide	Abbreviation	Quantity (µCi)
Terbium-151	Tb-151	100
Terbium-153	Tb-153	1,000
Terbium-154	Tb-154	100
Terbium-155	Tb-155	1,000
Terbium-156m (5.0h)	Tb-156m	1,000
Terbium-156m (24.4h)	Tb-156m	1,000
Terbium-156	Tb-156	100
Terbium-157	Tb-157	10
Terbium-158	Tb-158	1
Terbium-160	Tb-160	10
Terbium-161	Tb-161	100
Dysprosium-155	Dy-155	1,000
Dysprosium-157	Dy-157	1,000
Dysprosium-159	Dy-159	100
Dysprosium-165	Dy-165	1,000
Dysprosium-166	Dy-166	100
Holmium-155	Ho-155	1,000
Holmium-157	Ho-157	1,000
Holmium-159	Ho-159	1,000
Holmium-161	Ho-161	1,000
Holmium-162m	Ho-162m	1,000
Holmium-162	Но-162	1,000
Holmium-164m	Hp-164m	1,000
Holmium-164	Ho-164	1,000
Holmium-166m	Ho-166m	1
Holmium-166	Ho-166	100

Radionuclide	Abbreviation	Quantity (μCi)
Holmium-167	Ho-167	1,000
Erbium-161	Er-161	1,000
Erbium-165	Er-165	1,000
Erbium-169	Er-169	100
Erbium-171	Er-171	100
Erbium-172	Er-172	100
Thulium-162	Tm-162	1,000
Thulium-166	Tm-166	100
Thulium-167	Tm-167	100
Thulium-170	Tm-170	10
Thulium-171	Tm-171	10
Thulium-172	Tm-172	100
Thulium-173	Tm-173	100
Thulium-175	Tm-175	1,000
Ytterbium-162	Yb-162	1,000
Ytterbium-166	Yb-166	100
Ytterbium-167	Yb-167	1,000
Ytterbium-169	Yb-169	100
Ytterbium-175	Yb-175	100
Ytterbium-177	Yb-177	1,000
Ytterbium-178	Yb-178	1,000
Lutetium-169	Lu-169	100
Lutetium-170	Lu-170	100
Lutetium-171	Lu-171	100
Lutetium-172	Lu-172	100
Lutetium-173	Lu-173	10

Radionuclide	Abbreviation	Quantity (μCi)
Lutetium-174m	Lu-174m	10
Lutetium-174	Lu-174	10
Lutetium-176m	Lu-176m	1,000
Lutetium-176	Lu-176	100
Lutetium-177m	Lu-177m	10
Lutetium-177	Lu-177	100
Lutetium-178m	Lu-178m	1,000
Lutetium-178	Lu-178	1,000
Lutetium-179	Lu-179	1,000
Hafnium-170	Hf-170	100
Hafnium-172	Hf-172	1
Hafnium-173	Hf-173	1,000
Hafnium-175	Hf-175	100
Hafnium-177m	Hf-177m	1,000
Hafnium-178m	Hf-178m	0.1
Hafnium-179m	Hf-179m	10
Hafnium-180m	Hf-180m	1,000
Hafnium-181	Hf-181	10
Hafnium-182m	Hf-182m	1,000
Hafnium-182	Hf-182	0.1
Hafnium-183	Hf-183	1,000
Hafnium-184	Hf-184	100
Tantalum-172	Ta-172	1,000
Tantalum-173	Ta-173	1,000
Tantalum-174	Ta-174	1,000
Tantalum-175	Ta-175	1,000

Radionuclide	Abbreviation	Quantity (µCi)
Tantalum-176	Ta-176	100
Tantalum-177	Ta-177	1,000
Tantalum-178	Ta-178	1,000
Tantalum-179	Ta-179	100
Tantalum-180m	Ta-180m	1,000
Tantalum-180	Ta-180	100
Tantalum-182m	Ta-182m	1,000
Tantalum-182	Ta-182	10
Tantalum-183	Ta-183	100
Tantalum-184	Ta-184	100
Tantalum-185	Ta-185	1,000
Tantalum-186	Ta-186	1,000
Tungsten-176	W-176	1,000
Tungsten-177	W-177	1,000
Tungsten-178	W-178	1,000
Tungsten-179	W-179	1,000
Tungsten-181	W-181	1,000
Tungsten-185	W-185	100
Tungsten-187	W-187	100
Tungsten-188	W-188	10
Rhenium-177	Re-177	1,000
Rhenium-178	Re-178	1,000
Rhenium-181	Re-181	1,000
Rhenium-182 (12.7h)	Re-182	1,000
Rhenium-182 (64.0h)	Re-182	100
Rhenium-184m	Re-184m	10

Radionuclide	Abbreviation	Quantity (µCi)
Rhenium-184	Re-184	100
Rhenium-186m	Re-186m	10
Rhenium-186	Re-186	100
Rhenium-187	Re-187	1,000
Rhenium-188m	Re-188m	1,000
Rhenium-188	Re-188	100
Rhenium-189	Re-189	100
Osmium-180	Os-180	1,000
Osmium-181	Os-181	1,000
Osmium-182	Os-182	100
Osmium-185	Os-185	100
Osmíum-189m	Os-189m	1,000
Osmium-191m	Os-191m	1,000
Osmium-191	Os-191	100
Osmium-193	Os-193	100
Osmium-194	Os-194	1
Iridium-182	Ir-182	1,000
Iridium-184	Ir-184	1,000
Iridium-185	Ir-185	1,000
Iridium-186	Ir-186	100
Iridium-187	Ir-187	1,000
Iridium-188	Ir-188	100
Iridium-189	Ir-189	100
Iridium-190m	Ir-190m	1,000
Iridium-190	Ir-190	100
Iridium-192 (73.8d)	Ir-192	1

Radionuclide	Abbreviation	Quantity (μCi)
Iridium-192m (1.4 min.)	Ir-192m	10
Iridium-194m	Ir-194m	10
Iridium-194	Ir-194	100
Iridium-195m	Ir-195m	1,000
Iridium-195	Ir-95	1,000
Platinum-186	Pt-186	1,000
Platinum-188	Pt-188	100
Platinum-189	Pt-189	1,000
Platinum-191	Pt-191	100
Platinum-193m	Pt-193m	100
Platinum-193	Pt-193	1,000
Platinum-195m	Pt-195m	100
Platinum-197m	Pt-197m	1,000
Platinum-197	Pt-197	100
Platinum-199	Pt-199	1,000
Platinum-200	Pt-200	100
Gold-193	Au-193	1,000
Gold-194	Au-194	100
Gold-195	Au-195	10
Gold-198m	Au-198m	100
Gold-198	Au-198	100
Gold-199	Au-199	100
Gold-200m	Au-200m	100
Gold-200	Au-200	1,000
Gold-201	Au-201	1,000
Mercury-193m	Hg-193m	100

Radionuclide	Abbreviation	Quantity (µCi)
Mercury-193	Hg-193	1,000
Mercury-194	Hg-194	1
Mercury-195m	Hg-195m	100
Mercury-195	Hg-195	1,000
Mercury-197m	Hg-197m	100
Mercury-197	Hg-197	1,000
Mercury-199m	Hg-199m	1,000
Mercury-203	Hg-203	100
Thallium-194m	Tl-194m	1,000
Thallium-194	Tl-194	1,000
Thallium-195	Tl-195	1,000
Thallium-197	Tl-197	1,000
Thallium-198m	Tl-198m	1,000
Thallium-198	Tl-198	1,000
Thallium-199	Tl-199	1,000
Thallium-200	T1-200	1,000
Thallium-201	T1-201	1,000
Thallium-202	Tl-202	100
Thallium-204	T1-204	100
Lead-195m	Pb-195m	1,000
Lead-198	Pb-198	1,000
Lead-199	Pb-199	1,000
Lead-200	Pb-200	100
Lead-201	Pb-201	1,000
Lead-202m	Pb-202m	1,000
Lead-202	Pb-202	10

NUREG-1736 C-24

Radionuclide	Abbreviation	Quantity (µCi)
Lead-203	Pb-2023	1,000
Lead-205	Pb-205	100
Lead-209	Pb-209	1,000
Lead-210	Pb-210	0.01
Lead-211	Pb-211	100
Lead-212	Pb-212	1
Lead-214	Pb-214	100
Bismuth-200	Bi-200	1,000
Bismuth-201	Bi-201	1,000
Bismuth-202	Bi-202	1,000
Bismuth-203	Bi-203	100
Bismuth-205	Bi-205	100
Bismuth-206	Bi-206	100
Bismuth-207	Bi-207	10
Bismuth-210m	Bi-210m	0.1
Bismuth-210	Bi-210	1
Bismuth-212	Bi-212	10
Bismuth-213	Bi-213	10
Bismuth-214	Bi-214	100
Polonium-203	Po-203	1,000
Polonium-205	Po-205	1,000
Polonium-207	Po-207	1,000
Polonium-210	Po-210	0.1
Astatine-207	At-207	100
Astatine-211	At-211	10
Radon-220	Rn-220	1

Radionuclide	Abbreviation	Quantity (µCi)
Radon-222	Rn-222	1
Francium-222	Fr-222	100
Francium-223	Fr-223	100
Radium-223	Ra-223	0.1
Radium-224	Ra-224	0.1
Radium-225	Ra-225	0.1
Radium-226	Ra-226	0.1
Radium-227	Ra-227	1,000
Radium-228	Ra-228	0.1
Actinium-224	Ac-224	1
Actinium-225	Ac-225	0.01
Actinium-226	Ac-226	0.1
Actinium-227	Ac-227	0.001
Actinium-228	Ac-228	I
Thorium-226	Th-226	10
Thorium-227	Th-227	0.01
Thorium-228	Th-228	0.001
Thorium-229	Th-229	0.001
Thorium-230	Th-230	0.001
Thorium-231	Th-231	100
Thorium-232	Th-232	100
Thorium-234	Th-234	10
Thorium-natural		100
Protactinium-227	Pa-227	10
Protactinium-228	Pa-228	1
Protactinium-230	Pa-230	0.01

NUREG-1736

Radionuclide	Abbreviation	Quantity (µCi)
Protactinium-231	Pa-231	0.001
Protactinium-232	Pa-232	1
Protactinium-233	Pa-233	100
Protactinium-234	Pa-234	100
Uranium-230	U-230	0.01
Uranium-231	U-231	100
Uranium-232	U-232	0.001
Uranium-233	U-233	0.001
Uranium-234	U-234	0.001
Uranium-235	U-235	0.001
Uranium-236	U-236	0.001
Uranium-237	U-237	100
Uranium-238	U-238	100
Uranium-239	U-239	1,000
Uranium-240	U-240	100
Uranium-natural		100
Neptunium-232	Np-232	100
Neptunium-233	Np-233	1,000
Neptunium-234	Np-234	100
Neptunium-235	Np-235	100
Neptunium-236 (1.15x10 ⁵ y)	Np-236	0.001
Neptunium-236 (22.5h)	Np-236	1
Neptunium-237	Np-237	0.001
Neptunium-238	Np-238	10
Neptunium-239	Np-239	100
Neptunium-240	Np-240	1,000

Radionuclide	Abbreviation	Quantity (µCi)
Plutonium-234	Pu-234	10
Plutonium-235	Pu-235	1,000
Plutonium-236	Pu-236	0.001
Plutonium-237	Pu-237	100
Plutonium-238	Pu-238	0.001
Plutonium-239	Pu-239	0.001
Plutonium-240	Pu-240	0.001
Plutonium-241	Pu-241	0.01
Plutonium-242	Pu-242	0.001
Plutonium-243	Pu₌243	1,000
Plutonium-244	Pu-244	0.001
Plutonium-245	Pu-245	100
Americium-237	Am-237	1,000
Americium-238	Am-238	100
Americium-239	Am-239	1,000
Americium-240	Am-240	100
Americium-241	Am-241	0.001
Americium-242m	Am-242m	0.001
Americium-242	Am-242	10
Americium-243	Am-243	0.001
Americium-244m	Am-244m	100
Americium-244	Am-244	10
Americium-245	Am-245	1,000
Americium-246m	Am-246	1,000
Americium-246	Am-246	1,000
Curium-238	Cm-238	100

Radionuclide	Abbreviation	Quantity (µCi)
Curium-240	Cm-240	0.1
Curium-241	Cm-241	1
Curium-242	Cm-242	0.01
Curium-243	Cm-243	0.001
Curium-244	Cm-244	0.001
Curium-245	Cm-245	0.001
Curium-246	Cm-246	0.001
Curium-247	Cm-247	0.001
Curium-248	Cm-248	0.001
Curium-249	Cm-249	1,000
Berkelium-245	Bk-245	100
Berkelium-246	Bk-246	100
Berkelium-247	Bk-247	0.001
Berkelium-249	Bk-249	0.1
Berkelium-250	Bk-250	10
Californium-244	Cf-244	100
Californium-246	Cf-246	1
Californium-248	Cf-248	0.01
Californium-249	Cf-249	0.001
Californium-250	Cf-250	0.001
Californium-251	Cf-251	0.001
Californium-252	Cf-252	0.001
Californium-253	Cf-253	0.1
Californium-254	Cf-254	0.001
Any alpha emitting radionuclide not listed above or mixtures or alpha emitters of unknown composition		0.001

Radionuclide	Abbreviation	Quantity (µCi)
Einsteinium-250	Es-250	100
Einsteinium-251	Es-251	100
Einsteinium-253	Es-253	0.1
Einsteinium-254m	Es-254m	1
Einsteinium-254	Es-254	0.01
Fermium-252	Fm-252	1
Fermium-253	Fm-253	1
Fermium-254	Fm-254	10
Fermium-255	Fm-255	1
Fermium-257	Fm-257	0.01
Mendelevium-257	Md-257	10
Mendelevium-258	Md-258	0.01
Any radionuclide other than alpha emitter radionuclides not listed above, or mixtures of beta emitters of unknown composition		0.01

Note: For purposes of 10 CFR 20.1902(e), 20.1905(a), and 20.2201(a) where there is involved a combination of radionuclides in known amounts, the limit for the combination should be derived as follows: determine, for each radionuclide in the combination, the ratio between the quantity present in the combination and the limit otherwise established for the specific radionuclide when not in combination. The sum of such ratios for all radionuclides in the combination may not exceed "1" (i.e., "unity").

Discussion:

Appendix C to Part 20 is a listing of the quantities of licensed material requiring posting pursuant to 10 CFR 20.1902 or exempt from labeling pursuant to 10 CFR 20.1905. These quantities of licensed material are considered to present a minimal radiological hazard. The quantities listed in Appendix C were derived by taking one-tenth of the most restrictive, occupational, annual limit of intake listed in Appendix B, rounding to the nearest factor of ten, and arbitrarily constraining the values listed between 0.001 and 1,000 microcuries (37 and 3.7 X 10⁷ Bq).

Appendix D

United States Nuclear Regulatory Commission Regional Offices

Statement of Requirement:

Table D.1. Appendix D to Part 20 – United States Nuclear Regulatory Commission Regional Offices

	Address	Telephone (24 hour)
Region I: Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont.	USNRC, Region I 475 Allendale Road King of Prussia, PA 19406	(610) 337-5000 (800) 432-1156
Region II: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, Puerto Rico, South Carolina, Tennessee, Virginia, Virgin Islands, and West Virginia.	USNRC, Region II Atlanta Federal Center 61 Forsyth Street, SW Suite 23T85 Atlanta, GA 30303	(404) 562-4400 (800) 577-8510
Region III: Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, Ohio, and Wisconsin.	USNRC, Region III 801 Warrenville Road Lisle, IL 60532-4351	(708) 829-9500 (800) 522-3025
Region IV: Alaska, Arizona, Arkansas, California, Colorado, Hawaii, Idaho, Kansas, Louisiana, Montana, Nebraska, Nevada, New Mexico, North Dakota, Oklahoma, Oregon, South Dakota, Texas, Utah, Washington, Wyoming, and the U.S. territories and possessions in the Pacific.	USNRC, Region IV 611 Ryan Plaza Drive Suite 400 Arlington, TX 76011	(817) 860-8100 (800) 952-9677

Discussion:

N/A.

Appendix E – F RESERVED

Appendix G

Requirements for Transfers of Low-Level Radioactive Waste Intended for Disposal at Licensed Land Disposal Facilities and Manifests

Statement of Requirement:

I. Manifest

A waste generator, collector, or processor who transports, or offers for transportation, low-level radioactive waste intended for ultimate disposal at a licensed low-level radioactive waste land disposal facility must prepare a Manifest (OMB Control Numbers 3150-0164, -0165, and -0166) reflecting information requested on applicable NRC Forms 540 (Uniform Low-Level Radioactive Waste Manifest (Shipping Paper)) and 541 (Uniform Low-Level Radioactive Waste Manifest (Container and Waste Description)) and, if necessary, on an applicable NRC Form 542 (Uniform Low-Level Radioactive Waste Manifest (Manifest Index and Regional Compact Tabulation)). NRC Forms 540 and 540A must be completed and must physically accompany the pertinent low-level waste shipment. Upon agreement between shipper and consignee, NRC Forms 541 and 541A and 542 and 542A may be completed, transmitted, and stored in electronic media with the capability for producing legible, accurate, and complete records on the respective forms Licensees are not required by NRC to comply with the manifesting requirements of this part when they ship:

- (a) LLW for processing and expect its return (i.e., for storage under their license) prior to disposal at a licensed land disposal facility;
- (b) LLW that is being returned to the licensee who is the "waste generator" or "generator," as defined in this part; or
- (c) Radioactively contaminated material to a "waste processor" that becomes the processor's "residual waste."

For guidance in completing these forms, refer to the instructions that accompany the forms.

Copies of manifests required by this appendix may be legible carbon copies, photocopies, or computer printouts that reproduce the data in the format of the uniform manifest.

NRC Forms 540, 540A, 541, 541A, 542 and 542A, and the accompanying instructions, in hard copy, may be obtained from the Information and Records Management Branch, Office of Information Resources Management, U.S. Nuclear Regulatory Commission, Washington, DC 20555, telephone (301) 415-7232.

This appendix includes information requirements of the Department of Transportation, as codified in 49 CFR Part 172. Information on hazardous, medical, or other waste, required to meet Environmental Protection Agency regulations, as codified in 40 CFR Parts 259, 261 or elsewhere, is not addressed in this section, and must be provided on the required EPA forms. However, the required EPA forms must accompany the Uniform Low-Level Radioactive Waste Manifest required by this chapter.

G-1 NUREG-1736

APPENDIX G

As used in this appendix, the following definitions apply:

Chelating agent has the same meaning as that given in Section 61.2 of this chapter.

Chemical description means a description of the principal chemical characteristics of a low-level radioactive waste.

Computer-readable medium means that the regulatory agency's computer can transfer the information from the medium into its memory.

Consignee means the designated receiver of the shipment of low-level radioactive waste.

Decontamination facility means a facility operating under a Commission or Agreement State license whose principal purpose is decontamination of equipment or materials to accomplish recycle, reuse, or other waste management objectives, and, for purposes of this part, is not considered to be a consignee for LLW shipments.

Disposal container means a container principally used to confine low-level radioactive waste during disposal operations at a land disposal facility (also see "high integrity container"). Note that for some shipments, the disposal container may be the transport package.

EPA identification number means the number received by a transporter following application to the Administrator of EPA as required by 40 CFR Part 263.

Generator means a licensee operating under a Commission or Agreement State license who: (1) is a waste generator as defined in this part; or (2) is the licensee to whom waste can be attributed within the context of the Low-Level Radioactive Waste Policy Amendments Act of 1985 (e.g., waste generated as a result of decontamination or recycle activities).

High integrity container (HIC) means a container commonly designed to meet the structural stability requirements of Section 61.56 of this chapter, and to meet Department of Transportation requirements for a Type A package.

Land disposal facility has the same meaning as that given in Section 61.2 of this chapter.

NRC Forms 540, 540A, 541, 541A, 542, and 542A are official NRC Forms referenced in this appendix. Licensees need not use originals of these NRC Forms as long as any substitute forms are equivalent to the original documentation in respect to content, clarity, size, and location of information. Upon agreement between the shipper and consignee, NRC Forms 541 (and 541A) and NRC Forms 542 (and 542A) may be completed, transmitted, and stored in electronic media. The electronic media must have the capability for producing legible, accurate, and complete records in the format of the uniform manifest.

NUREG-1736 G-2

Package means the assembly of components necessary to ensure compliance with the packaging requirements of DOT regulations, together with its radioactive contents, as presented for transport.

Physical description means the items called for on NRC Form 541 to describe a low-level radioactive waste.

Residual waste means low-level radioactive waste resulting from processing or decontamination activities that cannot be easily separated into distinct batches attributable to specific waste generators. This waste is attributable to the processor or decontamination facility, as applicable.

Shipper means the licensed entity (i.e., the waste generator, waste collector, or waste processor) who offers low-level radioactive waste for transportation, typically consigning this type of waste to a licensed waste collector, waste processor, or land disposal facility operator.

Shipping paper means NRC Form 540 and, if required, NRC Form 540A, which includes the information required by DOT in 49 CFR Part 172.

Source material has the same meaning as that given in Section 40.4 of this chapter.

Special nuclear material has the same meaning as that given in Section 70.4 of this chapter.

Uniform Low-Level Radioactive Waste Manifest or uniform manifest means the combination of NRC Forms 540, 541, and, if necessary, 542, and their respective continuation sheets as needed, or equivalent.

Waste collector means an entity, operating under a Commission or Agreement State license, whose principal purpose is to collect and consolidate waste generated by others, and to transfer this waste, without processing or repackaging the collected waste, to another licensed waste collector, licensed waste processor, or licensed land disposal facility.

Waste description means the physical, chemical and radiological description of a low-level radioactive waste as called for on NRC Form 541.

Waste generator means an entity, operating under a Commission or Agreement State license, who (1) possesses any material or component that contains radioactivity or is radioactively contaminated for which the licensee foresees no further use, and (2) transfers this material or component to a licensed land disposal facility or to a licensed waste collector or processor for handling or treatment prior to disposal. A licensee performing processing or decontamination services may be a "waste generator" if the transfer of low-level radioactive waste from its facility is defined as "residual waste."

Waste processor means an entity, operating under a Commission or Agreement State license, whose principal purpose is to process, repackage, or otherwise treat low-level radioactive

G-3 NUREG-1736

APPENDIX G

material or waste generated by others prior to eventual transfer of waste to a licensed low-level radioactive waste land disposal facility.

Waste type means a waste within a disposal container having a unique physical description (i.e., a specific waste descriptor code or description; or a waste sorbed on or solidified in a specifically defined media).

Information Requirements

A. General Information

The shipper of the radioactive waste shall provide the following information on the uniform manifest:

- (1) The name, facility address, and telephone number of the licensee shipping the waste;
- (2) An explicit declaration indicating whether the shipper is acting as a waste generator, collector, processor, or a combination of these identifiers for purposes of the manifested shipment; and
- (3) The name, address, and telephone number, or the name and EPA identification number for the carrier transporting the waste.

B. Shipment Information

The shipper of the radioactive waste shall provide the following information regarding the waste shipment on the uniform manifest:

- (1) The date of the waste shipment;
- (2) The total number of packages/disposal containers;
- (3) The total disposal volume and disposal weight in the shipment;
- (4) The total radionuclide activity in the shipment;
- (5) The activity of each of the radionuclides H-3, C-14, Tc-99, and I-129 contained in the shipment; and
- (6) The total masses of U-233, U-235, and plutonium in special nuclear material, and the total mass of uranium and thorium in source material.

NUREG-1736 G-4

C. Disposal Container and Waste Information

The shipper of the radioactive waste shall provide the following information on the uniform manifest regarding the waste and each disposal container of waste in the shipment:

- An alphabetic or numeric identification that uniquely identifies each disposal container in the shipment;
- A physical description of the disposal container, including the manufacturer and model of any high integrity container;
- (3) The volume displaced by the disposal container;
- (4) The gross weight of the disposal container, including the waste;
- (5) For waste consigned to a disposal facility, the maximum radiation level at the surface of each disposal container;
- (6) A physical and chemical description of the waste;
- (7) The total weight percentage of chelating agent for any waste containing more than 0.1% chelating agent by weight, plus the identity of the principal chelating agent;
- (8) The approximate volume of waste within a container;
- (9) The sorbing or solidification media, if any, and the identity of the solidification media vendor and brand name;
- (10) The identities and activities of individual radionuclides contained in each container, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material. For discrete waste types (i.e., activated materials, contaminated equipment, mechanical filters, sealed source/devices, and wastes in solidification/stabilization media), the identities and activities of individual radionuclides associated with or contained on these waste types within a disposal container shall be reported;
- (11) The total radioactivity within each container; and
- (12) For wastes consigned to a disposal facility, the classification of the waste pursuant to Section 61.55 of this chapter. Waste not meeting the structural stability requirements of Section 61.56(b) of this chapter must be identified.

D. Uncontainerized Waste Information

The shipper of the radioactive waste shall provide the following information on the uniform manifest regarding a waste shipment delivered without a disposal container:

- (1) The approximate volume and weight of the waste;
- (2) A physical and chemical description of the waste;

APPENDIX G

- (3) The total weight percentage of chelating agent if the chelating agent exceeds 0.1% by weight, plus the identity of the principal chelating agent;
- (4) For waste consigned to a disposal facility, the classification of the waste pursuant to section 61.55 of this chapter. Waste not meeting the structural stability requirements of section 61.56(b) of this chapter must be identified;
- (5) The identities and activities of individual radionuclides contained in the waste, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material; and
- (6) For wastes consigned to a disposal facility, the maximum radiation levels at the surface of the waste.

E. Multi-Generator Disposal Container Information

This section applies to disposal containers enclosing mixtures of waste originating from different generators. (*Note:* The origin of the LLW resulting from a processor's activities may be attributable to one or more "generators" (including "waste generators") as defined in this part). It also applies to mixtures of wastes shipped in an uncontainerized form, for which portions of the mixture within the shipment originate from different generators.

- For homogeneous mixtures of waste, such as incinerator ash, provide the waste description applicable to the mixture and the volume of the waste attributed to each generator.
- (2) For heterogeneous mixtures of waste, such as the combined products from a large compactor, identify each generator contributing waste to the disposal container, and, for discrete waste types (i.e., activated materials, contaminated equipment, mechanical filters, sealed source/devices, and wastes in solidification/stabilization media), the identities and activities of individual radionuclides contained on these waste types within the disposal container. For each generator, provide the following:
 - (a) The volume of waste within the disposal container;
 - (a) A physical and chemical description of the waste, including the solidification agent, if any;
 - (a) The total weight percentage of chelating agents for any disposal container containing more than 0.1% chelating agent by weight, plus the identity of the principal chelating agent;
 - (a) The sorbing or solidification media, if any, and the identity of the solidification media vendor and brand name if the media is claimed to meet stability requirements in 10 CFR 61.56(b); and

(a) Radionuclide identities and activities contained in the waste, the masses of U-233, U-235, and plutonium in special nuclear material, and the masses of uranium and thorium in source material if contained in the waste.

II. Certification

An authorized representative of the waste generator, processor, or collector shall certify by signing and dating the shipment manifest that the transported materials are properly classified, described, packaged, marked, and labeled and are in proper condition for transportation according to the applicable regulations of the Department of Transportation and the Commission. A collector in signing the certification is certifying that nothing has been done to the collected waste that would invalidate the waste generator's certification.

III. Control and Tracking

- A. Any licensee who transfers radioactive waste to a land disposal facility or a licensed waste collector shall comply with the requirements in Paragraphs A.1 through 9 of this section. Any licensee who transfers waste to a licensed waste processor for waste treatment or repackaging shall comply with the requirements of Paragraphs A.4 through 9 of this section. A licensee shall:
 - (1) Prepare all wastes so that the waste is classified according to section 61.55 and meets the waste characteristics requirements in Section 61.56 of this chapter;
 - (2) Label each disposal container (or transport package if potential radiation hazards preclude labeling of the individual disposal container) of waste to identify whether it is Class A waste, Class B waste, Class C waste, or greater then Class C waste, in accordance with section 61.55 of this chapter;
 - (3) Conduct a quality assurance program to assure compliance with sections 61.55 and 61.56 of this chapter (the program must include management evaluation of audits);
 - (4) Prepare the NRC Uniform Low-Level Radioactive Waste Manifest as required by this appendix;
 - (5) Forward a copy or electronically transfer the Uniform Low-Level Radioactive Waste Manifest to the intended consignee so that either: (i) receipt of the manifest precedes the LLW shipment; or (ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;
 - (6) Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in Paragraph A.5 of this section;
 - (7) Receive acknowledgment of the receipt of the shipment in the form of a signed copy of NRC Form 540;
 - (8) Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer of licensed material as required by 10 CFR Parts 30, 40, and 70 of this chapter; and

G-7 NUREG-1736

APPENDIX G

- (9) For any shipments or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with Paragraph E of this appendix.
- B. Any waste collector licensee who handles only prepackaged waste shall:
 - Acknowledge receipt of the waste from the shipper within one week of receipt by returning a signed copy of NRC Form 540;
 - (2) Prepare a new manifest to reflect consolidated shipments that meet the requirements of this appendix. The waste collector shall ensure that, for each container of waste in the shipment, the manifest identifies the generator of that container of waste;
 - (3) Forward a copy or electronically transfer the Uniform Low-Level Radioactive Waste Manifest to the intended consignee so that either: (i) Receipt of the manifest precedes the LLW shipment; or (ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;
 - (4) Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in Paragraph B.3 of this section;
 - (5) Receive acknowledgment of the receipt of the shipment in the form of a signed copy of NRC Form 540;
 - (6) Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer of licensed material as required by 10 CFR Parts 30, 40, and 70 of this chapter;
 - (7) For any shipments or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with Paragraph E of this appendix; and
 - (8) Notify the shipper and the Administrator of the nearest Commission Regional Office listed in Appendix D of this part when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.
- C. Any licensed waste processor who treats or repackages waste shall:
 - Acknowledge receipt of the waste from the shipper within one week of receipt by returning a signed copy of NRC Form 540;
 - (2) Prepare a new manifest that meets the requirements of this appendix. Preparation of the new manifest reflects that the processor is responsible for meeting these requirements. For each container of waste in the shipment, the manifest shall identify the waste generators, the preprocessed waste volume, and the other information as required in Paragraph I.E. of this appendix;

- (3) Prepare all wastes so that the waste is classified according to section 61.55 of this chapter and meets the waste characteristics requirements in section 61.56 of this chapter;
- (4) Label each package of waste to identify whether it is Class A waste, Class B waste, or Class C waste, in accordance with Sections 61.55 and 61.57 of this chapter;
- (5) Conduct a quality assurance program to assure compliance with sections 61.55 and 61.56 of this chapter (the program shall include management evaluation of audits);
- (6) Forward a copy or electronically transfer the Uniform Low-Level Radioactive Waste Manifest to the intended consignee so that either: (i) Receipt of the manifest precedes the LLW shipment; or (ii) the manifest is delivered to the consignee with the waste at the time the waste is transferred to the consignee. Using both (i) and (ii) is also acceptable;
- (7) Include NRC Form 540 (and NRC Form 540A, if required) with the shipment regardless of the option chosen in Paragraph C.6 of this section;
- (8) Receive acknowledgment of the receipt of the shipment in the form of a signed copy of NRC Form 540:
- (9) Retain a copy of or electronically store the Uniform Low-Level Radioactive Waste Manifest and documentation of acknowledgment of receipt as the record of transfer of licensed material as required by 10 CFR Parts 30, 40, and 70 of this chapter;
- (10) For any shipment or any part of a shipment for which acknowledgment of receipt has not been received within the times set forth in this appendix, conduct an investigation in accordance with Paragraph E of this appendix; and
- (11) Notify the shipper and the Administrator of the nearest Commission Regional Office listed in Appendix D of this part when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.

D. The land disposal facility operator shall:

- (1) Acknowledge receipt of the waste within one week of receipt by returning, as a minimum, a signed copy of NRC Form 540 to the shipper. The shipper to be notified is the licensee who last possessed the waste and transferred the waste to the operator. If any discrepancy exists between materials listed on the Uniform Low-Level Radioactive Waste Manifest and materials received, copies or electronic transfer of the affected forms must be returned indicating the discrepancy;
- (2) Maintain copies of all completed manifests and electronically store the information required by 10 CFR 61.80(l) until the Commission terminates the license; and
- (3) Notify the shipper and the Administrator of the nearest Commission Regional Office listed in Appendix D of this part when any shipment, or part of a shipment, has not arrived within 60 days after receipt of an advance manifest, unless notified by the shipper that the shipment has been canceled.

G-9 NUREG-1736

APPENDIX G

- E. Any shipment or part of a shipment for which acknowledgment is not received within the times set forth in this section must:
 - (1) Be investigated by the shipper if the shipper has not received notification or receipt within 20 days after transfer; and
 - (2) Be traced and reported. The investigation shall include tracing the shipment and filing a report with the nearest Commission Regional Office listed in Appendix D to this part. Each licensee who conducts a trace investigation shall file a written report with the appropriate NRC Regional Office within 2 weeks of completion of the investigation.

Discussion:

N/A.

NUREG-1736

Appendix H

Summary of Comments Received on Draft NUREG-1736, Part 20

Appendix H - Summary of Comments Received on Draft NUREG-1736, Part 20

Comments Provided by the Academic & Medical Radiation Safety Officers (AMRSO), Dated November 22, 2000

Location	Subject	Comment
Entire Document	Comment Period	This document is about 350 pages long and affects every NRC licensee and most Agreement State licensees. Because of this, the AMRSO group feels even the original 90 days is an insufficient time to conduct a thorough review and to submit considered comments and that this problem is exacerbated by the unavoidable delay imposed by distributing them by mail. We feel that, otherwise, it will be difficult for interested licensees to provide the considered feedback that is the purpose of having a review period.
		It is for this reason that we request that the Nuclear Regulatory Commission extend the official comment period for the referenced publication to March 31, 2001.

NRC Staff Response: We consider the 90-day comment period to be of sufficient length for interested parties to review the document and provide comments, particularly since the draft document was available on the NRC web site with an online comment submission form. Also, NRC believes that it was important to finalize the document so that it can be used. NRC believes that use of the document by licensees and license reviewers will provide an opportunity for additional comments. These comments will be incorporated into the document during a planned revision in 2004.

APPENDIX H

Comments Provided by American Nuclear Insurers (ANI), Dated December 18, 2000

Location	Subject	Comment
Entire Document	Definition – public dose	I have reason to believe that because of the wording in the final rule in the 1995 Federal Register, regardless of how it may be resolved in NUREG 1736, there will remain some confusion on the issue of whether a member of the public is subject to occupational dose limits when he enters a restricted area as defined in Part 20. In one sense this is surprising since the primary reason for the 1995 revision to Part 20 was to redefine "Occupational dose," "Member of the public," "Public dose," and "Occupational dose" in order to clarify that very issue. The term "Controlled Area" also appears to be adding to the confusion.
		It seems to me that NUREG 1736 is an excellent opportunity to address the entire issue by explaining the history of the rule change, whether Q&A 26 is finally retired or revised. I expect that the most useful way to accomplish this might be to build on some of the quotations above from the <i>Federal Register</i> as you have done in several other sections of the draft.

NRC Staff Response: The current Part 20 defines Occupational and Public Doses in a manner that clarifies the confusion that previously existed between the two terms and their application to specific situations. It would be difficult to improve on these definitions. The staff agrees with the part of the comment that refers to Q&A 26, and this Q&A has been marked as obsolete, at least until it is updated. We agree that the definition and use of the term Controlled Area still causes some difficulties. However, we believe that the discussion in connection with the definition of this term makes the meaning clear, or at least clearer, and there is little that can be added to clarify the meaning further.

NUREG-1736 H-2

Comments Provided by J. Bacquet, Dated February 8, 2001

Location	Subject	Comment
Definitions & Subpart G, Sections 20.1601 and 20.1602	Entrance or Access points	The definition states this is any location through which an individual could gain access to a radiation area or radioactive material. This includes portals of sufficient size to permit human entry, irrespective of their intended use. What does "sufficient size" mean? Is there a specific opening size indicated? For security access we have an actual size opening that would be considered accessible (100 sq inches with a minimum dimension of 8" on any side). Would the same size limitation be considered reasonable for access to an RN HRA or VHRA?

NRC Staff Response: There are no prescriptive numerical size (dimensional) criteria for entrance or access points for high radiation areas (HRA) or very high radiation areas (VHRA). The Part 20 definition (entrance or access point) is performance-based, allowing the licensees needed flexibility, given the many different HRA and VHRA configurations across the wide spectrum of facility types. Licensees may establish administrative definitions for accessibility specific to their particular situations and for ease and consistency in implementation of radiological controls. The test is a performance standard based on the reasonableness for an individual to gain access to the area or material.

H-3 NUREG-1736

APPENDIX H

Comments Provided by the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR), Dated February 20, 2001

Location	Subject	Comment
Entire Document	Format and content of the consolidated guidance report	While it is the objective of NRC to provide a single, comprehensive source of guidance concerning 10 CFR 20 by combining the multitude of guidance information previously available in a variety of formats, the draft has not effectively achieved this purpose. The draft consolidated guidance could be vastly improved if it integrated the text of the numerous guidance references (e.g., Q&As, HPPOS and circulars) wherever possible, into the text of the discussion of the consolidated guidance. The volume of text in the Q&A documents is usually very brief and could easily be inserted if not condensed into the relevant discussion sections of the NUREG. This would provide the opportunity to edit and update the guidance as needed. Limiting the list of references to more lengthy detailed guidance that could not be practically integrated such as other NUREGS or Regulatory Guides would result in a more comprehensive guidance document that would serve as the definitive handbook to Part 20 compliance. An alternative to the production of a printed document would be an electronic version on the NRC web site that could still include the lists of implementing guidance where links to individual documents, also available on the web site, would be provided.

NRC Staff Response: The document was not modified in response to this comment. The purpose of the Discussion is to provide a plain-language restatement of the main requirements in the rule text. While there was a desire to have this report as comprehensive and inclusive as possible, there was a counter requirement to keep it to a manageable and usable length. The compromise was to address the Part 20 questions and answers (Q&As) and health physics positions (HPPOS) by reference, rather than direct inclusion. The approach was deemed reasonable because the Q&As and HPPOSs are included on the NRC web site and therefore readily available to most potential users of the report. See http://www.nrc.gov/NRC/NMSS/HP/POS/index.html. Please note that the Q&As and HPPOSs identified in this NUREG as "outdated" are not identified as such in the original documents referenced as hyperlinks above.

NUREG-1736 H-4

Location	Subject	Comment
Entire Document	Word usage and definition	In some parts of the NUREG, the terms "dose" and "exposure" are used indiscriminately in discussions such as those regarding surveys and monitoring, monitoring of occupational dose, determination of prior occupational dose, and records of individual monitoring results. This sometimes occurs in the same sentence (see the discussion on page 3-168). This can be confusing and should, at least for the sake of technical consistency, be addressed throughout the guidance document.
		There is a similar problem with use of the terms radioactive "waste" and "materials" as they are used in discussions regarding records of waste disposal, disposal of specific wastes, transfer for disposal and manifests, method for obtaining approval of proposed disposal procedures, and the general requirements in 3.20.2001. A more fundamental problem is the fact that nowhere in this NUREG is there a definition of "waste," nor is there any guidance that can help licensees determine the distinction between material to be transferred for potential reuse or recycling from those materials that are transferred directly to a disposal site.
		Appendix G contains detailed guidance on the content and format of manifests that includes definitions for waste collector, waste description, waste generator and waste processor. However, there is no definition for waste itself. This leaves any guidance in this NUREG relevant to disposal of radioactive material incomplete and open to subjective interpretation. This definition is lacking not only in this guidance but also everywhere else in NRC regulation and guidance documentation. We strongly recommend that this need be addressed in this comprehensive guidance document.

H-5 NUREG-1736

Location

Subject

NRC Staff Response: The staff does not share the concern with word usage ("dose" and "exposure," "waste" and "materials") that was expressed in the comment. Word usage in Discussions and other sections of this document reflect common usage and do not introduce technical inconsistencies, especially with respect to "exposure," as it is consistently not used as a quantity or amount but as a condition. Also, for each appearance of these words, the context aids in discerning the meaning as used.			
With respect to the suggestion that this document provide a regulatory definition of "waste," since the meaning of the word "waste" as used in Part 20 does not differ from common usage, a definition has not been included in section 20.1003 or in guidance relating to Part 20.			
No changes to the to	ext of the document	were made in response to this comment.	
3.20.1002	Scope	Guidance in this section should address the situation where radioactive material could be either by-product material or NARM or both.	
NRC Staff Respon to the discussion for	NRC Staff Response: The staff agrees with the comment, and additional guidance was added to the discussion for section 20.1001.		
3.20.1003	Definitions	(1) The discussion on page 3-17 states that "'Reference Man,' also called 'Standard Man,' is a set of standardized physical parameters" This is incorrect. Reference Man has replaced Standard Man and it was the physical parameters of Reference Man that were used in ICRP 26 and 30 dose modeling as the basis of 10 CFR 20 standards for radiation protection. The reference to Standard Man should be removed, as it is obsolete.	
		(2) The discussion on page 3-19 concerning stochastic effects states that "according to the linear-no-threshold hypothesis, the risks resulting from doses below the regulatory limit for the effective dose equivalent are not zero." It would be appropriate to state after this that the linear-no-threshold model (rather than hypothesis), considered conservative by most experts in the field, is applied as a prudent	

Comment

Location	Subject	Comment
		measure even though it may in fact overstate risk. The effects predicted by this model have never been observed in populations exposed to levels of radiation within occupational limits.
		(3) The discussion at the top of page 3-21 includes a statement that deterministic effects resulting from acute exposures are commonly known as "radiation sickness." This statement is incorrect and misleading. There are deterministic effects resulting from acute doses other than "radiation sickness," which include erythema, induction of cataracts, impairment of fertility, and tissue degeneration from fractional dose.
		The statement that "the rem is defined using the quality factor for cancer as the end point of interest" is confusing because it implies that there is just one quality factor when in fact the quality factor is dependent on the type of radiation, dose-rate, and the tissue exposed.
		(4) The shallow-dose equivalent (R~), when applied to small areas (i.e., <30 cm²) of skin exposed due to local contamination or hot particles, is designed to protect against potential deterministic effects which have thresholds that are factors of 30 or 100 or more above the U.S. NRC limit. In this case, both the limit and the unit are inappropriate and need to be changed and discussed.

H-7 NUREG-1736

Location	Subject	Comment	
this error. The staff this comment. The made in the text. To quality factor. Alth specified for radiation in the case of neutro clarification was man	NRC Staff Response: The staff agrees with comment (1). The text was changed to correct this error. The staff agrees with comment (2) and corrections were made in the text to reflect this comment. The staff also agrees with the first part of comment (3) and corrections were made in the text. The staff disagrees with the second part of the comment, referring to the quality factor. Although the RBE is dependent on the factors mentioned, the quality factor as specified for radiation protection work is only dependent on the type of incident radiation and, in the case of neutrons, on its energy. It does not depend on the tissue exposed. Some clarification was made in the text. Although possibly correct, comment (4) is beyond the scope of the guidance, because addressing it requires changing the rule.		
3.20.1201	Dose response model	(1) In the discussion on page 3-38, it says, "the scientific community generally assumes that any exposure to ionizing radiation may cause undesirable biological effects and that the likelihood of these effects increases as the dose increases." We disagree with this statement. While the "scientific community" generally accepts that exposures to ionizing radiation should be reduced to levels as low as reasonably achievable, many among this group believe that there is no likelihood of increased risk from stochastic effects below a certain threshold. This threshold may be above the occupational limits as the effects, predicted by the model projecting an increase in effects as the dose increases, have never been observed in populations exposed at these levels. (2) On page 3-40, the discussion concerning the relation between doses recorded on the abdomen and	
		the back should consider the guidance in NCRP Report Number 122.	
NRC Staff Response: (1) The discussion is a statement of the generally accepted linear no threshold model used as a basis for NRC regulations. We recognize that there are differences of opinion within the scientific community regarding the appropriateness of this model, but the linear no threshold model is still considered the most reasonable as a basis for radiation control positions. (2) The guidance documents listed in NUREG-1736 are NRC documents.			
3.20.1202	doses	The guidance statement on page 3-43 should address the situation where an individual receives a DDE close to 5.0 rem and an intake < 10% which is not required to be measured but may be greater than zero to the extent that the TEDE exceeds 5.0 rem.	

1

Location	Subject	Comment
NRC Staff Respon	se: We believe that	the regulation is clear that if you are not required to

NRC Staff Response: We believe that the regulation is clear that if you are not required to monitor intake, i.e., less than 10% of the limits, any exposure would not have to be added to the external exposure, no matter how close an individual may be to the 5 rem limit.

H-9 NUREG-1736

Location	Subject	Comment
3.20.1301	Public dose, exceptions	(1) The list of public doses not subject to this regulation on page 3-66 should include those that come as a result from exposure to radioactive materials legally in transport and members of the public who provide support to a nuclear medicine patient.
		(2) The guidance statement on page 3-70 should address the use of passive dosimeters at the perimeter of a site and other methods to demonstrate compliance with the external dose limit of 2 mrem in an hour, if results of these devices indicate the total annual dose from external exposure and from airborne releases do not exceed 100 mrem.

NRC Staff Response: The transit of properly packaged radioactive material is not considered a licensed activity in the context of Part 20 and, therefore, is not subject to the public dose limits. NRC licensees, both specific and general, must prepare and transport or offer for shipment, radioactive materials in accordance with the requirements of 10 CFR Part 71 and the Department of Transportation regulations governing hazardous material transport (49 CFR Parts 170 through 189), which provide adequate protection to the public from exposure to these materials. This section was revised to include this distinction.

Exposure to individuals administered radioactive material (e.g., nuclear medicine patient) and released in accordance with 10 CFR 35.75 is already specifically excluded from the public dose limits. If a patient was not releasable in accordance with 10 CFR 35.75 (and housed in accordance with the requirements of that section), then the public dose limits apply. Licensees may request alternative public dose limits (up to 500 millirem in a year). NRC will review and approve such requests on a case-by-case basis.

Location	Subject	Comment
With regard to comment (2), using passive dosimeters to demonstrate compliance with the 2 millirem in any one hour dose limit, the staff did not incorporate the comment. It would be incorrect to assume that complying with the 100 millirem dose limit at the perimeter of a licensee's site automatically demonstrated compliance with the 2 millirem in any one hour dose limit. If a licensee can show that radiological conditions on its site and at the perimeter do not change appreciably over the course of a year, compliance with both dose limits (annual and in any one hour) could be demonstrated. However, such findings must be made on a case-by-case basis. Therefore, no changes were made to the guidance.		
3.20.1500	Surveys	Although the meaning of the "survey" is clarified on page 3-19, it would be helpful to also include in the guidance statement on page 3-14 the fact that the performance of surveys in the field with a survey instrument, without assessing the resulting data, would not be considered having satisfied the requirement to perform an adequate survey. The important distinction made on 3-19 might otherwise be missed if one consults the guidance in 3.20.1500.
NRC Staff Response: The staff agrees that further clarification to the guidance for 10 CFR 20.1501 would be useful. Clarification was provided in this section. The staff could not determine where clarification was sought on page 3-14 of the guidance document.		

H-11 NUREG-1736

Location	Subject	Comment
3.20.1801	Storage	The guidance statement on page 3-133 states that "only active measures" would be sufficient to demonstrate compliance with the need to secure material from unauthorized materials. The implication is that material needs to be stored under lock and key. This guidance needs to take into account situations, such as those at manufacturers and distributors of radiopharmaceuticals and life science radiochemicals, where unit containers may be stored on shelves or bins in areas where trained employees can access them, keeping in mind that the access to the facility or the storage area would have positive restrictions to unauthorized access.
		During U.S. NRC workshops on the topic of securing licensed material, the general consensus was that small quantities ~1 00 ALI do not need to be secured behind locked doors, but can be treated like non-radioactive hazardous chemicals commonly found in research laboratories.

NRC Staff Response: The purpose of section 20.1801 is to assure that material is secured from "unauthorized" removal. In a situation where only authorized individuals are to have access to a storage area within a larger area such as a building, the licensee may apply active measures at the access point to the larger area such as the building entrance. With regard to security as related to small quantities, notwithstanding what may have been said during an NRC workshop, the requirement to secure materials is unrelated to the quantity of the licensed material involved.

3.20.1902	Guidance in this part should address situations where there may be a large number of labeled containers in an enclosure, such as a refrigerator or an autoclave, and how the requirements in 20.1905 relate to those for posting these enclosures or areas where they are located. The concern that needs to be considered is the avoidance of excessive posting and labeling.
	Promise and making

NRC Staff Response: Given the large variety of licensees that NRC regulates and the many different scenarios that could be described, we have elected not to try to address every possible scenario, but rather provide generally applicable guidance. Individual situations can be discussed with NRC technical staff during the licensing process or during NRC inspections.

Location	Subject	Comment
3.20.1904	Labeling containers	(1) On page 3-141 the requirement to include "radiation levels" on the label is redundant because licensees should be required to have instruments that can directly measure radiation fields in the vicinity of a container. This prescriptive provision could also be counterproductive, particularly for short-lived radioactive materials, because the routine measuring and labeling of the vial will incur more dose than is likely to be avoided. Also, warning of significant radiation fields are adequately provided by the requirement to post radiation areas.
		(2) The discussion at the bottom of page 3-141 implies that it is necessary to accurately determine the quantity of radioactive material and radiation fields. However, only order of magnitude assessments in containers are needed to provide adequate protection.
		(3) Some additional guidance on page 3-142 would be helpful on appropriate methods for defacing labels on containers prior to disposal.

NRC Staff Response: (1) and (2) The basic regulatory requirement is to label containers with sufficient information to permit individuals handling or using the containers to take precautions for avoiding or minimizing exposures. Parenthetically, the regulation states that such information as, among other things, radiation levels, may be appropriate. However, the regulation does not impose any prescriptive labeling requirement other than the radiation symbol and the words "Caution-Radioactive Material." (3) With regard to defacing labels, because of the multiplicity of types and composition of containers as well as labels and the methods of attachment, we chose not to provide any specific guidance.

H-13 NUREG-1736

Location	Subject	Comment
3.20.1906	Surveying of packages	The paragraph on the bottom of page 3-147 explains how a limit of 22,000 dpm would apply to the wipe of an area on a package of 100cm ² . This discussion should include a statement that this would apply to a beta, gamma, or low toxicity alpha-emitting contaminant. In addition, in practice the area will be greater than 100cm ² if all sides of a package are wiped. This should be considered in the guidance.
		A common problem is that licensees receiving packages will use inappropriate contamination monitoring instruments to measure the near surface radiation levels and TI. U.S. NRC should recommend the use of an energy-compensated side window GM detector with the window closed, or equivalent instruments.

NRC Staff Response: The comment in the first paragraph was adopted. With regard to specific instrumentation, licensees may choose instrumentation that is appropriate for the specific situation.

NUREG-1736 H-14

Location	Subject	Comment
3.20.2001	Waste disposal	(1) If the intent of U.S. NRC regulations is to limit decay in storage to 5 years, it would greatly simplify compliance if the NRC specified this or a 180-day half-life as a limit for decay in storage. The U.S. NRC and Agreement State regulator could still impose more restrictive license conditions, if appropriate.
		(2) The U.S. NRC definition of "effluent" to exclude releases to the sanitary sewer is bizarre and confusing. We would recommend that the term is defined as in common usage to include sewerage released (via the sewer) to the environment.

NRC Staff Response: The staff agrees with comment (1). Changes were made in the text to clarify this area. The staff disagrees with comment (2). The reason sewer disposal and effluents are separated is that the limits placed on each of the two categories of discharge were based on entirely different scenarios for potential exposures to members of the public. Effluents are discharged to bodies of water where they are diluted, whereas sewer discharges go to the sewer system and then to a sewage treatment facility where they are treated before being released to bodies of water. The exposure consequences of the different potential exposure scenarios lead to different restrictions on each type of release, and they are therefore not classified as a single type of discharge.

3.20.2003	Disposal into	The guidance statement on page 3-155 should explain
	sanitary sewerage	the proper handling of excreta from employees at
		licensed facilities who, as patients, have also been
ļ		administered licensed material. In other words, should
1		this material be accounted for in liquid releases when
1		there are other examples in the NUREG where
		material that is otherwise unregulated becomes
		regulated at licensed facilities?
ı	ı	_

NRC Staff Response: The staff believes that the discussion for this section is adequate. When employees become patients, even at the facility in which they work, they are no longer considered employees but patients, and any dose they receive in connection with their status as patients is not occupational dose. Their excreta is exempted from regulation as for any individual undergoing medical diagnosis or therapy.

H-15 NUREG-1736

Location	Subject	Comment
3.20.2103	Retention of survey records	The second sentence in the discussion section on page 3-165 needs to be reworded as, in its current condition, it does not read well and its meaning is unclear.

NRC Staff Response: The NRC staff agrees with this comment. The second and third sentences on page 3-165 were revised.

NUREG-1736

Location	Subject	Comment
Appendix B		(1) The introduction on page B-1 contains the statement, "an activity median aerodynamic diameter (AMAD) of 1 m" The AMAD should be 1 micron.
		(2) On page B-9, the statement that HT and T ₂ oxidize in air and in the body to HTO is misleading. In practice, the conversion is very slow and gas is only retained long enough for a fraction of a percent to convert to HTO. There should be a separate category for HT and T ₂ gas with ALI and DAC that are about four orders of magnitude higher than for HTO. Also, airborne effluent concentration limits for HT and T ₂ gas should be at least 100 times higher than for HTO in a rural environment where bacterial conversion in soil is the critical pathway, and up to four orders of magnitude higher in an urban environment where there is no soil. This technical error has been reported to the U.S. NRC on numerous occasions without effect.
		(3) The tables concerning 14C compounds should include other low risk radiochemicals in the categories containing carbon monoxide and carbon dioxide, such as methyliodide, methane, nitromethane, ethane, etc.

Location Subject	Comment
------------------	---------

NRC Staff Response: The staff agrees with comment (1), and changes were made in the text to correct the error. We agree with comment (2) regarding the oxidation of HT and T₂ to HTO. However, the table in Appendix B specifies, for conservatism, that the values for HTO be used even if HT or T₂ is present. Nevertheless, if the licensee can demonstrate that the HT and T₂ emitted from their facility oxidizes to only a very limited extent, and that most of the exposures result from HT or T₂ rather than HTO, then the licensee may apply to NRC for approval to use the appropriate HT values. The staff disagrees with comment (3). Because there are many compounds that could contain C-14, it would not be possible to list all of them in the table. Many entries in the table for other radionuclides are only partial listings, and there are many compounds that are not listed. For such unlisted compounds, licensees should check other sources for the appropriate classification of their compounds with respect to solubility following ingestion or inhalation. The table is intended only as guidance that includes the most frequently encountered compounds. It was not intended to be an exhaustive listing of all possible compounds that licensees may encounter.

H-18

Location	Subject	Comment
Appendix G		We strongly recommend that a definition of radioactive waste be provided in this section.

NRC Staff Response: See the NRC staff response to the CORAR second general comment ("entire document"), on word usage and definition.

Comments Provided by the Pennsylvania State University Radiation Safety Officer, Not Dated

Location	Subject	Comment		
Entire Document	Format and content of the Consolidated Guidance report	I believe this will be a very useful resource and I appreciate the amount of work that went into its preparation. I also look forward to a guidance document on Part 31. It would be able to describe the requirements for General Licensees in plainer language.		
NRC Staff Response: This comment on the draft document is appreciated, as it reflects the principal objective in creating the report. A guidance document for Part 31 is already available Refer to NUREG-1556, Vol. 16, "Consolidated Guidance About Materials Licenses: Program Specific Guidance About Licenses Authorizing Distribution to General Licensee," published December 2000 and available on the NRC web site at http://www.nrc.gov/NRC/NUREGS/SR1556/V16/index.html .				
Entire Document	Format and content of the Consolidated Guidance report	This guide must be written for the Health Physics professional as well as the part time person who was assigned the position of Radiation Safety Officer as part of his other duties. The people in the second group need more help than in the first group, I hope. Therefore, redundancy and clarity should be encouraged.		
NRC Staff Response: The document was not modified in response to this comment. Clarity and readability were a prime objective in preparing this report. An additional objective, to keep the report to a manageable and useable length, precluded extensive redundancy, but cross-references between or among sections were used when considered potentially helpful to the reader.				
3.20.1001	Sources of occupational radiation exposure	The discussion states "The annual dose limits apply to all doses received by the worker, at NRC and"		
		This discussion should explicitly state that doses from non-medical X-ray exposures are also included, as well as from Agreement State regulated radioactive material.		
NRC Staff Responsemake this point clea		and the discussion in section 20.1001 was modified to		

Location	Subject	Comment
3.20.1002	Scope	The discussion states what materials are covered, but should also state that the dose from all radioactive materials and X-rays must be considered.
	se: The staff agrees s modified to include	with the comment, and the guidance for this topic.
3.20.1003	Definition (distinguishable from background)	Distinguishable from background. Please add a discussion to this definition that leads the not full-time health physicist to a reference for acceptable methods for calculating Minimum Detectable Activity/ Concentration (MDA). There is considerable discussion in the literature concerning this concept, and the answer is not readily obvious to many people who work in the health physics field, much less others. MARSSIM is a potential reference. Another that can easily be found is in Minimum Detectable Activity Regarding Background Counting, by Daniel J. Strom and Paul S. Stansbury, in Health Physics, September 1992, Volume 63, no.3 pages 360-36J. The formulas for determining when a count is greater than background are clearer in this article than any others I have found. Adding this information will not be difficult or controversial, and will be an aid to the reader. Another good reference to cite would be NUREG-1505.
NRC Staff Response: Although we agree with the comment, it would be inappropriate to go into technical matters in this document. The concept of distinguishable from background is closely tied to counting statistics, and must be addressed by a person competent in counting statistics and setting up low-level counting equipment. Some clarification of the concept was added to a discussion in the text.		
3.20.1005	Units	Include in discussion that the SI units are required on manifests, but soon the curie may not be allowed on manifests.
NRC Staff Response: Although the comment is valid, the discussions in this guide reflect the existing conditions and do not anticipate changes, even though they are probable.		

H-21 NUREG-1736

Location	Subject	Comment
3.20.1101(c)	Program audits	The guidance in this section adds a requirement that is not included in the regulations. Specifically "should be performed by qualified persons who do not have direct responsibility over the program" {emphasis added}. Although I agree that this may be the best way to perform audits, this IS NOT included in the regulation. Although the guidance says "should" and the rule says "shall review annually," an obvious interpretation of the reading of this guidance document implies a requirement for an outside audit. This does not appear to have been part of the original intention of the requirement for the audit. The purpose of this document is to provide guidance, not to add additional requirements. The phrase "commensurate with the scope and extent of licensed activities and sufficient to ensure compliance with the provisions of this part" is clear and could be applied to the extent of the audit as well as to the extent of the Radiation Protection Program.

NRC Staff Response: The staff agrees that the statement "...should be performed by qualified persons who do not have direct responsibility over the program..." goes beyond previous NRC guidance concerning section 20.1101(c). While the staff agrees that following this "new" guidance may result in the performance of a very effective audit of a program, the questioned wording has been changed to reflect that this should be one of several ways an effective audit may be performed, if practical. The staff notes that as a function of program size and complexity, this may not be a reasonable or practicable audit approach for many small programs.

Location	Subject	Comment
3.20.1208	Reporting dose to embryo/fetus	Since NUREG-1736 will be used for many purposes, it should perhaps include information that goes beyond Part 20. At a Health Physics Meeting some years ago, an NRC staff member presented a talk on this particular subject (Cynthia Jones, I think). The speaker said that the dose estimates for a fetus and the declaration of pregnancy should NOT be included in any future report of the woman's exposure that is passed on to her next employer. This information should, in effect, be included the baby's exposure history, not in the mother's. Since this is the baby's exposure rather than the woman's exposure, this seems rather obvious, until you think how dosimetry information would be filed. If my memory is correct, include this information in the Consolidated Guidance. Including this information may save problems for licensees in the future.

NRC Staff Response: Section 20.2106 specifically states that the licensee shall maintain the records of dose to an embryo/fetus with the records of dose to the declared pregnant woman. If the entire pregnancy occurred during the employment at one licensee, there would be no reason to transfer the record to the new employer/licensee. If, on the other hand, the pregnant worker changed employers during the pregnancy, the records would have to be transferred.

H-23 NUREG-1736

Location	Subject	Comment
3.20.1801	Enforcement	The sections presenting guidance on these parts did not reference: "Enforcement Guidance Memorandum
3.20.1802		Categorizing the Severity Level of Violations Involving Security and Control of Radioactive Material," which was issued on April 24, 1998; or
		Enforcement Manual, NUREG/BR-0195, Rev. 2, (August 1998), Section 8.6.3, "Severity Level of
		Violations Involving Security and Control of Licensed Material." These documents specifically discuss these
		sections.
		The Draft Consolidated Guidance gives the erroneous impression that the NRC is as concerned with the loss of an LSC vial of tritium as with the loss of a used find hundle. Although the Guidance Statement of
		fuel bundle. Although the Guidance Statement as written is true, failing to at least to reference the guidance listed above does not give the full story.
		Please discuss the graded enforcement and reference the two documents listed above. This information will
		provide licensees with research facilities to establish
		similar graded enforcement policies, which is the NRC's intent.

NRC Staff Response: The purpose of this document is to provide guidance on complying with the regulatory requirements. The specific sanctions that may result from the failure to comply with regulatory requirements is beyond the scope of this document.

H-24

NUREG-1736

Location Subject	Comment
1904 Defacing label	The discussion states "The removal or defacing of labels ON {emphasis added} empty containers is of particular importance." NRC Information Notice 97-03 states that the hazard of opening containers to deface containers is probably not worth the risk. "Additionally, these actions would place licensees in violation of the Occupational Safety and Health Administration Regulation 29 CFR 1910.1030(d)(1), which requires precautions to prevent contact with blood or other potentially infectious materials, including recommendations not to manipulate used syringes/needles by hand." Although this information notice is referenced, I think the discussion in this Guidance Document should more explicitly discuss this issue.
C Staff Response: A specific ron.	reference to Information Notice 97-03 was added to this
2003(a)(1) Disposal into sanitary sewer	The material is readily soluble (or is readily dispersible biological material) in water. The NRC should make clear in this section that in liquid chemical mixtures of non-radioactive and radioactive labeled molecules, only the molecules with radioactive elements attached need to be readily soluble. Again for biological research institutions, radiolabeled RNA and DNA are biological material and therefore
	_

NRC Staff Response: The staff believes that it would be difficult to make the type of statement suggested because there may be situations where, although the radioactive molecules are readily soluble as listed in a standard reference, the presence of the non-radioactive component may alter this solubility by chemical or physical processes. The solubility of a particular type of discharge should therefore be determined on a case-by-case basis by the licensee. Because RNA and DNA are not the only molecules that might be classified as biological materials, it would not be appropriate to list specific molecules in this guidance, because such a list cannot be exhaustive and may therefore be misleading by omission.

Location	Subject	Comment
3.20.2003(b)	Excreta from individuals	Excreta from individuals undergoing medicalare not subject to these limitations.
		I believe that excreta from animals which have undergone medical diagnosis or therapy are also exempt from regulation. If I am correct, this fact should also be included in the Guidance.
	y from individuals u	ees with the comment. The regulations in this section indergoing medical diagnosis or therapy, and therefore
3.20.2005	Disposal of specific wastes	The discussion should include a caution to the reader that disposal of less than 50 nCi/gram is exempt, but the exemption for shipping requirements in 71.10 only applies at less than 2 nCi/gram.
		The discussion should also indicate that this exemption does not apply to animal waste or bedding (I think), and it may not be averaged over multiple animals (I think). Please clarify.
NRC Staff Respon guidance to include		with both comments. Changes were made in the
3.20.2101	Units	The discussion of this section in the Draft Consolidated Guidance says that "SI or SI and special units, must be used on shipping manifests." A notice of proposed rulemaking July 17, 2000 (page 44359), on changing IOCFR7I into compatibility with ST-I, suggested that special units would not be allowed on shipping papers. Although the Guidance is currently correct, a caution in this section would be appropriate.
	se: The staff disagre CFR Part 20, which i	es with this comment. NUREG-1736 is based on the s currently in effect.

NUREG-1736

Location	Subject	Comment
3.20.2104	Prior occupational exposure	Please be more emphatic that no prior history is required for individuals who are not likely to receive 500 mrem per year of exposure. At the university where I work, we frequently receive exposure history requests from locations where the likelihood of receiving 50 mrem is minimal.

NRC Staff Response: The staff agrees with this comment. The Guidance Statement was revised to indicate that no prior history is required for individuals who are unlikely to receive an occupational exposure exceeding 500 mrem in a year.

H-27 NUREG-1736

Comments Provided by Exelon Generation Company (EGC), Dated February 26, 2001

Location	Subject	Comment
3.20.1601	Control of access to high radiation areas	[This section] discusses guidance for control of access to high radiation areas. Regulatory Guide (RG) 8.38, "Control of Access to High and Very High Radiation Areas in Nuclear Power Plants," Section 2.4, "Alternative Methods for Access Control," describes a pre-approved alternative method to the NRC requirements for the control of access to high radiation areas. This alternate method should be specifically referenced in the draft regulatory guide, preferably in the "Guidance Statement" section (i.e., page 3-101).

NRC Staff Response: The staff agrees with the comment and added a specific reference to the option for applying to the Commission for approval of alternative methods of control for HRAs. An example of an acceptable method for alternative controls is listed in Regulatory Guide 8.38; however, the comment's use of the phrase "pre-approved" could be misleading. A word of caution for licensees: *before* a licensee implements any alternative controls (in lieu of those in Part 20) for HRAs or VHRAs, it must first apply in writing to the Commission and receive specific Agency review and approval.

Comments Provided by Lester Slayback, Dated March 6, 2001

Location	Subject	Comment
3.20.1003	Definitions	(1) Pg 3-5 (Airborne radioactivity area): While it is outside the scope of this publication to change this definition, which was carried over from the old 10 CFR 20, it appears that it is disproportionate in comparison to the posting requirements for external sources of radiation exposure. At a 12 DAC-hour exposure in a week this posting threshold is equivalent to 0.75 mrem/hr compared to the lowest posting requirement for external sources of 5 mrem/hr. Some discussion as to why this lower threshold is important would aid the user in understanding the rule.
		(2) Pg 3-10 (Controlled area): The first sentence ending in "in controlled or unrestricted areas" creates the impression that these are separate and distinct. The point should be made that a controlled area is just a special kind of unrestricted area with all the constraints of an unrestricted area.
		(3) Pg 3-12 (Distinguishable from background): There is not any added discussion provided for this item despite voluminous guidance from NRC on this topic. Given that NRC has not established a replacement for BRC, and that voluminous guidance exists from NRC on this concept as applied to different regulatory issues, some discussion on this topic would be valuable for many of the licensees using this document.
		(4) Pg 3-13 (High radiation area): Presumably the example of inserting an arm into a port is referring to the upper arm since exposure to an extremity is not a basis for defining a High Radiation Area? Also, presumably the source of the exposure is more than

H-29 NUREG-1736

Location	Subject	Comment
		30 cm distant from the arm given that element of the definition?
		A further comment: Presumably the intent of the NRC in the definition of a High Radiation Area is to limit risk, i.e., to limit the potential for exposures that might exceed the limits. Elsewhere NRC has assumed a simplified (some would say simplistic) model for determining dose, i.e., asserting that the highest exposed point represents the dose to be applied against the annual limit. While this model simplifies dosimetry and regulatory compliance interpretations, it has the unintended consequence of making certain types of Radiation Area and High Radiation Area postings excessively conservative in terms of risk. These types are primarily those that represent partial body exposures and geometries that require unrealistic assumptions to achieve the exposure. The 'arm' example given represents both of these, e.g., a partial body exposure that reflects a risk that is a small fraction of that for a similar whole body exposure and the default presumption that a person will fully insert the arm for at least an hour (for a field of 100 mrem/hr) through this small hole with no rationale for doing so. While this document is probably not the forum to introduce area averaging, perhaps it is appropriate to discuss in more detail a more appropriate interpretation of what is meant by accessible. ANSIIANS-15.1 1-1993 provides a candidate definition that might be considered. On the other hand, if such is not done then the offered discussion needs to be expanded to provide the NRC rationale of why small, partial body exposures at 100 mrem in one hour must be classified as High Radiation Areas so that the non-expert licensee can anticipate the NRC position.
		As a last point this legalistic tightrope chain of thought (HRA – dose – highest exposed point – any point excluding the extremities) results in required

NUREG-1736 H-30

Location	Subject	Comment
		posting in some situations where any reasonably trained worker knows that the associated risk is minimal, e.g., for a square centimeter beam of radiation. This has the serious potential of devaluing the meaning and effectiveness of the High Radiation Area posting. Some guidance or warning to the licensee on this issue in this discussion is needed.
		(5) Pg 3-14 (Licensed material): A discussion point should be added that material not classified as licensed by NRC might well be regulated by an Agreement State regulator.
		(6) Pg 3-15 (Member of the public): NUREG/CR-6204 was published prior to the revision of the definition of the member of the public. Can one presume that 6204 responses were reviewed in light of the changes to the rule? The revision to that definition was explicitly intended to ensure that mere presence in a restricted area was not a basis for being classified as occupationally exposed. I suggest that a person whose desk location results in exposure to a licensed source is not any more occupationally exposed than a member of the public walking through the area, or a person employed in a nearby home subject to the same source of radiation. The draft sentence would basically result in everyone in a hospital or in a university being classed as occupationally exposed simply on the basis of proximity. Further, it is not clear in this sentence how this proximity basis meets the requirement that "the individual's assigned duties involve exposure" In one sentence in the discussion proximity is a basis and in another (the delivery person) it is not. Clarification is needed.

Location	Subject	Comment
		(7) Pg 3-16 (Occupational dose): Some discussion to expand on the meaning of "in the course of employment" and "in which the individual's duties involve exposure" is needed. In the first case this does not require the receipt of money. In the second it requires something more than simple geographic proximity related to employment.
		(8) Pg 3-16 (Planned special exposure): For the vast majority of licensees this category of exposure clearly represents an extraordinary event. This point should be made in a discussion point.
		(9) Pg 3-18 (Restricted area): Please expand this comment to clarify the NRC intent by requiring control over access to a restricted area, rather than simply limiting access as specified by the definition. The definition says access shall be limited, which according to the common dictionary definition of the word is a less stringent constraint than the word "control."
		In addition, security over access to radioactive material in restricted areas was a major issue several years ago, and remains one today. This aspect of a restricted area should be commented upon.
		(10) Pg 3-21 (Weighting factor): A comment cautioning licensees on the use of tables from post-1990 publications that might be using ICRP 60 models and values should be provided. A similar caution relating to neutron quality factors would also be appropriate.

NUREG-1736 H-32

Location	Subject	Comment
		(11) Pg 3-22 (Year): A comment demonstrating how a licensee can change the year starting date without omitting a day or using the same day in consecutive years would be useful.
		(12) Pg 3-25 (Discussion of roentgen): Clarify the discussion of kerma, and R. The quantity kerma is used in place of the quantity Exposure, and the unit 'rad' that is used with kerma replaces that of R which is used with Exposure. Further, the quantity kerma requires that the target medium be identified for the measurement to be meaningful. In the case of calibrations in place of the quantity Exposure, the phrase 'air kerma' is typically used to make this point. Technically, this would be different from a calibration in terms of 'tissue kerma,' albeit a small difference in most instances. As a further note, while air kerma is used in place of Exposure, in fact it is a different quantity with technical differences that users should be cognizant of.
		Also see the previous comment about the need for a cautionary statement relating to the differing ICRP quality factors, and data derived from those.

H-33 NUREG-1736

Location	Subject	Comment
----------	---------	---------

NRC Staff Response: Comment (1): The staff agrees that discussion of this topic is beyond the scope of this guidance document. The staff also agrees that the postings noted in the comment appear to be disproportionate. However, one of the reasons for the apparent disproportion in posting is that assessment of internal dose is much more prone to error and uncertainty than assessment of external dose; hence, more caution is usually exercised with respect to internal exposures.

Comment (2): The staff disagrees with the comment. A controlled area is not "just a special kind of unrestricted area." As defined in the rule, and as the name implies, access to a controlled area is controlled for some purpose, often security, whereas access to unrestricted areas is not controlled at all.

Comment (3): The staff added some guidance in the text on this subject. However, this is a technical issue, not a regulatory one, and therefore its discussion is beyond the scope of this document. In addition, the idea of distinguishable from background and that of BRC are not related in any way.

Comment (4): The staff agrees that the upper arm is normally the body part of interest in such situations, since it is part of the whole body. However, the definition of high radiation area does not specify the body part for which the dose equivalent is to be assessed. The dose in the definition should therefore be viewed as defining a radiation field, rather than defining the dose to a person or body part. The distance from the source or surface of 30 cm is part of the definition and must therefore be considered. In the case of the port, the high radiation area can be posted based on the dose at the port opening since the sources within the steam generator, which is normally where such ports are located, or a reactor beam port, is well within the system, beyond the 30 cm range.

The staff disagrees with the rest of this comment. The high radiation area is defined in terms of a radiation field at a given location and not in terms of the dose actually assigned or received by an individual. It would be impossible to define areas for posting and access control based on the distribution of dose in an individual who may happen to walk into the area, because there are many factors that would determine such a dose. The staff would also like to point out that, in connection with the example of the arm noted in the comment, NRC permits a type of dose averaging by allowing different parts of the body to be monitored separately, with the assigned

Location	Subject	Comment
----------	---------	---------

dose for the monitoring period being the highest dose to any of the separately monitored regions. The staff also disagrees that posting high radiation areas devalues the meaning and effectiveness of such a posting. There is no particular meaning attached to such a posting, other than that there exists in the posted area a radiation field that is above a certain level and therefore warrants that certain reasonable precautions be taken that would not otherwise be the case in areas with lower fields. This is an eminently reasonable approach if one accepts the linear non-threshold hypothesis for stochastic effects and the idea of ALARA as a sound operating principle.

Comment (5): The staff agrees with this comment, and the discussion in section 20.1001 was modified to address this issue.

Comment (6): The staff disagrees with the reviewer's interpretation of occupational exposure.

In the example given of a person sitting at a desk at a location that results in exposure, the classification depends on what the person is doing. If the person's job requires that the desk be placed in an area that involves radiation exposure, for example a radiation control technician at an access control desk, then that exposure is part of that person's job, and is occupational. On the other hand, if the person is not required to be in that radiation area, then the person is not occupationally exposed, and sitting in that area is poor radiological practice. The staff also disagrees with the comment that proximity is a basis for classification of the type of exposure. Proximity to a source of radiation is not an issue in this matter, and therefore, not everyone in a hospital or university is occupationally exposed by being in these types of buildings.

Comment (7): The staff disagrees that additional guidance is needed to resolve issues such as proximity and payment. Proximity and payment are not part of the definitions of occupational or public doses and were only introduced by the reviewer. Neither is relevant in deciding whether an exposure is occupational or public.

Comment (8): The staff disagrees with this comment. The fact that planned special exposures may be a rare occurrence in the industry does not affect the regulatory requirements that must be observed in exercising this option.

Location	Subject	Comment
----------	---------	---------

Comment (9): The staff disagrees with the comment. It is not clear what the distinction is between "limiting access" to an area and "controlling access" to that area. If access is to be limited, then some type of control must be in place that would enable the licensee to exclude from entry those who are not supposed to enter. In this context, the staff believes that "control access" is not more stringent than "limit access," because the latter cannot be accomplished without the former. Limit access in this context simply means that some, but not all, those desiring access to the area will be permitted such access.

Comment (10): The staff disagrees and believes that adding a discussion of the weighting factors in ICRP Publication 60 may confuse matters for those not familiar with these issues. The guidance as it stands is clear in that it provides the factors to be used in calculating the effective dose equivalent. The same applies to neutron quality factors. In addition, licensees may apply to NRC for approval to use weighting factors and quality factors that are different from those listed in Part 20, provided a sufficient justification exists.

Comment (11): The staff agrees with this comment, and some guidance was added to the text to discuss this issue.

Comment (12): The staff disagrees and believes that a discussion of kerma and R would be beyond the scope of this guidance document because these are technical matters. Although the staff agrees that the technical considerations involved in the distinctions between the various dosimetric and field quantities are important, they are matters for experts in the field, and do not directly affect the interpretation of the regulations in Part 20.

3.20.1009 Office of Managemen Budget appr	
---	--

NRC Staff Response: The text of the discussion was not changed in response to this comment. The staff agrees that the discussion probably has little practical use for everyday licensee activities; however, it may be useful in clarifying this section of the regulation. It also informs licensees of their rights with respect to official requests for information.

Location	Subject	Comment
3.20.1101	Constraint on effluents	Pg 3-36 (Discussion): In fact a note of reality could be added. A survey of all major NRC licensees demonstrated that no licensee approached this criterion. If a licensee's operation was projected to approach this limit, that operation should be carefully reviewed simply on the basis that it is not the norm for the industry. Providing such a scale would give the reader a practical perspective to judge a planned operation.
NRC Staff Response: This "constraint" on effluents is not a <i>limit</i> , as the comment suggests (see Part 20, Definitions section). The suggestion to add guidance relative to licensee operational performance in maintaining effluents below constraint levels is outside the scope of this document.		
3.20.1201	Eye dose	Pg 3-39 (Guidance): Very nice, succinct summary. Perhaps an added hint that eye dose is likely to need specific monitoring only when exposure to relatively high energy electrons occurs would be useful.
NRC Staff Response: The need for specific monitoring may occur in situations other than		

NRC Staff Response: The need for specific monitoring may occur in situations other than with high energy electrons. In any case, the regulation is clear that where there is a potential for a significant dose to the lens of the eye, the licensee must perform an additional evaluation to assess that dose.

H-37

Location	Subject	Comment
3.20.1202	Summation of doses	Pg 3-43 (Discussion: "Almost everyall tissue irradiated."): This sentence is somewhat inaccurate. While the dose modeling for internal sources represents the best estimate that can practically be achieved, the dose assignment for external exposures is purposefully biased towards the highest possible dose assignment, and hence frequently reflects an unrealistic risk. Slight rephrasing can avoid this issue while still expressing the main desired point, e.g., that external and internal assigned doses be summed in an equitable fashion. The subject of equitable risk is best addressed elsewhere.
		Another point that should be mentioned to the reader is that there might be reasons other than 10 CFR 20 requirements for monitoring worker exposures, e.g., liability, work practices, ALARA implementation. The licensee should consult appropriate professionals to discuss these issues.
position on the issu- summing external a	e of total risk insofar and internal dose. Re	es that the Discussion accurately reflects NRC's as its applicability to the regulatory requirement for assons for monitoring workers' exposures other than the beyond the scope of this document.
3.20.1203	External dose from airborne material	(1) Pg 3-45 (Guidance: "The preferred method"): Very good point, but a stronger statement would be that "A dose estimated based on the Part 20 DAC value will seriously overestimate the dose in virtually all occupational exposure situations for most noble gas radionuclides. Hence the preferred method". Very simply, the semi-infinite hemisphere assumption used to calculate the numerical DAC values rarely exists in occupational exposure situations.
		(2) Pg 3-45 (Note): The phrase "from other than noble gases" is confusing in this Note. As per pg 3-46, other than noble gas airborne radioactivity should be assessed by measurements and DAC values. Further this first sentence in the note conflicts with the second sentence. Presumably a uniform cloud of 41Ar

Location	Subject	Comment
		is not excluded by the conditions of the first sentence so it is implied that airborne radioactivity measures and DAC
		values should be used, which conflicts with the second sentence. The whole Note needs to be revised.
		(3) Pg 3-45 (Discussion): It is the rare geometry where the internal dose from a noble gas (excluding radon isotopes and others with radioactive daughters) is controlling. It would not be much work for this document to identify those situations (e.g., the room size for a typical transition volume, which is likely to be the size of a very small closet) and simply state that for other exposure geometries the external source term is controlling.
		(4) Pg 3-45, 46: The Note on pg 3-45 states "airborne radioactivity measurements should not be used" but the Discussion on pg 3-46 states airborne radioactivity measurements should be used. Each addresses a different exposure geometry (e.g., external vs. internal). For clarity, the document should reinforce the context of these comments by adding a phrase like "from external sources" or "from internal disposition."

Location	Subject	Comment
----------	---------	---------

NRC Staff Response: (1) Since the Part 20 DAC is based on the submersion dose, the DAC will overestimate the dose, but not seriously so. The Guidance Statement was amended to reflect this. (2) The Note is a direct quote from the regulations and simply addresses the need to include the contribution that airborne radioactivity makes to the deep-dose equivalent. For other than noble gases, DAC values cannot be used for this purpose, but rather should be based on direct measurement of exposure using appropriate instrumentation or personnel monitoring devices. (3) While it is true that for a small enclosure, the internal dose from noble gases could exceed what would be calculated using the DAC, section 20.1203 makes no attempt to ascertain whether external or internal dose is "controlling." (4) The entire focus of this section is on the contribution of the airborne radioactivity to the total external dose. Nothing in this section should be interpreted as precluding the necessity of addressing airborne radioactivity in terms of internal exposure.

Location	Subject	Comment
3.20.1204(c)	Adjustment to ALIs and DACs	Pg 3-49 (Statement of Applicability): This statement is presumably in the context of those licensees using the ALIs and DACs to assign a dose. Presumably this does not apply to those following the guidance on pg 3-46 to do direct bioassay and dose modeling, but do not derive an adjusted ALI or DAC. If this is not true then further clarification is needed.

NRC Staff Response: This section allows licensees to calculate the committed effective dose equivalent to workers, based on specific information that would result in a committed effective dose equivalent different than if the ALIs and DACs in Appendix B to Part 20 were used. The staff assumes that such specific information would be obtained through bioassay measurements and supported associated calculations using those results. If a licensee wished to use the ALIs and DACs in Appendix B, without modification or adjustment, then this section would not apply. The Statement of Applicability section of the guidance was clarified.

3.20.1206	Pg 3-58/9 (Discussion): Have there been any Planned Special Exposures by materials licensees since this
	two, a clear statement of that fact would emphasize the rarity of this provision.

NRC Staff Response: This section of the regulations provides licensees with operational flexibility in managing situations that may require higher exposures than normally permitted. The purpose of this document is to provide guidance on implementing the requirement. The frequency with which a particular regulation is used does not change the requirement or the guidance.

APPENDIX H

Location	Subject	Comment
3.20.1207	Dose to minors	Pg 3-61 (Discussion): This is a bit of an overstatement in terms of the age duration of elevated risk. Since many minors get some, albeit minimal, exposure during their later school years, a more precise statement would be preferred so as to encourage a proper perspective of their risk (typically for exposures in the mid to late teens). Appropriate references should also be provided. Also, the reduced limit is more a reflection of simple conservatism than it is of the actual increased risk. Hence, the last sentence is not strictly correct, unless some statement relating to added conservatism is added. I suspect universities and other similar organizations would be very sensitive to the implication that minors aged 15-17 are a factor of ten more sensitive than the adult population.
NRC Staff Response: The discussion was modified to present a more accurate statement regarding risk. It was pointed out, however, that the regulations do not attempt to quantify the sensitivity of minors of different ages, nor does the document claim that minors are a factor of 10 more sensitive than adults.		ver, that the regulations do not attempt to quantify the
3.20.1208	Declared pregnancies	Pg 3-63 (Statement of Applicability): Shouldn't the sentence "A separate written declaration should be submitted" read "must be submitted?" Don't previous declarations become moot at the cessation of the pregnancy?
NRC Staff Response: If a worker does not "undeclare" her pregnancy between pregnancies, e.g., in the event of a miscarriage, it may not be necessary to redeclare. The right to declare and "undeclare" a pregnancy is a legal right, unrelated to the actual physical circumstances.		
3.20.1501(c)	Dosimetry processing	Pg 3-90 (Statement of Applicability): Add to the last sentence " and electronic dosimeters."
NRC Staff Respon	se: The comment wa	as incorporated into the Statement of Applicability.

Location	Subject	Comment
3.20.1601 Overexposures		Pg 3-98 (Discussion:) Replace the word overexposures with the phrase "exposures in excess of regulatory limits." The word overexposure has a risk connotation for most readers while the NRC scheme of dose limitation defines the regulatory dose in a manner that can result in minimal risk, even at doses well in excess of the limits. The suggested phrase is more precise in terms of the potential result from the described circumstance.
NRC Staff Response: The term "overexposures" (as used in the NUREG's guidance statement) is commonly used in industry and by the NRC staff when referring to personal exposures in excess of regulatory limits. The staff sees no significant distinction between the terms and sees no need to change the document.		
3.20.1602	Control of access to very high radiation areas Pg 3-106: The phrases "even death" and "life threatening" should be qualified as to apply to situations well in excess of the posting threshold and to substantial, upper body exposures. The most common VHRA geometry in industry and research facilities, e.g., a small radiation beam, in fact would basically result in a freckle.	
NRC Staff Response: Regulatory Guide 8.38, Section 3, page 5 uses the same terms for describing the potential hazards to workers from HRA and VHRAs. The staff sees no need to modify the wording.		

H-43 NUREG-1736

APPENDIX H

	Subject	Comment	
3.20.1703 3.20.1704	OSHA & NRC programmatic requirements and	Pg 3-113 thru 3-132: There does not appear to be any discussion on the use of respirators under OSHA approved programs for non-radiological purposes	
3.20.1705	interface	where there is airborne radioactivity at levels that do not precipitate the subpart H requirements. The Statement of Consideration on subpart R and a letter of interpretation issued by NRC make it clear that such usage with the relating incidental radiological exposure is permissible. Many licensees are in this situation, i.e., industrial use of respirators under an OSHA program in areas with potential non-zero airborne radioactivity that represents a minimal, incidental exposure. The draft Regulatory Guide is ambiguous, at best, on this issue. This point should be clarified in these pages.	
Definitive guidance	on this specific issu	agrees that this issue is important and merits discussion. e can be found in the referenced guidance document, piratory Protection Against Radioactive Material,"	
3.20.1905	Security	Pg 3-143 (Discussion): It would be very beneficial to licensees if this discussion, i.e., not enough to present a significant radiation hazard, applied to 20.1801 (pg 3-133) in terms of a lessened level of security expectation.	
NRC Staff Response: As stated in the Statement of Applicability for 20.1801, the requirement to secure material from unauthorized removal or access is unrelated to the quantity of licensed material involved.			

Location	Subject	Comment
3.20.2101	Records – units	(1) Pg 3-163 (Guidance): The statement in bold is puzzling. After allowing SI units to be added parenthetically, this statement asserts that these parenthetical entries are " not in lieu of the special units." Previous text has clearly stated that the results in terms of special units must always be provided. What is the issue intended to be covered by this bolded sentence? If it is important for the licensee to understand, then more explanation is needed. If it is simply legal boilerplate, then can it be so identified?
		(2) Pg 3-163 (Guidance): This forthright admission of non-conformance to the NRC's own policy begs the question, why? NRC should at least provide a reference that defends or explains this schizophrenia.
NRC Staff Respondiscussion was dele		agrees with these comments. The bolded sentence under
3.20.2201	Report of theft or loss	(1) Pg 3-180 (Discussion: "The degree of exposure is not specified."): This statement may be an accurate observation but it is remarkably unhelpful. Is it intended to impart that the degree of exposure is not relevant, not important, to be determined by the licensee, or some other alternative? Since any source of any radionuclide, no matter how many light-years distant, can result in a non-zero exposure to anyone on earth, the words in the Requirement really need some supplementary interpretation.
		(2) Pg 3-180: Some guidance on the action desired by the NRC of the licensee for quantities less than those specified in 20.2201 would be useful. It is presumed that the significant quantities of the discussion refer to 20.2201(a)(1)(i) and the lesser quantities to 2201(a)(1)(ii).

deleted, and the guidance has been clarified.

H-45 NUREG-1736

APPENDIX H

Location	Subject	Comment

Also, concerning the second comment, licensees should report to NRC pursuant to requirements of the NRC regulations and can develop their own specific guidance for quantities of radioactive material below the NRC regulatory reporting threshold.

NUREG-1736 H-46

Location	Subject	Comment
3.20.2202	Notification of incidents	Pg 3-183 (Discussion): The phrase 'may cause' is much more encompassing than the regulatory requirement 'threatens to cause'. The phrase 'threatens to cause' has an immediacy that one would interpret to mean high likelihood. While NRC should reasonably ask licensees to use a conservative judgement in deciding to make such a report in the discussion section, a more accurate description is needed of the meaning of 'threatens to cause'.
		Also, the NRC should caution the licensee not to use this reporting mechanism as a means simply of informing the NRC of something that is a very unusual condition for the licensee. As part of this caution the NRC response to such reports might be described.
NRC Staff Respon Also, a statement w (events) on a volun	as added to indicate	with this comment. The guidance has been clarified. that licensees may inform NRC of unusual conditions
3.20.2206	Reports of individual monitoring	(1) Pg 3-192 (Discussion): You should probably add "and some types of research reactors." Under testing facilities defined in 50.2 (which to be accurately interpreted for some facilities requires a carefully reading of 10 CFR 50.~(c), 50.21(b), 50.22, and section 31 of the Atomic Energy Act), some of the NRC licensed research and test reactors are also required to make this report. Any simplification of the very twisted path through these references would be useful.
		(2) Pg 3-192 (Guidance): It is stated that Form Ss must be submitted for those who were provided monltoring. The rule appears to require such a report only for those who were required to be monitored. Please clarify.

H-47

Location	Subject	Comment

NRC Staff Response: The staff agrees with the comments made on this section. The staff revised the Discussion on page 3-192 to indicate that research reactors not classified as testing facilities are not required to submit exposure records. Also, the last sentence of the Discussion was revised to indicate "required" monitoring.

Comments Provided by Brian Douglas Farris, Dated March 12, 2001

Location	Subject	Comment
Entire Document	Outdated guidance	The consolidation of numerous guidance documents into a single source is an excellent initiative. The format for each section is logical, although I would recommend the addition of a listing of outdated guidance within each section for reference purposes.
incorporated. Each Documents" and ou	section, as appropriated "Implementing	utdated guidance has, in fact, already been ate, includes listings of outdated "Regulatory Guidance of Guidance Documents." For some sections, there is word, fourth paragraph, for a description of these
Entire Document	NUREG revisions	The ability to access this document via the Internet is a definite plus. The capability provides timely data to all users without excessive costs. I would recommend updating annually, with a monthly notice to users of changes.
appropriate in 2004.	NRC Staff Response: This consolidated guidance NUREG is scheduled for review/revision a appropriate in 2004. At a minimum, there will be notices in the <i>Federal Register</i> when the draft for comment is published and when the final revised version is published.	
Entire Document	Overall comment	The scope of this document is adequate for the purpose of ready reference. The document will serve as an invaluable tool for research and as an informational database for all users.
NRC Staff Respons	NRC Staff Response: This positive statement as to the utility of this document is appreciated.	
20.2106	Access to records of individual monitoring results	In addition to this document, I would suggest that the NRC develop an Internet database. This database could track employee exposure levels for both transient and permanent employees who work with nuclear radiation. The information would help ensure employers do not allow employees to exceed the exposure limits set in this document.

NUREG-1736

Location	Subject	Comment

NRC Staff Response: The Discussion for this section notes that individual monitoring records are covered by various State privacy laws and cannot be made public without the individual's written consent. Further, if these records are received by NRC, they are covered by the Privacy Act of 1974.

NRC FORM 335 U.S. NUCLEAR REGULATORY COMMISSION (2-89) NRCM 1102, 3201, 3202 BIBLIOGRAPHIC DATA SHEET	REPORT NUMBER (Assigned by NRC, Add Vol., Supp., Rev., and Addendum Numbers, if any.)
(See instructions on the reverse) 2. TITLE AND SUBTITLE	NUREG 1736
Consolidated Guidance: 10 CFR Part 20 - Standards for Protection Against Radiation Final Report	3. DATE REPORT PUBLISHED MONTH YEAR October 2001 4. FIN OR GRANT NUMBER
5. AUTHOR(S) R.E. Zelac, G. W. Purdy, J. L. Cameron, H. Karagiannis, J.R. McGrath, S. S. Sherbini, M. L. Thomas, J. E. Wigginton	6. TYPE OF REPORT Final 7. PERIOD COVERED (Inclusive Dates)
8. PERFORMING ORGANIZATION - NAME AND ADDRESS (if NRC, provide Division, Office or Region, U.S. Nuclear Regulatory Commprovide name and mailing address.) Office of Nuclear Materials Safety and Safeguards Division of Industrial and Medical Nuclear Safety US Nuclear Regulatory Commission Washington, DC 20555-0001 9. SPONSORING ORGANIZATION - NAME AND ADDRESS (If NRC, type "Same as above"; if contractor, provide NRC Division, Office of and mailing address.) Same As Above	
11. ABSTRACT (200 words or less) This document, "Consolidated Guidance: 10 CFR Part 20 - Standards for Protection Against R guidance into a single comprehensive source by reference to numerous guidance documents. NUREG-1556 series, "Consolidated Guidance about Materials Licenses." Since Part 20 appli varying degrees, it extends beyond the materials scope of NUREG-1556. Each section in "Cor Part 20 - Standards for Protection Against Radiation," provides the following: o A statement of the requirement (reflecting revisions published in the Federal Register throug o A discussion of the requirement o A statement of the requirement o A statement of the requirement's applicability o A guidance statement o A list of existing regulatory guidance (Regulatory Guides, NUREG reports) o A list of existing implementation guidance (Information Notices, health physics positions, Paretc.). "Consolidated Guidance: 10 CFR Part 20 - Standards for Protection Against Radiation," also id now outdated and in some cases subject to withdrawal or revision.	It complements the les to all NRC licensees, in a solidated Guidance: 10 CFR h October 13, 1999)
12. KEY WORDS/DESCRIPTORS (List words or phrases that will essist researchers in locating the report.) Part 20 guidance	13. AVAILABILITY STATEMENT UNIImited 14. SECURITY CLASSIFICATION (This Page) UNClassified (This Report) UNClassified 15. NUMBER OF PAGES



Federal Recycling Program

UNITED STATES

NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001

OFFICIAL BUSINESS PENALTY FOR PRIVATE USE, \$300